

STN SEARCH TRANSCRIPT 10/615,329

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:septa1623xt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR 7):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 "Ask CAS" for self-help around the clock
 NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
 NEWS 4 MAY 10 CA/Caplus enhanced with 1900-1906 U.S. patent records
 NEWS 5 MAY 11 KOREAPAT updates resume
 NEWS 6 MAY 19 Derwent World Patents Index to be reloaded and enhanced
 NEWS 7 MAY 30 IPC 8 Rolled-up Core codes added to CA/Caplus and
 USPATFULL/USPAT2
 NEWS 8 MAY 30 The F-Term thesaurus is now available in CA/Caplus
 NEWS 9 JUN 02 The first reclassification of IPC codes now complete in
 INPADOC
 NEWS 10 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
 display fields
 NEWS 11 JUN 28 Price changes in full-text patent databases EFPULL and PCTFULL
 NEWS 12 JUL 11 CHEMSAFE reloaded and enhanced
 NEWS 13 JUL 14 FSTA enhanced with Japanese patents
 NEWS 14 JUL 19 Coverage of Research Disclosure reinstated in DWPI
 NEWS 15 AUG 09 INSPEC enhanced with 1998-1998 archive
 NEWS 16 AUG 28 ADISCTI Reloaded and Enhanced
 NEWS 17 AUG 30 CA(SM)/Caplus(SM) Austrian patent law changes
 NEWS 18 SEP 11 CA/Caplus enhanced with more pre-1907 records
 NEWS 19 SEP 21 CA/Caplus fields enhanced with simultaneous left and right
 truncation

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
 MACINTOSH VERSION IS V6.0c(RMG) AND V6.0c(JP),
 AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPOB For general information regarding STN implementation of IPC 8
 NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 12:05:24 ON 25 SEP 2006

=> FILE REQ
 COST IN U.S. DOLLARS

SOURCE FILE TOTAL
 ENTRY SESSION

FULL ESTIMATED COST

0.21 0.21

FILE 'REGISTRY' ENTERED AT 12:05:43 ON 25 SEP 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 24 SEP 2006 HIGHEST RN 908333-13-8
 DICTIONARY FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprope.html>

=> Uploading C:\Program Files\Stnexp\Queries\HeP C FUSED RING COMPOUNDS.str




chain nodes :
 10 12 13
 ring nodes :
 1 2 3 4 5 6 7 8 9
 chain bonds :
 8-10 9-13
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
 exact/norm bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-10 9-13
 exact bonds :
 8-9
 isolated ring systems :
 containing 1 :

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 12:Atom 13:Atom
 Generic attributes :
 10:
 Saturation : Unsaturation
 Type of Ring System : Monocyclic
 13:
 Saturation : Saturated

L1 STRUCTURE UPLOADED

=> D L1
 L1 HAS NO ANSWERS
 L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.


=> S L1
 SAMPLE SEARCH INITIATED 12:06:04 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 25356 TO ITERATE
 7.9% PROCESSED 2000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

10 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 497594 TO 516646
 PROJECTED ANSWERS: 1860 TO 3210

L2 10 SEA SSS SAM L1

=> Uploading C:\Program Files\Stnexp\Queries\HeP C FUSED RING COMPOUNDS.str




chain nodes :
 10 12 13
 ring nodes :
 1 2 3 4 5 6 7 8 9
 chain bonds :
 8-10 9-13
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
 exact/norm bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-10 9-13
 exact bonds :

8-9
 isolated ring systems :
 containing 1 :

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 12:Atom 13:Atom
 Generic attributes :
 10:
 Saturation : Unsaturation
 Type of Ring System : Monocyclic
 13:
 Saturation : Saturated

L3 STRUCTURE UPLOADED

=> D L3
 L3 HAS NO ANSWERS
 L3 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> S L3
 SAMPLE SEARCH INITIATED 12:10:04 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 25356 TO ITERATE
 7.9% PROCESSED 2000 ITERATIONS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

8 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 497594 TO 516646
 PROJECTED ANSWERS: 1424 TO 2632


L4 8 SEA SSS SAM L3

=> D 8

L4 ANSWER 8 OF 8 REGISTRY COPYRIGHT 2006 ACS on STN
 RN 347165-68-8 REGISTRY
 ED Entered STN: 20 Jul 2001
 CN 1H-Benz[e]imidazole-5-carboxylic acid, 1-cyclopentyl-2-[[4-[[4-methoxyphenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)

← FIRST, BENZIMIDAZOLES
 (ELECTED SP.)

MF C27 H26 N2 O4
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> FILE CAPLUS
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 5.42 5.63

FILE 'CAPLUS' ENTERED AT 12:10:28 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 24 Sep 2006 (20060924/ED)


Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L4
L5 6 L4

=> D 1-6 IBIB ABS HISTR

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:141029 CAPLUS
DOCUMENT NUMBER: 142:240430
TITLE: Preparation of heterocyclic compounds as hepatitis C virus polymerase inhibitors
Oka, Takahiro; Yata, Shinji; Ikegashira, Kazutaka; Noji, Satoru; Akaki, Tetsuo; Hirashima, Shintaro;



● HCl

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:991104 CAPLUS
DOCUMENT NUMBER: 142:126546
TITLE: Non-Nucleoside Benzimidazole-Based Allosteric Inhibitors of the Hepatitis C Virus NS5B Polymerase: Inhibition of Subgenomic Hepatitis C Virus RNA Replicons in Huh-7 Cells
AUTHOR(S): Beaulieu, Pierre L.; Bousquet, Yves; Gauthier, Jean; Gillard, James; Marquis, Martin; McRercher, Ginette; Pellerin, Charles; Valois, Serge; Kukolj, George
CORPORATE SOURCE: Departments of Chemistry and Biological Sciences, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S2G5, Can.
SOURCE: Journal of Medicinal Chemistry (2004), 47(27), 6884-6892
CODEN: JMCHEM; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:126546


AB A previously disclosed series of nonnucleoside allosteric inhibitors of the NS5B polymerase of the hepatitis C virus (HCV) was optimized to yield novel compds. with improved physicochem. properties and activity in cell-based assays. Replacement of ionizable carboxylic acids with neutral substituents in lead compds. produced inhibitors with cellular permeability and antiviral activity in a cell-based assay of subgenomic HCV RNA replication (replicon EC50 as low as 1.7 μM). The improvement in potency in this ex vivo model of HCV RNA replication validates, in part, the mechanism by which this class of allosteric benzimidazole deriva. inhibits the polymerase and represents a significant step forward in the discovery of novel HCV therapeutics.

IT 390812-47-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(non-nucleoside benzimidazole-based allosteric inhibitors of hepatitis C virus NS5B polymerase and inhibition of subgenomic hepatitis C virus RNA replicons in huh-7 cells)

RN 390812-47-2 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-[(1S)-2-[(2-

Patent Assignee(s): Niwa, Yasushi; Ando, Isuru; Sato, Toshihiro
SOURCE: Japan Tobacco Inc., Japan
PCT Int. Appl., 467 pp.
CODEN: PIAAXD
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014543	A1	20050217	WO 2004-JP11640	20040806
M: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TO				
PRIORITY APPLN. INFO.:		JP 2003-288296		A 20030806
		JP 2003-288298		A 20030806
OTHER SOURCE(S):		MARPAT 142:240430		
GI				




AB The title compds. I [G1 = CR1, N; G2 = CR2, N; G3 = CR3, N; G4 = CR4, N; G5, G6, G8, G9 = C, N; G7 = O, etc.; R1 - R4 = H, halo, etc.; R5, R6 = H, halo, etc.; ring Cy (un)substituted cycloalkyl, etc.; ring A = aryl, etc.; X = H, halo, etc.] are prepared. Thus, 2-[4-[(2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzoyloxy)phenyl]-3-cyclohexyl-1-methyl-1H-indole-6-carboxylic acid was prepared in a multistep process starting from Me 3-aminobenzoate. In an in vitro test for hepatitis C virus polymerase inhibiting activity, compds. of this invention showed IC50 values of < 0.01 μM to < 1 μM. Formulations are given.

IT 844892-33-JP
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as hepatitis C virus polymerase inhibitors)

RN 844892-33-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4-chloro-4-(3-oxo-4-morpholinyl)-1,1'-biphenyl)-2-yl)methoxy]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)

(dimethylamino)ethylamino]-1-[(4-hydroxyphenyl)methyl]-2-oxoethyl]-2-(3-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:203407 CAPLUS
DOCUMENT NUMBER: 138:238181
TITLE: Preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C
INVENTOR(S): Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito
PATENT ASSIGNER(S): Japan Tobacco Inc., Japan
SOURCE: U.S. Pat. Appl. Publ., 406 pp., Cont.-in.-part of Appl. No. PCT/JP00/09181.
CODEN: USXKCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003050320	A1	20030313	US 2001-939374	20010824
US 6770666	B2	20040803		
WO 2001047883	A1	20010705	WO 2000-391904	20001225
M: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BW, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MN, MW, MX, NA, NZ, PL, PT, RO, RU, SD, SE, SO, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AT, BE, BG, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, SF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TO				
JP 2001247550	A2	20010911	JP 2000-391904	20001225
ZA 2001001393	A	20040715	ZA 2003-1193	20020626
US 2004097438	A1	20040520	US 2003-615329	20030708
PRIORITY APPLN. INFO.:		JP 1999-369008		A 19991227
		WO 2000-JP9181		A2 20001222
		JP 2000-391904		A 20001225
		JP 2001-193786		A 20010626
		US 2001-939374		A3 20010824

OTHER SOURCE(S): MARPAT 138:238181
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds. I [the dotted line in rings B1 and B2 indicates a single or double bond; G1 = N, CR1; G2 = N, CR2; G3 = N, CR3; G4 = N, CR4; G5, G6, G8, G9 = C, N; G7 = O, S, CR7, etc.; R1-R4 = H, NO2, etc.; ring Cy = (un)substituted cycloalkyl ring, etc.; ring A = Ph, cycloalkyl, etc. R5, R6 = H, halo, etc.; X = H, CN, etc.; R7 = H, alkyl] are prepared and formulated. Compds. I showed HCV polymerase inhibitory activity (data given). E.g., a multi-step synthesis of 11.HCl, starting from 2-bromo-5-nitrotoluene and Me 2-(2-fluoro-4-hydroxyphenyl)-1-cyclohexylbenzimidazole-5-carboxylate, was given.

IT 347165-68-8P 347168-00-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C)


RN 347165-68-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[(4-methoxyphenyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 347168-00-7 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 2-[5-(3-chlorophenyl)-2-furanyl]-1-cyclopentyl- (9CI) (CA INDEX NAME)




IT 347174-08-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C)

RN 347174-08-7 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-methoxy[1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, ethyl ester (9CI) (CA INDEX NAME)




AB Fused cyclic compds. represented by the following general formula [I] or pharmaceutically acceptable salts thereof and remedies for hepatitis C containing these compds.: I wherein each symbol is as defined in the description. Because of having an effect against hepatitis C virus (HVC) based on an HCV polymerase inhibitory effect, these compds. are useful as remedies or preventives for hepatitis C.

IT 347165-68-8P 480462-40-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(fused cyclic compds. as hepatitis C virus polymerase inhibitors and antiviral agents)


RN 347165-68-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[(4-methoxyphenyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 480462-40-6 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-methyl(methylsulfonyl)amino)[1,1'-biphenyl]-2-yl)methoxy]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RS FORMAT

L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:5773 CAPLUS

DOCUMENT NUMBER: 138:66657

TITLE: Fused cyclic compounds and medicinal use thereof

INVENTOR(S): Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito

PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan

SOURCE: PCT Int. Appl., 603 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000254	A1	20030103	WO 2002-JP6405	20020626
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, GN, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GU, GW, HK, HR, NE, NG, NI, NO, NP, PA, PG, PH, PK, PR, PY, RW, SC, SD, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
JP 2003212846	A2	20030710	JP 2002-185241	20030626
CA 2423800	AA	20030325	CA 2002-2423800	20030626
BR 2002005684	A	20030617	BR 2002-5684	20030626
EP 1400241	A1	20040324	EP 2002-743728	20030626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IR, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001193	A	20040715	ZA 2003-1193	20030626
TR 200300544	T1	20050822	TR 2003-544	20030626
US 2004082635	A1	20040429	US 2003-344997	20030218
NO 2003006032	A	20030422	NO 2003-832	20030221
PRIORITY APPLN. INFO.:				
JP 2001-193786 A 20010626				
JP 2001-351537 A 20011116				
WO 2002-JP6405 W 20020626				

OTHER SOURCE(S): MARPAT 138:66657

GI




● HCl

IT 347174-08-7P, Ethyl 2-[4-[2-(4-Chlorophenyl)-5-methoxybenzyloxy]phenyl]-1-cyclohexylbenzimidazole-5-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(fused cyclic compds. as hepatitis C virus polymerase inhibitors and antiviral agents)

RN 347174-08-7 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-methoxy[1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RS FORMAT

L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002:51438 CAPLUS

DOCUMENT NUMBER: 136:116447

TITLE: Preparation of benzimidazolecarboxylates and related compounds as viral polymerase inhibitors

INVENTOR(S): Beaulieu, Pierre Louis; Fazal, Gulrez; Gillard, James; Kukolj, George; Austel, Volkhard

PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.

SOURCE: PCT Int. Appl., 322 pp.


CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004425	A2	20020117	WO 2001-CA989	20010704
M:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RM:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NG, SN, TD, TO			
US 2002065418	A1	20020530	US 2001-898297	20010703
US 6446281	B2	20020910		
CA 2412718	AA	20020117	CA 2001-2412718	20010704
EP 1301487	A2	20030416	EP 2001-951274	20010704
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004502761	T1	20040129	JP 2002-509292	20010704
US 6479508	B1	20021112	US 2001-995099	20011127
CA 2439176	AA	20020912	CA 2002-2439176	20020306
WO 2002070739	A2	20020912	WO 2002-CA323	20020306
WO 2002070739	A3	20030530		
M:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RM:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GD, GM, ML, MR, NE, NG, SN, TD, TO			
EP 1370682	A2	20031217	EP 2002-712681	20020306
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004520839	T2	20040715	JP 2002-570761	20020306
NZ 526644	A	20050527	NZ 2002-526644	20020306
US 2003232816	A1	20031218	US 2002-232822	20020910
US 6794404	B2	20040921		
US 2004110126	A1	20040610	US 2004-471164	20040205
US 2004224955	A1	20041111	US 2004-851710	20040521
PRIORITY APPLN. INFO.:			US 2000-216084P	P 20000706
			US 2001-274374P	P 20010308
			US 2001-281343P	P 20010405
			US 2001-898297	A3 20010703
			WO 2001-CA989	W 20010704
			US 2001-995099	A3 20011127
			WO 2002-CA323	W 20020306
			US 2002-232822	A1 20020910

OTHER SOURCE(S): MARPAT 136:118447
GI



AB Title compds. [1; X = CH, N; Y = O, S; Z = OH, NH2, NMeR3, NHR3, OR3, 5-6 membered (substituted) heterocyclyl; A = N, COK7, CR3; R5 = H, halo, alkyl; R7 = H, alkyl; X and A are not both N; R6 = H, halo, alkyl, OR7; R7 = H, alkyl; R1 = (substituted) hetero(bi)cyclyl, Ph, phenylalkyl, alkenyl, phenylalkenyl, cycloalkyl, alkyl, CP3; R2 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, bicycloalkyl, adamantyl, Ph, pyridyl; R3 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, alkenyl, cycloalkylalkenyl, arylalkenyl, dialkylamino, heterocyclyl, etc.; n = 0, 1, were prepared. Thus, Me 3-amino-4-cyclohexylaminobenzoate (preparation given), 2-pyridinecarboxaldehyde, and Oxone were stirred in DMF to give 80% 1-cyclohexyl-2-pyridin-2-yl-1H-benzimidazole-5-carboxylate, which was saponified with aqueous NaOH in MeOH to give 91% 1-cyclohexyl-2-pyridin-2-yl-1H-benzimidazole-5-carboxylic acid. The latter inhibited hepatitis C virus RNA dependant polymerase (NS5B) with IC50 = 1-5 µM.

IT 390810-93-2P 390812-47-2P 390815-29-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of benzimidazolecarboxylates and related compds. as viral polymerase inhibitors)

RN 390810-93-2 CAPLUS

CN Benzenebutanoic acid, α-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-4-hydroxy-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 390812-47-2 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-[[[1S]-2-[[[2-(dimethylamino)ethyl]amino]-1-[[4-hydroxyphenyl]methyl]-2-oxoethyl]-2-(3-furanyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 390815-29-9 CAPLUS

CN L-Tyrosine, N-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



LS ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:489367 CAPLUS

DOCUMENT NUMBER: 135:76874

TITLE: Preparation of heterocyclic compounds as remedies for hepatitis C

INVENTOR(S): Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito

PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan

SOURCE: PCT Int. Appl., 438 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGES: Japanese

FAMILY ACC. NUM. COUNT: 3


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047883	A1	20010705	WO 2000-JP9181	20001222
M:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RM:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NG, SN, TD, TO			
CA 2363274	AA	20010705	CA 2000-2363274	20001222
EP 1162196	A1	20011212	EP 2000-987728	20001222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

APPLICANTS AGAIN

IR, SI, LT, LV, FI, RO				
BR 2000008525	A	20020102	BR 2000-8525	20001222
TR 200103147	T1	20020621	TR 2001-3147	20001222
NZ 514403	A	20021025	NZ 2000-514403	20001222
AU 763356	B2	20030717	AU 2001-24017	20001222
RU 2223761	C2	20040220	RU 2001-126283	20001222
CN 1623984	A	20050608	CN 2004-10055872	20001222
NO 2001004134	A	20011022	NO 2001-4134	20010824
US 2003050320	A1	20030313	US 2001-939374	20010824
US 6770666	B2	20040803		
ZA 2001007870	A	20020925	ZA 2001-7870	20010928
US 2004097438	A1	20040520	US 2003-615329	20030708
PRIORITY APPLN. INFO.:			JP 1999-369008	A 19991227
			WO 2000-JP9181	W 20001222
			JP 2000-391904	A 20001225
			JP 2001-193786	A 20010626
			US 2001-939374	A1 20010824

OTHER SOURCE(S): MARPAT 135:76874
GI



AB The title compds. I [the dotted line in rings B1 and B2 indicates a single or double bond; G1 = N, CR1; G2 = N, CR2; G3 = N, CR3; G4 = N, CR4; G5, G6, G8, G9 = C, H; G7 = O, etc.; R1 = R4 = H, nitro, etc.; ring Cy = (un)substituted cycloalkyl ring, etc.; ring A = C3-C8 cycloalkyl, etc. R5, R6 = H, halo, etc.; X = H, cyano, etc.] are prepared. The benzimidazole derivative II in vitro showed IC50 of 0.011 µM against hepatitis C virus polymerase. A formulation is given.

IT 347165-68-8P 347168-00-7P


RL: SAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of heterocyclic compds. as remedies for hepatitis C)


RN 347165-68-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[[4-


methoxyphenyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 347168-00-7 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 2-[5-(3-chlorophenyl)-2-furanyl]-1-cyclopentyl- (9CI) (CA INDEX NAME)



IT 347174-08-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. as remedies for hepatitis C)
RN 347174-08-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-methoxy[1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FILE REG
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE ENTRY 31.12
TOTAL SESSION 36.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY -4.50
TOTAL SESSION -4.50

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 12:11:20 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGTERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8
DICTIONARY FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8

New CAS Information Use Policies, enter HELP USAGTERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> D HIS

(FILE 'HOME' ENTERED AT 12:05:24 ON 25 SEP 2006)

FILE 'REGISTRY' ENTERED AT 12:05:43 ON 25 SEP 2006

L1 STRUCTURE UPLOADED
L2 10 S L1
L3 STRUCTURE UPLOADED
L4 8 S L3

FILE 'CAPLUS' ENTERED AT 12:10:28 ON 25 SEP 2006
6 S L4

FILE 'REGISTRY' ENTERED AT 12:11:20 ON 25 SEP 2006

=> S L4 SSS FULL
FULL SEARCH INITIATED 12:11:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 504916 ITERATE

100.0% PROCESSED 504916 ITERATIONS
SEARCH TIME: 00.00.06

1643 ANSWERS

L6 1643 SEA SSS FUL L3

=> FILE CAPLUS

COST IN U.S. DOLLARS

SINCE FILE ENTRY 166.94
TOTAL SESSION 203.69

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY 0.00
TOTAL SESSION -4.50

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 12:11:39 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGTERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 24 Sep 2006 (20060924/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L6
L7 24 L6

=> S L7 NOT L5
L8 18 L7 NOT L5

=> D 1-18 1818 ABS HITSTR

L8 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:646457 CAPLUS

DOCUMENT NUMBER: 145:224326


TITLE: Benzimidazole Derivatives Bearing Substituted Biphenyls as Hepatitis C Virus NS5B RNA-Dependent RNA Polymerase Inhibitors: Structure-Activity Relationship Studies and Identification of a Potent and Highly Selective Inhibitor JTK-109

AUTHOR(S): Hirashima, Shintaro; Suzuki, Takayoshi; Ishida, Tomio; Noji, Satoru; Yata, Shinji; Ando, Izuru; Komatsu, Masakazu; Ikeda, Satoru; Hashimoto, Hiromasa
CORPORATE SOURCE: Central Pharmaceutical Research Institute, Japan Tobacco Inc., Osaka, 569-1125, Japan
SOURCE: Journal of Medicinal Chemistry (2006), 49(15), 4721-4736

CODEN: JMCMAR; ISSN: 0022-2623
American Chemical Society

PUBLISHER: Journal
DOCUMENT TYPE: Journal
LANGUAGE: English

GI



I

AB Following the discovery of a new series of benzimidazole derivs. bearing a diarylmethyl group as inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase (HCV NS5B RdRp), we extended the structure-activity relationship (SAR) study to analogs bearing a substituted biphenyl group and succeeded in a significant advancement of activity. The compds. efficiently blocked subgenomic viral RNA replication in the replicon cell assay at low submicromolar concns. Among the new compds., JTK-109 (I) exhibited favorable pharmacokinetic profiles, high selectivity for NS5B, and good safety profiles, suggesting the potential for a clin. candidate in the treatment of hepatitis C.

IT 347165-40-6P 347166-63-6P 347166-90-9P

347167-09-3P 347167-15-1P 347167-54-8P

347173-21-1P 347173-34-6P 347173-37-9P

347173-62-0P 347173-63-1P 347173-66-4P

347173-76-6P 347173-93-7P 480460-89-7P

480461-04-9P 480461-08-3P 480461-12-9P

480461-16-3P 480461-28-7P 480461-42-5P

480461-53-8P 480461-74-3P 480461-75-4P

480462-42-8P 480462-43-9P 480462-47-3P

480462-53-1P 501371-90-0P 760936-10-5P

785039-11-4P 789480-83-7P 905459-42-9P

905459-43-0P 905459-44-1P 905459-45-2P

905459-46-3P 905459-47-4P 905459-48-5P

905459-49-6P 905459-50-9P 905459-51-0P

905459-52-1P 905459-53-2P 905459-54-3P


905459-55-4P 905459-56-5P 905459-57-6P

905459-58-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USBS (Uses)
(diarylmethyl benzimidazoles as inhibitors of hepatitis C virus RNA-dependent RNA polymerase)

RN 347165-40-6 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-methoxy[1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)




RN 347166-63-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4-chloro-4'-methoxy[1,1'-biphenyl]-2-yl]methoxy]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)




RN 347166-90-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[5-chloro-2-(3-pyridinyl)phenyl]methoxy]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)




RN 347167-09-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4-carboxy-4'-chloro[1,1'-biphenyl]-2-yl]methoxy]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)



RN 347167-15-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4'-(aminocarbonyl)-4-chloro[1,1'-biphenyl]-2-yl]methoxy]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)




RN 347167-54-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[3-(4-chlorophenyl)-2-pyridinyl]methoxy]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)




RN 347173-21-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4-(aminosulfonyl)-4'-chloro[1,1'-biphenyl]-2-yl]methoxy]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)

NAME)




RN 347173-34-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4-(aminocarbonyl)-4'-chloro[1,1'-biphenyl]-2-yl]methoxy]phenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 347173-37-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4'-chloro-4-[[1-(dimethylamino)carbonyl]-1,1'-biphenyl]-2-yl]methoxy]phenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 347173-62-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4'-chloro-4-[[1-(methylethyl)amino]carbonyl]-1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 347173-63-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4'-chloro-4-[[1-(piperidinyl)carbonyl]-1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 347173-66-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-[(4-hydroxy-1-piperidinyl)carbonyl][1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 347173-76-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-cyano[1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 347173-93-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-[(phenylmethyl)amino]carbonyl][1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 480460-89-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(4,4'-dichloro[1,1'-biphenyl]-2-yl)methoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 480461-04-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chlorophenyl)-2-methyl-5-thiazolyl]methoxy]phenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 480461-08-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-[(methylamino)carbonyl][1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 480461-13-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-[(dimethylamino)carbonyl][1,1'-biphenyl]-2-yl)methoxy]-2-fluorophenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 480461-16-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-[(dimethylamino)carbonyl][1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 480461-28-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-acetyl-4'-chloro[1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 480461-42-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4'-chloro-5-[(dimethylamino)carbonyl][1,1'-biphenyl]-2-yl]methoxy]phenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 480461-53-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4-chloro-4'-cyano[1,1'-biphenyl]-2-yl]methoxy]phenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 480461-74-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4'-chloro-4-[(propylamino)carbonyl][1,1'-biphenyl]-2-yl]methoxy]phenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 480461-75-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4'-chloro-4-[[[(dimethylamino)carbonyl]amino][1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 480462-42-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4-(acetamino)-4'-chloro[1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 480462-43-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4-(acetylethylamino)-4'-chloro[1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 480462-47-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4-(acetylethylamino)-4'-chloro[1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 480462-53-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4-(acetylethylamino)-4'-chloro[1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 501371-90-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-[[4'-chloro-4-(2-oxo-1-pyrrolidinyl)(1,1'-biphenyl)-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-], monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 760936-10-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-[[4'-chloro-4-[[[2-hydroxyethyl]amino]carbonyl](1,1'-biphenyl)-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-], (9CI) (CA INDEX NAME)




RN 785039-11-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-[[4'-chloro-4-(2-methyl-5-pyrimidinyl)methoxy]phenyl]-1-cyclohexyl-], (9CI) (CA INDEX NAME)



RN 789480-83-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-[[4'-chloro-4-(4-morpholinylcarbonyl)(1,1'-biphenyl)-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-], (9CI) (CA INDEX NAME)




RN 905459-42-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 905459-43-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 905459-44-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 905459-45-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 905459-46-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 905459-47-4 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 905459-48-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 905459-49-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 905459-50-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 905459-51-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● 2 HCl


RN 905459-52-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 905459-53-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 905459-54-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 905459-55-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 905459-56-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 905459-57-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




● HCl

RN 905459-58-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



● HCl

IT 347166-08-9
Rb: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diarylmethyl benzimidazoles as inhibitors of hepatitis C virus RNA-dependent RNA polymerase)
RN 347166-08-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-([1,1'-biphenyl]-2-ylmethoxy)phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)




IT 347174-29-2 501371-88-6 808125-98-6
905459-60-1 905459-76-9 905459-77-0
905459-78-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(diarylmethyl benzimidazoles as inhibitors of hepatitis C virus
RNA-dependent RNA polymerase)


RN 347174-29-2 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-[(1,1'-dimethylethoxy)carbonyl][1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, methyl ester (9CI) (CA INDEX NAME)




RN 501371-88-6 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-nitro[1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, methyl ester (9CI) (CA INDEX NAME)




RN 808125-98-6 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-[(1,1'-dimethylethoxy)carbonyl][1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, methyl ester (9CI) (CA INDEX NAME)




RN 905459-60-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 905459-76-9 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 905459-77-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



RN 905459-78-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED



IT 347165-37-1P 347165-39-3P 347173-91-5P

480461-07-2P 480461-15-2P 480462-61-1P


501371-89-7P 905459-61-2P 905459-62-3P

905459-63-4P 905459-64-5P 905459-80-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(diarylmethyl benzimidazoles as inhibitors of hepatitis C virus
RNA-dependent RNA polymerase)


RN 347165-37-1 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(2-bromo-5-chlorophenyl)methoxy]phenyl]-1-cyclohexyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 347165-39-3 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(4,4'-dichloro[1,1'-biphenyl]-2-yl)methoxy]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 347173-91-5 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-[(methyamino)carbonyl][1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, methyl ester (9CI) (CA INDEX NAME)




RN 480461-07-2 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4-carboxy-4'-chloro[1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, 5-methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 480461-15-2 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4-carboxy-4'-chloro[1,1'-biphenyl]-2-yl)methoxy]-2-fluorophenyl]-1-cyclohexyl-, 5-methyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 480462-61-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-(2-oxo-1-pyrrolidinyl)[1,1'-biphenyl]-2-yl)methoxy]-2-fluorophenyl]-1-cyclohexyl-, methyl ester (9CI) (CA INDEX NAME)




RN 501371-89-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4-amino-4'-chloro[1,1'-biphenyl]-2-yl)methoxy]-2-fluorophenyl]-1-cyclohexyl-, methyl ester (9CI) (CA INDEX NAME)




RN 905459-61-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 905459-62-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 905459-63-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 905459-64-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 905459-80-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 2 OF 18 CAPLUS COPYRIGHT 2006 ACS on STM
ACCESSION NUMBER: 2006:180880 CAPLUS
DOCUMENT NUMBER: 144:432742
TITLE: Benzimidazole inhibitors of hepatitis C virus NS5B polymerase: Identification of 2-[(4-diarylmethoxy)phenyl]-benzimidazole
AUTHOR(S): Ishida, Tomio; Suzuki, Takeyoshi; Hirashima, Shintaro; Mizutani, Kenji; Yoshida, Atsuhito; Ando, Isuru; Ikeda, Satoru; Adachi, Tauroshi; Hashimoto, Hiromasa
CORPORATE SOURCE: Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc, Osaka, 569-1125, Japan
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(7), 1859-1863
CODEN: BMCL68; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of 1-cycloalkyl-2-phenyl-1H-benzimidazole-5-carboxylic acid deriva. was synthesized and evaluated for inhibitory activity against hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. A SAR study led to identify the 2-[(4-diarylmethoxy)phenyl]benzimidazoles as potent inhibitors. They inhibit subgenomic HCV RNA replication in the replicon cells at low micromolar concns. (EC50 \approx 1.1 μ M). They are selective against DNA polymerases (IC50 > 10 μ M) and exhibit low cytotoxicity.
IT 347165-42-8P 347165-63-3P 347166-09-0P
347166-42-1P 347166-53-4P 347166-54-5P
347166-68-1P 347166-73-8P 347166-78-3P
347166-79-4P 347173-78-8P 885312-85-6P
885312-86-7P 885312-87-8P 885312-88-9P
885312-89-0P 885312-91-4P 885312-92-5P
885312-93-6P 885312-94-7P 885312-95-8P
885312-96-9P 885312-97-0P 885312-98-1P
885312-99-2P 885313-00-8P 885313-03-1P
885313-04-2P 885313-05-3P 885313-06-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 2-[(4-diarylmethoxy)phenyl]benzimidazoles as potent inhibitors of hepatitis C virus NS5B polymerase)
RN 347165-42-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 347165-63-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4-carboxyphenyl)methoxy]phenyl]-1-cyclopentyl- (9CI) (CA INDEX NAME)




RN 347166-09-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 347166-42-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cycloheptyl-2-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 347166-53-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[bis(4-methylphenyl)methoxy]phenyl]-1-cyclohexyl]- (9CI) (CA INDEX NAME)




RN 347166-54-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[bis(4-fluorophenyl)methoxy]phenyl]-1-cyclohexyl]- (9CI) (CA INDEX NAME)




RN 347166-68-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[bis(4-fluorophenyl)methoxy]-2-fluorophenyl]-1-cyclohexyl]- (9CI) (CA INDEX NAME)




RN 347166-73-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[1,1'-biphenyl]-2-yloxy]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)




RN 347166-76-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-(2-[[1,1'-biphenyl]-2-ylethoxy]phenyl)-1-cyclohexyl]- (9CI) (CA INDEX NAME)




RN 347166-79-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[1,1'-biphenyl]-3-ylmethoxy]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)



RN 347173-78-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[bis(4-(dimethylamino)carbonyl)phenyl)methoxy]-2-fluorophenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)




RN 885312-85-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[[4-(trifluoromethyl)phenyl)methoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885312-86-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[[4-(trifluoromethyl)phenyl)methoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885312-87-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[[4-(1,1-dimethylethyl)phenyl)methoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885312-88-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4-chlorophenyl)methoxy]phenyl]-1-cyclopentyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885312-89-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[(4-methoxyphenyl)methoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885312-91-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(2-chlorophenyl)methoxy]phenyl]-1-cyclopentyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885312-92-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(3-chlorophenyl)methoxy]phenyl]-1-cyclopentyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885312-93-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[(3,5-dichlorophenyl)methoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885312-94-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-[(3,4-dichlorophenyl)methoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885312-95-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(3-phenylpropoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885312-96-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(5-phenylpentyl)oxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885312-97-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(2-phenoxylethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885312-98-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(2,2-diphenylethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885312-99-2 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(1,1'-biphenyl)-2-ylmethoxy]phenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885313-00-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(2-phenylethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885313-03-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(benzylideneamino)oxy]phenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885313-04-2 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(bis(4-fluorophenyl)methoxy)phenyl]-1-cyclohexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 885313-05-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-(diphenylmethoxy)-2-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 885313-06-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[2-fluoro-4-(phenyl-3-pyridinylmethoxy)phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl


IT 347165-51-9P 885312-82-3P 885312-83-4P
885313-01-9P 885313-02-0P 885313-14-4P
885313-15-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-[[4-diarylmethoxy]phenyl]benzimidazoles as potent inhibitors of hepatitis C virus NS5B polymerase)
RN 347165-51-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclopentyl-2-[4-(phenylmethoxy)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 885312-82-3 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-(phenylmethoxy)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 885312-83-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-(phenylmethoxy)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 885313-01-9 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(3-bromophenyl)methoxy]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)




RN 885313-02-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(2-bromophenyl)methoxy]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)



RN 885313-14-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(5-phenylpentyl)oxy]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 885313-15-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-(diphenylmethoxy)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2006 ACS ON STM
ACCESSION NUMBER: 2005:1330561 CAPLUS
DOCUMENT NUMBER: 144:69828
TITLE: Preparation of fused heterocyclic compounds having anti-HCV (hepatitis C virus) activity
INVENTOR(S): Fujishita, Toshio; Abe, Kenji; Naito, Akira; Makino, Itsuo; Matsumoto, Hiroshi; Onodera, Naohiro; Endoh, Takeshi; Iwata, Minko
PATENT ASSIGNER(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 294 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2005121133	A1	20051222	MO 2005-JP10548	20050609
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, GR, GU, HK, HN, ID, IL, IN, JP, KE, KG, KH, KR, KZ, LC, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SL, SM, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,			

AZ, BY, KD, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO

PRIORITY APPL. INFO.: J2 2004-173757 A 20040611
J2 2005-117548 A 20050414
OTHER SOURCE(S): MARPAT 144:69822
OI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Fused heterocyclic compds. represented by the formula (I), pharmaceutically acceptable salts thereof, or solvates of them [A = N or CH; Het = O-Q10; wherein R¹ = H, each (un)substituted alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or CONH₂, CO₂H or its ester; R = each (un)substituted alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or CONH₂, CO₂H or its ester; R² = H, each (un)substituted alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, heterocyclyl, arylcarbonyl, heteroarylcarbonyl, aryloxy, arylthio, arylsulfonyl, or NH₂; R³ = any group listed in R¹, HO, alkylthio, alkylsulfonyl; R⁴ = each (un)substituted alkyl or NH₂, alkenyl, halo, NO₂, alkoxy; p = an integer of 0-3] are prepared. These compds. exhibit antiviral activity against flavivirus, hepacivirus, and pestivirus, preferably HCV, as well as direct inhibitory activity against various enzymes of virus, inhibit replication or proliferation of HCV, and possess excellent metabolic stability, CYP (cytochrome P 450) inhibition, and solubility. They are useful as anti-HCV agents and therapeutic agents for hepatitis C. Thus, 303 mg 1-cyclohexyl-2-(furan-3-yl)-1H-benzimidazole-5-carboxylic acid was dissolved in 3 mL DMF, successively treated with 486 mg HOBT and 690 mg EDC at room temperature, stirred for 30 min, cooled to -50°, successively treated with 680 mg 2-amino-4'-chloroacetophenone hydrochloride and 1.05 mL Et₃N, warmed to room temperature, stirred for 1 h to give, after workup and silica gel chromatog., 560 mg 1-cyclohexyl-2-(furan-3-yl)-1H-benzimidazole-5-carboxylic acid N-[2-(4-chlorophenyl)-2-oxoethyl]amide (II). A solution of 84 mg II in 0.6 mL POCl₃ was stirred at 100° for 1 h and 110° for 2 h to give, after silica gel chromatog., 54 mg 5-[5-(4-chlorophenyl)oxazol-2-yl]-1-cyclohexyl-2-(furan-3-yl)-1H-benzimidazole which was converted into the dihydrochloride salt (III). In a replicon cell assay, III showed IC₅₀ of 50.1 µM against HCV subgenomic 1b-N replicon cells.

IT 871928-52-6P 871930-32-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of fused heterocyclic compds. as anti-HCV (hepatitis C virus) agent)


RN 871928-52-6 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[2-(4-chlorophenyl)-2-oxoethyl]-1-cyclohexyl-2-(3-furanyl)- (9CI) (CA INDEX NAME)

followed by mass spectrometry anal. of the enzyme. A novel binding site has been localized for these inhibitors at the junction of the thumb domain and the N-terminal finger loop. Furthermore, the isolation and characterization of resistant replicon mutants that co-localize to this region distinguished this class of compds. from other non-nucleoside NS5B inhibitors that bind to distinct allosteric sites. Resistant mutations that emerged with the benzimidazole-5-carboxamide and related compds. were found at three amino acid positions in the thumb domain: Pro495 with substitutions to Ser, Leu, Ala, or Thr; Pro496 substitutions to Ser or Ala; and a V499A substitution. Mutations at each of these positions conferred different levels of resistance to this drug class: the Pro495 changes provided the greatest shifts in compound potency, followed by moderate changes in potency with the Pro496 substitutions, and finally only minor shifts in potency with V499A. Combinations that include the benzimidazole 5-carboxamide polymerase inhibitors and compds. that bind other sites or other HCV targets, including HCV protease inhibitors, are complementary in cell culture models of HCV RNA replication at suppressing the emergence of resistant variants. This novel class of compds. and unique binding site expand the diversity of HCV antivirals currently under development and offer the potential to improve the treatment of chronic HCV infection.



IT 390810-32-9 491583-88-1
RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitor-binding site and resistance to non-nucleoside inhibitors of hepatitis C virus NS5B polymerase)
RN 390810-32-9 CAPLUS
CN L-Tryptophan, N-[2-(4-[2-[[2-((4-benzoylbenzoyl)amino)ethyl]amino]-2-oxoethoxy]phenyl]-1-cyclohexyl-1H-benzimidazol-5-yl)carbonyl]-5-(carboxymethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



RN 871930-32-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-(3-furanyl)-, 2-[[4-(fluorophenyl)acetyl]hydrazide] (9CI) (CA INDEX NAME)




REFERENCE COUNT: 83 THERE ARE 83 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2006 ACS ON STM
ACCESSION NUMBER: 2005:1235073 CAPLUS
DOCUMENT NUMBER: 144:123735
TITLE: Binding Site Characterization and Resistance to a Class of Non-nucleoside Inhibitors of the Hepatitis C Virus NS5B Polymerase
AUTHOR(S): Kulolj, George; McGibbon, Graham A.; McKercher, Ginette; Marquis, Martin; Lafabvre, Sylvain; Thauvette, Louise; Gauthier, Jean; Goulet, Sylvie; Poupart, Marc-Andre; Beaulieu, Pierre L.
CORPORATE SOURCE: Departments of Biological Sciences and Chemistry, Research and Development, Boehringer Ingelheim, Ltd., Laval, QC, H7S 2G5, Can.
SOURCE: Journal of Biological Chemistry (2005), 280(47), 39260-39267
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The virally encoded NS5B RNA-dependent RNA polymerase has emerged as a prime target in the search for specific HCV antivirals. A series of benzimidazole 5-carboxamide compds. inhibit the cellular RNA replication of a HCV subgenomic replicon, and we have advanced our understanding of this class of inhibitors through a combination of complementary approaches that include biochem. crosslinking expts. with a photoreactive analog

RN 491583-88-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2006 ACS ON STM
ACCESSION NUMBER: 2005:410483 CAPLUS
DOCUMENT NUMBER: 143:91635
TITLE: Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay
AUTHOR(S): Ludmerer, Steven W.; Graham, Donald J.; Boots, Evelyn; Murray, Edward M.; Simcoe, Amy; Markel, Eric J.; Grobler, Jay A.; Flores, Osvaldo A.; Olsen, David B.; Hazuda, Daria J.; LaPerna, Robert L.
CORPORATE SOURCE: Department of Antiviral Research, Merck Research Laboratories, West Point, PA, 19486, USA
SOURCE: Antimicrobial Agents and Chemotherapy (2005), 49(5), 2059-2069
CODEN: AACCCQ; ISSN: 0066-4804
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The innate genetic variability characteristic of chronic hepatitis C virus (HCV) infection makes drug resistance a concern in the clin. development of HCV inhibitors. To address this, a transient replication assay was developed to evaluate the replication fitness and the drug sensitivity of NS5B sequences isolated from the sera of patients with chronic HCV infection. This novel assay directly compares replication between NS5B isolates, thus bypassing the potential sequence and metabolic differences which may arise with independent replicon cell lines. Patient-derived NS5B sequences were similar to those of the established HCV genotypes, but isolates from each patient shared genetic variability specific to that patient, with addnl. genetic variability observed across the individual isolates. Every sample provided functional NS5B isolates which supported subgenomic replication, frequently to levels comparable to that of laboratory-optimized replicons. All isolates were equivalently sensitive to an active-site nucleoside inhibitor, but the sensitivities to a panel of nonnucleoside inhibitors which targeted three distinct sites on NS5B varied among the isolates. In concl, the original laboratory-optimized replicon, the NS5B S282T substitution confers resistance to the nucleoside inhibitor but impairs replication. This substitution was engineered into both genotype 1a and genotype 1b isolates. Replication was severely

debilitated, demonstrating that no compensatory residues were encoded within these genetically diverse sequences to increase the replication fitness of the mutated replicase. This work describes a transient replicon-based assay that can support the clin. development of compds. which target NS5B and demonstrates its utility by examining several patient-derived NS5B isolates for replication fitness and differential sensitivity to NS5B inhibitors.

IT 658693-60-8
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay)

RN 658693-60-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-[(4-hydroxy-1-piperidinyl)carbonyl][1,1'-biphenyl]-2-yl)methoxy]-2-fluorophenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2005:106895 CAPLUS
DOCUMENT NUMBER: 142:328921
TITLE: Development and Preliminary Optimization of Indole-N-Acetylamide Inhibitors of Hepatitis C Virus NS5B Polymerase
AUTHOR(S): Harper, Steven; Pacini, Barbara; Avolio, Salvatore; Di Filippo, Marcello; Migliacetto, Giovanni; Laufer, Ralph; De Francesco, Raffaele; Rowley, Michael; Narjes, Frank
CORPORATE SOURCE: IRBM, Merck Research Laboratories Rome, Pomezia, Rome, 00040, Italy
SOURCE: Journal of Medicinal Chemistry (2005), 48(5), 1314-1317
CODEN: JMCMAJ; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:328921
AB Allosteric inhibition of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase enzyme has recently emerged as a viable strategy toward blocking replication of viral RNA in cell-based systems. We report here a

novel class of allosteric inhibitor of NS5B that shows potent affinity for the NS5B enzyme and effective inhibition of subgenomic HCV RNA replication in Huh-7 cells. Inhibitors from this class have promising characteristics for further development as anti-HCV agents.

IT 658693-60-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(indoleacetamide inhibitors of hepatitis C virus NS5B polymerase)

RN 658693-60-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-chloro-4-[(4-hydroxy-1-piperidinyl)carbonyl][1,1'-biphenyl]-2-yl)methoxy]-2-fluorophenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2005:67469 CAPLUS
DOCUMENT NUMBER: 142:309250
TITLE: Inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors
AUTHOR(S): Ma, Han; Leveque, Vincent; De Witte, Anniek; Li, Weixing; Hendricks, Than; Clausen, Sandra M.; Cammack, Nick; Klump, Klaus
CORPORATE SOURCE: Roche Palo Alto LLC, Palo Alto, CA, 94304, USA
SOURCE: Virology (2005), 332(1), 8-15
CODEN: VIRLAX; ISSN: 0042-6822
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A number of nucleotide and non-nucleoside inhibitors of HCV polymerase are currently under investigation as potential antiviral agents to treat HCV-infected patients. HCV polymerase is part of a replicase complex including the polymerase subunit NS5B together with other viral and host proteins and viral RNA. The RNA synthesis activity of the native replicase complex was inhibited by 3'-deoxy-CTP, a chain-terminating nucleotide analog, but not inhibited by non-nucleoside NS5B polymerase inhibitors of three different structural classes. The HCV replicase was also resistant to heparin, a broad-spectrum, RNA-competitive polymerase inhibitor. Prebinding of the recombinant NS5B protein with a RNA template rendered the polymerase largely resistant to the inhibition by heparin and the non-nucleoside inhibitors, but did not affect the inhibitory potency of 3'-deoxy-CTP. Therefore, the HCV replicase showed a similar pattern of

inhibitor sensitivity as compared to RNA-bound NS5B. These results suggest that the native HCV replicase complex represents a stable and productive polymerase-RNA complex. The allosteric non-nucleoside NS5B polymerase inhibitors are inactive against established HCV replicase but may function antagonistically with the formation of a productive enzyme-template complex.

IT 347167-03-7
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of native hepatitis C virus replicase by nucleotide and non-nucleoside inhibitors)

RN 347167-03-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[(4'-acetamido-4'-chloro[1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2004:1080873 CAPLUS
DOCUMENT NUMBER: 142:56309
TITLE: Preparation of substituted imidazole derivatives as antiviral agents
INVENTOR(S): Roberts, Christopher Don; Shi, Dong-Fang; Griffith, Ronald Conrad
PATENT ASSIGNEE(S): Genelabs Technologies, Inc., USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108087	A2	20041216	WO 2004-0517856	20040604
WO 2004108087	A3	20050825		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BM, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, BO, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GN, GW, GM, ML, MR, NE, SH, TD, TG			
AU 2004245559	A1	20041216	AU 2004-245559	20040604

CA 2528044 AA 20041216 CA 2004-2528044 20040604
US 2005154040 A1 20050714 US 2004-861765 20040604
EP 1631554 A2 20060308 EP 2004-776308 20040604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, KG, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
BR 2004010967 A 20060704 BR 2004-10967 20040604
CN 1798740 A 20060705 CN 2004-80015278 20040604
NO 2005006100 A 20060301 NO 2005-6100 20051221
PRIORITY APPLN. INFO.: US 2003-476141P P 20030604
WO 2004-0517856 W 20040604
OTHER SOURCE(S): MARPAT 142:56309
OI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. represented by the formula I (wherein R1 = (un)substituted alkoxy or amino; R2, R12 = independently H, (un)substituted (cyclo)alkyl, alkenyl, aryl, etc.; R2R12 = (un)substituted (hetero)cyclic ring; R3 = H or alkyl; R2R3 = (un)substituted (hetero)cyclic ring; R4 = halo, nitro, (un)substituted amino, cyano, hydroxyl; Q = O, SO, NR3; n = 0-2; X = O, S, NR11; R11 = H or alkyl; R5 = (un)substituted alkylene; R6 = (un)substituted (hetero)aryl; n = 0-3; and pharmaceutically acceptable salts thereof) were prepared as antiviral agents. For example, II was given in a multi-step synthesis starting from Me 4-chloro-3-nitrobenzoate. The pharmaceutical formulation comprising the compound I is disclosed. I and their pharmaceutical compns. are useful as antiviral agents for the treatment of Flaviviridae family virus infections, such as Hepatitis C virus (no date).

IT 808125-93-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted indazole derivs. for treatment of Flaviviridae family virus infections)

RN 808125-93-1 CAPLUS
CN L-Tryptophan, N-[(1-cyclohexyl-2-[4-(phenylmethoxy)phenyl]-1H-benzimidazol-5-yl)carbonyl]-5-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT 808125-89-5P 808125-90-8P 808125-91-9P
808125-92-0P 808125-94-2P 808125-96-4P
808126-11-6P 808126-13-8P 808126-15-0P
808126-17-2P 808126-19-4P 808126-21-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Uses)

(preparation of substituted imidazole deriva. for treatment of Flaviviridae family virus infections)


RN 808125-89-5 CAPLUS
CN L-Tryptophan, N-[[2-[4-[[4-(aminocarbonyl)-4'-chloro[1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-1H-benzimidazol-5-yl]carbonyl]-5-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


PAGE 1-B



RN 808125-90-8 CAPLUS
CN L-Tryptophan, N-[[2-[4-[[4'-chloro-4-[(4-hydroxy-1-piperidinyl)carbonyl]phenyl]methoxy]-2-fluorophenyl]-1-cyclohexyl-1H-benzimidazol-5-yl]carbonyl]-5-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B



RN 808125-91-9 CAPLUS
CN L-Tryptophan, N-[[2-[4-[[2-bromo-5-[(4-hydroxy-1-piperidinyl)carbonyl]phenyl]methoxy]-2-fluorophenyl]-1-cyclohexyl-1H-benzimidazol-5-yl]carbonyl]-5-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



● HCl


PAGE 1-B



RN 808125-92-0 CAPLUS
CN L-Tryptophan, N-[[1-cyclohexyl-2-[2-fluoro-4-[[3-[(4-hydroxy-1-piperidinyl)carbonyl]phenyl]methoxy]phenyl]-1H-benzimidazol-5-yl]carbonyl]-5-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




● HCl

PAGE 1-B




RN 808125-94-2 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[(1S)-2-amino-1-[(5-hydroxy-1H-indol-3-yl)methyl]-2-oxoethyl]-1-cyclohexyl-2-[4-(phenylmethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 808125-96-4 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[2-[4-[[4-(aminocarbonyl)-4'-chloro[1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 808126-11-6 CAPLUS
CN L-Tryptophan, N-[[1-cyclohexyl-2-[4-(phenylmethoxy)phenyl]-1H-benzimidazol-5-yl]carbonyl]-5-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 808126-13-8 CAPLUS
CN L-Tryptophan, N-[[2-[4-[[4-(aminocarbonyl)-4'-chloro[1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-1H-benzimidazol-5-yl]carbonyl]-5-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




RN 808126-15-0 CAPLUS
CN L-Tryptophan, N-[[2-[4-[[2-bromo-5-[(4-hydroxy-1-piperidinyl)carbonyl]phenyl]methoxy]-2-fluorophenyl]-1-cyclohexyl-1H-benzimidazol-5-yl]carbonyl]-5-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A

Br




PAGE 1-B




RN 808126-17-2 CAPLUS
CN L-Tryptophan, N-[[1-cyclohexyl-2-[2-fluoro-4-[[1-[(4-hydroxy-1-piperidinyl)carbonyl]phenyl]methoxy]phenyl]-1H-benzimidazol-5-yl]carbonyl]-5-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 808126-19-4 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[(1S)-2-amino-1-[(5-hydroxy-1H-indol-3-


yl)methyl]-2-oxoethyl]-1-cyclohexyl-2-[4-(phenylmethoxy)phenyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 808126-21-8 CAPLUS
CN L-Tryptophan, N-[[2-[4-[[4'-chloro-4-[(4-hydroxy-1-piperidinyl)carbonyl][1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-1H-benzimidazol-5-yl]carbonyl]-5-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B




IT 347166-09-0P 503859-29-8P 658693-60-8P
755744-19-5P 773050-52-5P 808125-97-5P
808125-98-6P 808125-99-7P 808126-00-3P

808126-01-4P 808126-02-5P 808126-03-6P


808126-04-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted imidazole deriva. for treatment of Flaviviridae family virus infections)


RN 347166-09-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 503859-29-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-(phenylmethoxy)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 658693-60-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4'-chloro-4-[(4-hydroxy-1-piperidinyl)carbonyl][1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)




RN 755744-19-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4-(aminocarbonyl)-4'-chloro[1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)




RN 773050-52-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4-carboxy-4'-chloro[1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-, 5-methyl ester (9CI) (CA INDEX NAME)




RN 808125-97-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[2-bromo-5-[(1,1-dimethylethoxy)carbonyl]phenyl]methoxy]-2-fluorophenyl]-1-cyclohexyl-, methyl ester (9CI) (CA INDEX NAME)



RN 808125-98-6 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4'-chloro-4-[(1,1-dimethylethoxy)carbonyl][1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-, methyl ester (9CI) (CA INDEX NAME)




RN 808125-99-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4-(aminocarbonyl)-4'-chloro[1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-, methyl ester (9CI) (CA INDEX NAME)




RN 808126-00-3 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4'-chloro-4-[(4-hydroxy-1-piperidinyl)carbonyl][1,1'-biphenyl]-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-, methyl ester (9CI) (CA INDEX NAME)



RN 808126-01-4 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[2-bromo-5-[(4-hydroxy-1-piperidinyl)carbonyl]phenyl]methoxy]-2-fluorophenyl]-1-cyclohexyl-, methyl ester (9CI) (CA INDEX NAME)




RN 808126-02-5 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[2-bromo-5-[(4-hydroxy-1-piperidinyl)carbonyl]phenyl]methoxy]-2-fluorophenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)




RN 808126-03-6 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[[3-[(1,1-dimethylethoxy)carbonyl]phenyl]methoxy]-2-fluorophenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 808126-04-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[2-fluoro-4-[[3-[(4-hydroxy-1-piperidinyl)carbonyl]phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:747614 CAPLUS

DOCUMENT NUMBER: 141:374419

TITLE: Drug design: Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategy

AUTHOR(S): LePlante, Steven R.; Jakalian, Araz; Aubry, Norman; Bousquet, Yves; Ferland, Jean-Marie; Gillard, James; Lefebvre, Sylvain; Poirier, Martin; Tsantrizos, Youla S.; Kukolj, George; Beaulieu, Pierre L.

CORPORATE SOURCE: Research and Development, Departments of Chemistry and Biological Sciences, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S2G5, Can.

SOURCE: Angewandte Chemie, International Edition (2004), 43(33), 4306-4311

CODEN: ACHIEP; ISSN: 1433-7851

Wiley-VCH Verlag GmbH & Co. KGaA

PUBLISHER: Journal

DOCUMENT TYPE: English

LANGUAGE: English


AB A novel strategy involving NMR, medicinal chemical, and mol. modeling is described for determining the binding mode of ligands and the binding roles of their substituents. The first solution structure of an inhibitor bound to hepatitis C virus (HCV) polymerase provides practical information for the rational design of potential therapeutics against HCV infections.

IT 390811-66-2 669070-60-4


RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (drug design and binding mode determination of benzimidazole inhibitors of

hepatitis C virus RNA polymerase by a structure and dynamics strategy)
 RN 390811-66-2 CAPLUS
 CN L-Tyrosine, 3-[(1E)-2-carboxyethenyl]-N-[(1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 669070-60-4 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-[4-{2-[(3-(dimethylamino)propyl)amino]-2-oxoethoxy}phenyl]- (9CI) (CA INDEX NAME)



PAGE 1-B

—(CH₂)₃—NMe₂


REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 10 OF 18 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2004:633560 CAPLUS
 DOCUMENT NUMBER: 141:174170
 TITLE: A preparation of heterocyclic compounds, useful as inhibitors of RNA dependent RNA polymerases, such as hepatitis C virus polymerase
 INVENTOR(S): Poupart, Marc-Andre; Beaulieu, Pierre Louis; Rancourt,

Patent Assignee(s): Jean Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co Kg
 SOURCE: PCT Int. Appl., 77 pp.
 CODEN: PIKX22
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064925	A1	20040805	WO 2004-CA17	20040119
N: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GR, HE, GM, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MU, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RU, SA, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SW, SY, SZ, TD, TH, TJ, TM, TR, TT, TZ, UA, UG, UZ, VC, VE, VU, WG, WI, WO, WS, XG, YU, ZA, ZM, ZW				
US 2004186125	A1	20040923	US 2004-755544	20040112
US 7098231	B2	20060829		
CA 2511301	AA	20040805	CA 2004-2511301	20040119
EP 1587585	A1	20051026	EP 2004-703128	20040119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, SI, SK, TR, UA, US, ZA, ZM, ZW				
JP 2006515364	T2	20060525	JP 2006-500428	20040119
US 2006189672	A1	20060824	US 2006-405144	20060417
PRIORITY APPLN. INFO.: US 2003-441674P P 20030122				
US 2004-755544 A1 20040112				
WO 2004-CA17 W 20040119				


OTHER SOURCE(S): MARPAT 141:174170
 GI




II

AB The invention relates to a preparation of heterocyclic compds. of formula I [wherein: R1 is (cyclo)alkyl, cycloalkenyl, 4 to 7-membered heterocyclic ring, etc.; R2 is halogen or (un)substituted (hetero)aryl; S is N and A is (CH₂)_n or (CH₂)_n-etc.; B is (C and A is O, S, or NH, etc.; M1 and M2 are independently selected from CR3; M3 and M4, when not linked to -C(Y)Z, is CR3; R3 is H, halogen, CN, or azido, etc.], useful as inhibitors of RNA dependent RNA polymerases, particularly those viral polymerases within Flaviviridae family, more particularly to hepatitis C virus (HCV) polymerase. For instance, HCV RNA dependent RNA polymerase inhibition of pyridinylindole derivative II was determined (compound 101, table 1; IC50 < 1μM).


IT 733035-45-5P 733035-46-6P 733035-48-8P
 733035-50-2P 733035-51-3P 733035-53-5P
 733035-54-6P 733035-56-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclic compds., useful as inhibitors of RNA dependent RNA polymerases)
 RN 733035-45-5 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-cyclopentyl-N-(phenylsulfonyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 733035-46-6 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-(phenylsulfonyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 733035-48-8 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-[(2,5-dimethoxyphenyl)sulfonyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 733035-50-2 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-cyclopentyl-N-[(2,5-dimethoxyphenyl)sulfonyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 733035-51-3 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-cyclopentyl-2-(3-furanyl)-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 733035-53-5 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-cyclopentyl-N-[(2,5-dimethoxyphenyl)sulfonyl]-2-(3-furanyl)- (9CI) (CA INDEX NAME)



RN 733035-54-6 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-2-(3-furanyl)-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 733035-56-8 CAPLUS
 CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-[(2,5-dimethoxyphenyl)sulfonyl]-2-(3-furanyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LA ANSWER 11 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:143100 CAPLUS
 DOCUMENT NUMBER: 140:199315
 TITLE: Preparation of iminothiazolidinone amino acid derivatives as inhibitors of HCV replication
 INVENTOR(S): Romine, Jeffrey Lee; Martin, Scott W.; Snyder, Lawrence B.; Serrano-Wu, Michael; Deshpande, Milind; Whitehouse, Darren; Lemm, Julie; O'Boyle, Donald; Gao, Min; Colonna, Richard
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 127 pp.
 CODEN: PIKX2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014852	A2	20040219	WO 2003-US24717	20030808
WO 2004014852	A3	20040432		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, SP, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003261434	A1	20040225	AU 2003-261434	20030808
US 2005069522	A1	20050331	US 2003-637156	20030808
US 2005096364	A1	20050505	US 2003-637099	20030808
PRIORITY APPLN. INFO.:			US 2002-402661P	P 20020812
			US 2002-403694P	P 20020815
			WO 2003-US24717	W 20030808

OTHER SOURCE(S): MARPAT 140:199315

OI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compound I [R1 = C1-C6 alkyl, C3-C7 cycloalkyl, C6-C10 aryl, C1-C6 alkoxy, C6-C10 aryloxy, C6-C10 aryl(C1-C6)alkyl, C6-C10 aryl(C1-C6)alkoxy, etc.; R2, R3 = independently C1-C6 alkyl, C3-C7 cycloalkyl, C6-C10 aryl, C1-C6 alkoxy, C6-C10 aryloxy, heterocyclyl, C6-C10 aryl(C1-C6)alkyl, C6-C10 aryl(C1-C6)alkoxy, etc., with the proviso that one of R2 or R3 can be a bond and R2 and R3 are joined to form a cyclic structure; R4 = C1-C4

LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, SP, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003264038 A1 20040225 AU 2003-264038 20030808
 US 2005069522 A1 20050331 US 2003-637156 20030808
 US 2005096364 A1 20050505 US 2003-637099 20030808
 PRIORITY APPLN. INFO.:

US 2002-402661P P 20020812
 US 2002-403694P P 20020815
 WO 2003-US25036 W 20030808

OTHER SOURCE(S): MARPAT 140:199742


OI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Disclosed are combination pharmaceutical agents for the treatment of an HCV infection comprising a compound which is effective in inhibiting the function of the HCV NS5A protein and another compound having anti-HCV activity. Comps. which can inhibit the function of the NS5A protein have structure I [R1, R2, R3 are (cyclo)alkyl, aryl, alkoxy, aryloxy, arylalkyl, etc.; R4 is alkyl, optionally substituted by halogen, oxygen, or nitrogen; R2/R3 and R4/R5 can form rings] or their pharmaceutically-acceptable salt or prodrugs. Comps. having anti-HCV activity are selected from HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, etc. Thus, compound II was prepared by reaction of 5-(4-aminophenyl)-2-[(3-fluorophenyl)imino]-3-(furan-2-ylmethyl)thiazolidin-4-one (preparation given) with N-(benzyloxycarbonyl)-L-alanyl chloride (Cbz-L-Ala-Cl) and showed EC50 = 0.1-1 µM in the HCV replicon cell line assay.

IT 491583-42-7 CAPLUS
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of iminothiazolidinone amino acid derivs. as combination pharmaceutical agents for use as inhibitors of HCV replication)
 RN 491583-42-7 CAPLUS
 CN 2-Propenoic acid, 3-[[4-[[[1-[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



alkyl, optionally substituted with 1-3 halo, 1-3 oxygen, or 1-3 nitrogen, said R4 having an S stereoconfiguration; R5 = H or a bond wherein R4 and R5 are joined to form a cyclic structure] were prepared as inhibitors of HCV replication. Thus, reaction of 5-(4-aminophenyl)-2-(3-fluorophenylimino)-3-furan-2-ylmethylthiazolidin-4-one (preparation given) with N-benzyloxycarbonyl-L-alanyl chloride gave compound II. The prepared comds. were assayed for the inhibition of HCV replicon cell line and were classified with activity of EC50 < 0.1 µM, 0.1 µM ≤ EC50 ≤ 1 µM, 1 µM ≤ EC50 ≤ 5 µM, or EC50 ≥ 5 µM.

IT 491583-42-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of iminothiazolidinone amino acid derivs. as inhibitors of HCV replication in co-administration with)
 RN 491583-42-7 CAPLUS
 CN 2-Propenoic acid, 3-[[4-[[[1-[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



LA ANSWER 12 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:142910 CAPLUS
 DOCUMENT NUMBER: 140:199742

TITLE: Preparation of iminothiazolidinone amino acid derivatives as combination pharmaceutical agents for use as inhibitors of HCV replication
 INVENTOR(S): Romine, Jeffrey Lee; Martin, Scott W.; Snyder, Lawrence B.; Serrano-Wu, Michael; Deshpande, Milind; Whitehouse, Darren
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 129 pp.
 CODEN: PIKX2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014313	A2	20040219	WO 2003-US25036	20030808
WO 2004014313	A3	20051215		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,			

LA ANSWER 13 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:106793 CAPLUS
 DOCUMENT NUMBER: 140:387701
 TITLE: Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate
 AUTHOR(S): McKercher, Gilette; Beaulieu, Pierre L.; Lamer, Daniel; LePlante, Steven; Lefebvre, Sylvain; Pellerin, Charles; Thauvette, Louise; Kukolj, George
 CORPORATE SOURCE: R&D, Department of Biological Sciences, Boehringer Ingelheim Canada Ltd., Laval, QC, H7S 2G5, Can.
 SOURCE: Nucleic Acids Research (2004), 32(2), 422-431
 CODEN: NARHAD; ISSN: 0305-1048
 PUBLISHER: Oxford University Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The interaction of the hepatitis C virus (HCV) RNA-dependent RNA polymerase with RNA substrate is incompletely defined. The authors have characterized the activities of the HCV NS5B polymerase, modified by different deletions and affinity tags, with a routinely used homopolymeric substrate, and established apparent affinities of the various NS5B constructs both for the NTP and the template/primer substrates. The authors identified a uniquely tagged HCV NS5B RNA polymerase construct with a lower affinity (higher Km) than mature HCV NS5B for template/primer substrate and highlighted the use of such a polymerase for the identification of inhibitors of NS5B activity, particularly inhibitors of productive RNA binding. The characterization of specific benzimidazole-5-carboxamide-based inhibitors, identified in a screening campaign, revealed that this class of comds. was non-competitive with regard to NTP incorporation and had no effect on processive elongation, but inhibited an initiation phase of the HCV polymerase activity. The potency of these comds. vs. a panel of different NS5B polymerase constructs was inversely proportional to the enzymes' affinities for template/primer substrate. The benzimidazole-5-carboxamide comds. also inhibited the full-length, untagged NS5B de novo initiation reaction using HCV 3'-UTR substrate RNA and expand the diversifying pool of potential HCV replication inhibitors.


IT 390810-78-3 390810-83-0 390810-89-6
 669070-60-4
 RL: RSU (Biological study, unclassified); BIOL (Biological study) (inhibitors of hepatitis C virus RNA-dependent RNA polymerase NS5B with lower affinity for template/primer substrate inhibition by benzimidazole-5-carboxamide-based inhibitors)
 RN 390810-78-3 CAPLUS
 CN Benzenecarboxic acid, α-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-3,4-dimethoxy-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 390810-83-0 CAPLUS
 CN L-Tyrosine, N-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 390810-89-6 CAPLUS
CN L-Tyrosine, O-((carboxymethyl)-N-[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 669070-60-4 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-[[2-(3,4-dimethoxyphenyl)ethyl]-2-(4-{2-[[3-(dimethylamino)propyl]amino]-2-oxoethoxy]phenyl}- (9CI) (CA INDEX NAME)



PAGE 1-A

PAGE 1-B

-(CH₂)₃-NMe₂

REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LE ANSWER 14 OF 18 CAPLUS COPYRIGHT 2006 ACS on STM

ACCESSION NUMBER: 2004:99289 CAPLUS

DOCUMENT NUMBER: 140:296868

TITLE: Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency

AUTHOR(S): Beaulieu, Pierre L.; Boes, Michael; Bousquet, Yves; DeRoy, Patrick; Fazal, Gulrez; Gauthier, Jean; Ollard, James; Ouellet, Sylvie; McKercher, Ginette; Poupard, Marc-Andre; Valois, Serge; Kukolj, George
CORPORATE SOURCE: Research and Development, Department of Chemistry, Boehringer Ingelheim (Canada) Ltd., Laval, QC, 2100, Can.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(4), 967-971
CODEN: BMCLEB; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 140:296868

AB Optimization of benzimidazole 5-carboxamide deriva. previously identified as specific inhibitors of the NS5B polymerase of the hepatitis C virus (HCV) has led to the discovery of potent analogs that inhibit the enzyme at low-nanomolar concns. Greater than 800-fold improvement in potency from the original lead structure was achieved through the combined effects of conformational rigidification, mol. size extension and the identification of previously unexploited interactions. Furthermore, these inhibitors retain specificity for HCV polymerase relative to other viral and mammalian RNA polymerases.

IT 390810-78-3P 390810-83-0P 390812-20-1P

390814-22-9P 390814-23-0P 390814-36-5P

390814-37-6P 390814-48-9P 676618-19-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(benzimidazole 5-carboxylic amide deriva. as inhibitors of hepatitis C virus NS5B polymerase)

RN 390810-78-3 CAPLUS

CN Benzeneacetic acid, α -[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-3,4-dimethoxy-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 390810-83-0 CAPLUS


CN L-Tyrosine, N-[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 390812-20-1 CAPLUS
CN L-Phenylalanine, N-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 390814-22-9 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-[[1S]-1-(3,4-dimethoxyphenyl)ethyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 390814-23-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-[[1R]-1-(3,4-dimethoxyphenyl)ethyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 390814-36-5 CAPLUS

CN Benzeneacetic acid, α -[[[1-cyclohexyl-2-(2-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]amino]-3,4-dimethoxy-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 390814-37-6 CAPLUS


CN L-Tyrosine, N-[[1-cyclohexyl-2-(2-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 390814-48-9 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-[[1S]-1-(3,4-dimethoxyphenyl)methyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 676618-19-2 CAPLUS
CN L-Phenylalanine, N-[[1-(cyclohexyl)-2-(2-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:981461 CAPLUS
DOCUMENT NUMBER: 140:246106
TITLE: Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives
AUTHOR(S): Beaulieu, Pierre L.; Bos, Michael; Bousquet, Yves; Fazal, Oulrez; Gauthier, Jean; Gillard, James; Goulet, Sylvie; Laplante, Steven; Poupart, Marc-Andre; Lefebvre, Sylvain; McKercher, Ginette; Pellerin, Charles; Austel, Volkhard; Kukolj, George
CORPORATE SOURCE: Department of Chemistry, Research and Development, Boehringer Ingelheim (Canada) Ltd., Laval, QC, H7S 2G5, Can.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(1), 119-124
CODEN: BMCL58; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:246106
AB Benzimidazole 5-carboxamide derive. from a combinatorial screening library were discovered as specific inhibitors of the NS5B polymerase of the hepatitis C virus (HCV). Initial hit-to-lead activities taking advantage of high-throughput parallel synthetic techniques, identified a 1,2-disubstituted benzimidazole 5-carboxylic acid scaffold as the min. core for biol. activity. Potent analogs in this series inhibit the polymerase at low micromolar concns. and provide an attractive 'drug-like' lead structure for further optimization and the development of potential HCV therapeutics.



RN 669070-61-5 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-[[1-(3,4-dimethoxyphenyl)ethyl]carbonyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:970508 CAPLUS
DOCUMENT NUMBER: 140:174511
TITLE: Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase
AUTHOR(S): Tomei, Lucia; Altamura, Sergio; Bartholomew, Linda; Siroccio, Antonino; Ceccacci, Alessandra; Pacini, Laura; Marjes, Frank; Gennari, Nadia; Bisbocci, Monica; Incitti, Ilario; Orsatti, Laura; Harper, Steven; Stensfield, Ian; Rowley, Michael; De Francesco, Raffaele; Migliaccio, Giovanni
CORPORATE SOURCE: Istituto di Ricerche di Biologia Molecolare "P. Angeletti", Pomezia-Rome, 00040, Italy
SOURCE: Journal of Virology (2003), 77(24), 13225-13231
CODEN: JOVIAH; ISSN: 0022-538X
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The RNA-dependent RNA polymerase of hepatitis C virus (HCV) is the catalytic subunit of the viral RNA amplification machinery and is an appealing target for the development of new therapeutic agents against HCV infection. Nonnucleoside inhibitors based on a benzimidazole scaffold have been recently reported. Compds. of this class are efficient inhibitors of HCV RNA replication in cell culture, thus providing attractive candidates for further development. Here we report the detailed anal. of the mechanism of action of selected benzimidazole inhibitors. Kinetic data and binding expts. indicated that these compds. act as allosteric inhibitors that block the activity of the polymerase prior to the elongation step. Escape mutations that confer resistance to

IT 669070-60-4P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(discovery and preliminary SAR of benzimidazole derive. as inhibitors of hepatitis C virus NS5B polymerase)
RN 669070-60-4 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-[[2-(3,4-dimethoxyphenyl)ethyl]-2-[4-[2-[[3-(dimethylamino)propyl]amino]-2-oxoethoxy]phenyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B

-(CH2)3-NMe2


IT 390811-96-8P 390814-48-9P 669070-61-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(discovery and preliminary SAR of benzimidazole derive. as inhibitors of hepatitis C virus NS5B polymerase)
RN 390811-96-8 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-[[2-(3,4-dimethoxyphenyl)ethyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 390814-48-9 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-[[2-(3,4-dimethoxyphenyl)methyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

these compds. map to proline 495, a residue located on the surface of the polymerase thumb domain and away from the active site. Substitution of this residue is sufficient to make the HCV enzyme and replicons resistant to the inhibitors. Interestingly, proline 495 lies in a recently identified noncatalytic GTP-binding site, thus validating it as a potential allosteric site that can be targeted by small-mol. inhibitors of HCV polymerase.

IT 658693-60-8
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of hepatitis C virus RNA-dependent RNA polymerase)
RN 658693-60-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4'-chloro-4-[[4-hydroxy-1-piperidinyl]carbonyl] (1,1'-biphenyl)-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:261620 CAPLUS
DOCUMENT NUMBER: 138:287673
TITLE: Preparation of phenylbenzimidazole compounds useful for treating hepatitis C virus
INVENTOR(S): Priestley, Eldon Scott; Decicco, Carl P.; Hudyma, Thomas W.; Zheng, Xiaofan
PATENT ASSIGNER(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: P13X22
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026587	A2	20030403	WO 2002-US30989	20020926
WO 2003026587	A3	20031106		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BY, BZ, CA, CH, CN, CO, CR, CU, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GH, GM, GR, GU, HK, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MU, MV, MW, MY, MZ, NA, NG, NI, NO, NZ, OM, OS, PA, PE, PG, PH, PK, PL, PT, QA, RO, RU, RW, SA, SC, SD, SE, SG, SH, SI, SK, SL, SM, SN, SO, SR, ST, SV, SW, SY, SZ, TD, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VG, VI, VN, YU, ZA, ZM, ZW

LS, LT, LU, LV, MA, MD, ME, MK, ML, MN, MX, MY, NZ, OM, PH, PL, PT, RD, RU, SD, SE, SF, SG, SH, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

RN: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TO


US 2003134653 A1 20030717 US 2002-259041 20020926
EP 1429759 A2 20040623 EP 2002-773657 20020926

R: AT, BE, CH, DE, DK, EE, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, SE, SK

US 2004067976 A1 20040408 US 2003-648873 20030827
US 4603374 B2 20041012

PRIORITY APPLN. INFO.: US 2001-324874P P 20010926
US 2002-259041 B1 20020926
WO 2002-US30989 W 20020926


OTHER SOURCE(S): MARPAT 138:287673
GI




AB Comps. of formula I [Q = CH, N; R1 = tetrazolyl, MeCONHSO2, PhCONHSO2, etc.; R2 = CH2-aryl, CHPh2, etc.; R3 = cycloalkyl] are prepared which are useful in treating viral hepatitis C. Thus, II was prepared and had an IC50 of 0.14 μ M against HCV NS5B RdRp (RNA-dependent RNA polymerase).

IT 503857-59-8P 503857-60-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylbenzimidazole compds. for treating hepatitis C viral infection)

RN 503857-59-8 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-2-[4-(phenylmethoxy)phenyl]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 503857-60-1 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-(methylsulfonyl)-2-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




IT 347166-09-0P 503859-29-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylbenzimidazole compds. for treating hepatitis C viral infection)

RN 347166-09-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)





RN 503859-29-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-(phenylmethoxy)phenyl]-, methyl ester (9CI) (CA INDEX NAME)



L6 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:76609 CAPLUS
DOCUMENT NUMBER: 138:153533
TITLE: Preparation of benzimidazoles as viral polymerase inhibitors

INVENTOR(S): Beaulieu, Pierre Louis; Fasal, Gulez; Goulet, Sylvie; Kukolj, George; Poirier, Martin; Tsantrizos, Youla S.
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 166 pp.
CODEN: PIXX23
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003007945	A1	20030130	WO 2002-CA1129	20020718
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RD, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TO				
CA 2448737	AA	20030130	CA 2002-2448737	20020718
US 2003236251	A1	20031225	US 2002-198259	20020718
US 6841566	B2	20050111		
EP 1411928	A1	20040428	EP 2002-750716	20020718
R: AT, BE, CH, DE, DK, EE, ES, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, SE, SK				
JP 200501827	T2	20050120	JP 2003-513553	20020718
PRIORITY APPLN. INFO.: US 2001-306669P P 20010720 US 2001-338324P P 20011207 WO 2002-CA1129 W 20020718				
OTHER SOURCE(S): MARPAT 138:153533 GI				



AB Title compds. I [R1 = alkoxy, sulfonyl, carboxy, sulfonamido, amino, carboxamido, etc.; R2 = alkyl, haloalkyl, cycloalkyl, cycloalkenyl, etc.; B, D, X = N, CR5; R5 = H, halo, alkyl, etc.; Z = N, O, NR6; R6 = H, alkyl, cycloalkyl, etc.; R3-4 = H, alkyl, haloalkyl, cycloalkyl, etc.; Y1-2 = O, S; R7 = H, alkyl, cycloalkyl, etc.] are prepared. For instance, R1 4-chloro-3-nitrobenzoate (preparation given) is treated with cyclohexylamine (DMF, 60°, 5 h) and reduced to the corresponding aniline (MeOH, H2-Pd(OH)2/C). This intermediate is treated with 2-pyridinecarboxaldehyde (DMF, oxone) and the resulting adduct saponified (NaOH, HOAc) to give II. Example compds. have IC50 in the hepatitis C RNA-dependent polymerase assay of less than 25 μ M.

IT 491582-43-5P 491582-44-6P 491582-45-7P
491582-46-8P 491582-48-0P 491582-49-1P
491582-50-4P 491582-51-5P 491582-53-7P
491582-54-8P 491582-55-9P 491582-56-0P
491582-57-1P 491582-61-7P 491582-62-8P
491582-63-9P 491582-64-0P 491582-65-1P
491582-66-2P 491582-68-4P 491582-69-5P
491582-70-8P 491582-71-9P 491582-72-0P
491582-73-1P 491582-75-3P 491582-81-1P
491582-82-2P 491582-84-4P 491582-86-6P
491582-90-2P 491582-91-3P 491582-94-6P
491582-95-7P 491582-97-9P 491582-98-0P
491582-99-1P 491583-00-7P 491583-02-9P
491583-04-1P 491583-09-6P 491583-10-9P
491583-11-0P 491583-15-4P 491583-16-5P
491583-17-6P 491583-18-7P 491583-19-8P
491583-20-1P 491583-22-3P 491583-27-8P
491583-29-0P 491583-32-5P 491583-33-6P
491583-35-8P 491583-37-0P 491583-38-1P
491583-39-2P 491583-40-5P 491583-42-7P
491583-44-9P 491583-46-1P 491583-48-3P
491583-50-7P 491583-52-9P 491583-58-5P
491583-64-3P 491583-69-8P 491583-76-7P
491583-78-9P 491583-80-3P 491583-82-5P
491583-84-7P 491583-86-9P 491583-88-1P
491583-99-4P 491584-05-5P 491584-11-3P
491584-12-4P 491584-14-6P 491584-16-8P
491584-18-0P 491584-20-4P 491584-23-7P
491584-26-0P 491584-29-1P 491584-31-7P
491584-32-8P 491584-33-9P 491584-35-1P


491584-37-3P 491584-39-5P 491584-41-9P
 491584-44-2P 491584-48-6P 491584-49-7P
 491584-50-0P 491584-52-2P 491584-54-4P
 491584-56-6P 491584-58-8P 491584-60-2P
 491584-62-4P 491584-68-0P 491584-71-5P
 491584-74-8P 491584-77-1P 491584-79-3P
 491584-82-6P 491584-84-0P 491584-86-2P
 491584-88-4P 491584-90-8P 491584-92-0P
 491584-94-2P 491584-98-6P 491585-00-3P
 491585-02-5P 491585-04-7P 491585-06-9P
 491585-08-1P 491585-10-5P 491585-14-9P
 491585-16-1P 491585-17-2P 491585-19-4P
 491585-21-6P 491585-23-0P 491585-25-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of benzimidazoles as inhibitors of hepatitis C virus polymerase)

RN 491582-43-5 CAPLUS


CN Benzoic acid, 3-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RN 491582-44-6 CAPLUS


CN 2-Propenoic acid, 3-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491582-45-7 CAPLUS

CN Benzenebutanoic acid, 4-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 491582-50-4 CAPLUS

CN Benzenecetic acid, 3-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 491582-51-5 CAPLUS

CN Benzenecetic acid, 4-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 491582-53-7 CAPLUS

CN Benzenecetic acid, 4-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]- α-methyl- (9CI) (CA INDEX NAME)



RN 491582-46-8 CAPLUS


CN Benzenecetic acid, 3-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 491582-48-0 CAPLUS

CN 2-Propenoic acid, 3-[[4-[[[2E]-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]phenyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 491582-49-1 CAPLUS

CN 2-Propenoic acid, 3-[[4-[[[2E]-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]phenyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 491582-54-8 CAPLUS

CN 2-Propenoic acid, 3-[[2-chloro-5-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 491582-55-9 CAPLUS


CN Butanoic acid, 2-[[3-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]methylene]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491582-56-0 CAPLUS

CN 2-Furancarboxylic acid, 5-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 491582-57-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-3-methyl-1-oxopentyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 491582-61-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491582-62-8 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxo-4-phenylbutyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 491582-63-9 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]phenyl]acetyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491582-64-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]acetyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491582-65-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 491582-66-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-2-thienylacetyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491582-68-4 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-2-(3-furanyl)-N-[2-[(3'-hydroxy[1,1'-biphenyl]-3-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 491582-69-5 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-2-(3-furanyl)-N-[2-[(3'-hydroxy[1,1'-biphenyl]-3-yl)amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)




RN 491582-70-8 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[2-[(3'-amino[1,1'-biphenyl]-3-yl)amino]-1-methyl-2-oxoethyl]-1-cyclohexyl-2-(3-furanyl)- (9CI) (CA INDEX NAME)




RN 491582-71-9 CAPLUS
CN Acetic acid, [4-[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]-4-thiazolyl]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 491582-72-0 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[1R]-2-[(4-(2-amino-4-thiazolyl)phenyl)amino]-1-methyl-2-oxoethyl]-1-cyclohexyl-2-(3-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 491582-73-1 CAPLUS
CN Propanoic acid, 2-[4-[[[2R]-2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 491582-75-3 CAPLUS
CN 3-Furancarboxylic acid, 5-[4-[[[2R]-2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 491582-81-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 491582-82-2 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-2-(3-furanyl)-N-[[1R]-2-[[4-(3-furanyl)phenyl]amino]-1-methyl-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 491582-84-4 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491582-86-6 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-N-[[1R]-2-[[4-(2,5-dihydro-5-oxo-3-furanyl)phenyl]amino]-1-methyl-2-oxoethyl]-2-(3-furanyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 491582-90-2 CAPLUS
CN 2-Propenoic acid, 3-[3-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]-4-(4-morpholinyl)phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 491582-91-3 CAPLUS
CN 1H-Indole-2-carboxylic acid, 5-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 491582-94-6 CAPLUS
CN Benzeneprapanoic acid, 4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]-β-methoxy- (9CI) (CA INDEX NAME)




RN 491582-95-7 CAPLUS
CN Benzoic acid, 2-chloro-4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]- (9CI) (CA INDEX NAME)


INDEX NAME)



RN 491582-97-9 CAPLUS
CN Benzoic acid, 3-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)




RN 491582-98-0 CAPLUS
CN Glycine, N-[4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 491582-99-1 CAPLUS
CN Benzoic acid, 4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]benzoyl- (9CI) (CA INDEX NAME)


yl]carbonyl]amino]cyclopentyl]carbonyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)




RN 491583-00-7 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 491583-02-9 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, 1-cyclohexyl-2-(3-furanyl)-N-[1-[[[4'-hydroxy(1,1'-biphenyl)-4-yl]amino]carbonyl]cyclopentyl]- (9CI) (CA INDEX NAME)




RN 491583-04-1 CAPLUS
CN Benzenepropanoic acid, 3-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 491583-09-6 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]-, monomethyl ester (9CI) (CA INDEX NAME)




RN 491583-10-9 CAPLUS
CN Benzoic acid, 4-[[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)




RN 491583-11-0 CAPLUS
CN 2-Propenoic acid, 3-[[4-[[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491583-15-4 CAPLUS
CN Benzoic acid, 3-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 491583-16-5 CAPLUS
CN 2-Propenoic acid, 3-[[4-[[[2R]-2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




RN 491583-17-6 CAPLUS
CN 2-Propenoic acid, 3-[[4-[[[2R]-2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.




RN 491583-18-7 CAPLUS
CN Acetic acid, 4-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 491583-19-8 CAPLUS
CN Acetic acid, 3-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 491583-20-1 CAPLUS
CN 2-Furancarboxylic acid, 5-[4-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]- (2E)- (9CI) (CA INDEX NAME)




RN 491583-22-3 CAPLUS
CN 2-Furancarboxylic acid, 5-[3-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 491583-27-8 CAPLUS
CN 2-Propenoic acid, 3-[4-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491583-29-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopentyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491583-32-5 CAPLUS
CN 2-Propenoic acid, 3-[4-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-4-hydroxy-1-oxobutyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 491583-33-6 CAPLUS
CN 2-Furancarboxylic acid, 5-[3-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 491583-35-8 CAPLUS
CN 2-Furancarboxylic acid, 5-[4-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 491583-37-0 CAPLUS
CN Benzenepropanoic acid, 4-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 491583-38-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-2-ethenylcyclopropyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 491583-39-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[[2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-2-ethenylcyclopropyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 491583-40-5 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopropyl]carbonyl]amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491583-42-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491583-44-9 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclohexyl]carbonyl]amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491583-46-1 CAPLUS
CN Acetic acid, [[4-[[[2R]-2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 491583-48-3 CAPLUS
CN 3-Furancarboxylic acid, 5-[3-[[[2R]-2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 491583-50-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[2R]-2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxobutyl]amino]phenyl]-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 491583-52-9 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[2R]-2-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopentyl]amino]phenyl]-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 491583-58-5 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]acetyl]amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491583-64-3 CAPLUS
CN 2-Furancarboxylic acid, 5-[4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 491583-69-8 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-2-methyl- (2R)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491583-76-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-2-methyl- (2R)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491583-78-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-[[[1-(1R)-2-carboxyethenyl]phenyl]amino]carbonyl]-4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 491583-80-3 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 491583-82-5 CAPLUS
CN 2-Thiazolecarboxylic acid, 5-[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 491583-84-7 CAPLUS
CN Alaninamide, N-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]alanyl-N-[4-(3-carboxypropyl)phenyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B




RN 491583-86-9 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-2-methyl-1-oxopropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491583-88-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491583-99-4 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-4-piperidinyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 491584-05-5 CAPLUS
CN 2-Thiazolecarboxylic acid, 4-[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-2-methyl-1-oxopropyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 491584-11-3 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-ethyl-4-piperidinyl]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 491584-12-4 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[4-[[[4-[(aminocarbonyl)-2-thiazolyl]phenyl]amino]carbonyl]-1-ethyl-4-piperidinyl]-2-(3-furanyl)- (9CI) (CA INDEX NAME)




RN 491584-14-6 CAPLUS
CN 1H-Benzimidazole-5-carboxamide, N-[1-[[[4-[(2-amino-5-pyrimidinyl)phenyl]amino]carbonyl]cyclopentyl]-1-cyclohexyl-2-(3-furanyl)- (9CI) (CA INDEX NAME)




RN 491584-16-8 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(3-thienyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491584-18-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[2R]-2-[[[1-cyclohexyl-2-(2-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 491584-20-4 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[2R]-2-[[[1-cyclohexyl-2-phenyl-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 491584-23-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[2R]-2-[[[1-cyclohexyl-2-(1H-pyrrol-2-yl)-1H-benzimidazol-5-yl]carbonyl]amino]-1-oxopropyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 491584-26-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(2-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491584-29-3 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-phenyl-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491584-31-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(1H-pyrrol-2-yl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491584-32-8 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclopentyl-2-(1-methyl-1H-pyrrol-2-yl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491584-33-9 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclopentyl-2-(2-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 491584-35-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclopentyl-2-(2-phenyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 491584-37-3 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclopentyl-2-(2-thienyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


INDEX NAME)

Double bond geometry as shown.




RN 491584-39-5 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclopentyl-2-(2-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 491584-41-9 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclopentyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 491584-44-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclopentyl-2-(1H-pyrrol-2-yl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491584-48-6 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(1R,2S,4S)-bicyclo[2.2.1]hept-2-yl-2-(1-methyl-1H-pyrrol-2-yl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491584-49-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(1R,2S,4S)-bicyclo[2.2.1]hept-2-yl-2-(2-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491584-50-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(1R,2S,4S)-bicyclo[2.2.1]hept-2-yl-2-phenyl-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491584-52-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(1R,2S,4S)-bicyclo[2.2.1]hept-2-yl-2-(2-thienyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491584-54-4 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(1R,2S,4S)-bicyclo[2.2.1]hept-2-yl-2-(2-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491584-56-6 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(1R,2S,4S)-bicyclo[2.2.1]hept-2-yl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491584-58-8 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(1R,2S,4S)-bicyclo[2.2.1]hept-2-yl-2-(1H-pyrrol-2-yl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491584-60-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(1-cyclobutyl-2-(1-methyl-1H-pyrrol-2-yl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491584-62-4 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(1-cyclobutyl-2-(2-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 491584-68-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(1-cyclobutyl-2-phenyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 491584-71-5 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(1-cyclobutyl-2-(2-thienyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)


5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491584-74-8 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(1-cyclobutyl-2-(2-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491584-77-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(1-cyclobutyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491584-79-3 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(cyclobutyl-2-(1H-pyrrol-2-yl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491584-82-8 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(2,6-dimethylcyclohexyl)-2-(1-methyl-1H-pyrrol-2-yl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491584-84-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(2,6-dimethylcyclohexyl)-2-(2-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491584-86-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(2,6-dimethylcyclohexyl)-2-phenyl-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491584-88-4 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(2,6-dimethylcyclohexyl)-2-(2-thienyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491584-90-8 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(2,6-dimethylcyclohexyl)-2-(2-pyridinyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491584-92-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(2,6-dimethylcyclohexyl)-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491584-94-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(2,6-dimethylcyclohexyl)-2-(1H-pyrrol-2-yl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491584-98-6 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-(2,6-dimethylcyclohexyl)-2-(1-methyl-1H-pyrrol-2-yl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491585-00-3 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[2-(2-furanyl)-1-[(1R,2R)-2-methylcyclohexyl]-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491585-02-5 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[2-(2-furanyl)-1-[(1R,2R)-2-methylcyclohexyl]-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491585-04-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[2-(2-furanyl)-1-[(1R,2R)-2-methylcyclohexyl]-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491585-06-9 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[2-(2-furanyl)-1-[(1R,2R)-2-methylcyclohexyl]-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491585-08-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[2-(2-furanyl)-1-[(1R,2R)-2-methylcyclohexyl]-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491585-10-5 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[2-(2-furanyl)-1-[(1R,2R)-2-methylcyclohexyl]-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.




RN 491585-14-9 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[2-(2-furanyl)-1-[(1R,2R)-2-methylcyclohexyl]-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 491585-16-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[2-(2-furanyl)-1-[(1R,2R)-2-methylcyclohexyl]-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 491585-17-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(2-thienyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 491585-19-4 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(2-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B




RN 491585-21-8 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(2-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



PAGE 2-A


RN 491585-23-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(2-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 491585-25-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(2-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

==> LOG HOLD
COST IN U.S. DOLLARS
FULL ESTIMATED COST
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE
SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:18:32 ON 25 SEP 2006
Connecting via Winsock to STN

SINCE FILE	TOTAL
ENTRY	SESSION
97.04	100.73
SINCE FILE	TOTAL
ENTRY	SESSION
-13.50	-18.00

Welcome to STN International! Enter X:X

LOGINID:sesptal623act

PASSWORD:

***** RECONNECTED TO STN INTERNATIONAL *****
SESSION RESUMED IN FILE 'CAPLUS' AT 12:26:12 ON 25 SEP 2006
FILE 'CAPLUS' ENTERED AT 12:26:12 ON 25 SEP 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS SINCE FILE TOTAL

FULL ESTIMATED COST ENTRY 97.50 SESSION 301.19
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL
CA SUBSCRIBER PRICE -13.50 -18.00

=> D HIS

(FILE 'HOME' ENTERED AT 12:05:24 ON 25 SEP 2006)

FILE 'REGISTRY' ENTERED AT 12:05:43 ON 25 SEP 2006
L1 STRUCTURE UPLOADED
L2 10 S L1
L3 STRUCTURE UPLOADED
L4 8 S L3

FILE 'CAPLUS' ENTERED AT 12:10:28 ON 25 SEP 2006
L5 6 S L4

FILE 'REGISTRY' ENTERED AT 12:11:20 ON 25 SEP 2006
L6 1643 S L4 SSS FULL

FILE 'CAPLUS' ENTERED AT 12:11:39 ON 25 SEP 2006
L7 24 S L6
L8 18 S L7 NOT L5

=> FILE REG
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL
FULL ESTIMATED COST 97.96 301.65
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL
CA SUBSCRIBER PRICE -13.50 -18.00

FILE 'REGISTRY' ENTERED AT 12:26:45 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8
DICTIONARY FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\Hep C FUSED RING COMPOUNDS.str




chain nodes :
10 12 13
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
8-10 9-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-10 9-13
exact bonds :
8-9
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:Atom 13:Atom
Generic attributes :
10:
Saturation : Unsaturated
Type of Ring System : Monocyclic
13:
Saturation : Saturated

L9 STRUCTURE UPLOADED

=> D L9

L9 HAS NO ANSWERS
L9 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> S L9 SSS FULL
FULL SEARCH INITIATED 12:27:10 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 504916 TO ITERATE

100.0% PROCESSED 504916 ITERATIONS 3038 ANSWERS
SEARCH TIME: 00.00.06

L10 3038 SEA SSS FUL L9

=> S L10 NOT L7
L11 1395 L10 NOT L7

=> FILE CAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL
FULL ESTIMATED COST 169.14 470.79
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL
CA SUBSCRIBER PRICE 0.00 -18.00

FILE 'CAPLUS' ENTERED AT 12:30:18 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 24 Sep 2006 (20060924/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> S L10
L12 55 L10

=> S L12 NOT L7
L13 31 L12 NOT L7

=> S L13 NOT L5
L14 31 L13 NOT L5

=> D 1-31 ISIB ABS HITSTR

L14 ANSWER 1 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:333948 CAPLUS
DOCUMENT NUMBER: 145:42515
TITLE: Sensing Metal Ions with DNA Building Blocks:
Fluorescent Pyridobenzimidazole Nucleosides
Kim, Su Jeong; Kool, Eric T.
AUTHOR(S): Department of Chemistry, Stanford University,
Stanford, CA, 94305-5080, USA
CORPORATE SOURCE: Journal of the American Chemical Society (2006),
128(18), 6164-6171
SOURCE: CODEN: JACSA; ISSN: 0002-7863

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
G1

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The authors describe novel fluorescent N-deoxyribosides (I and II) having
2-pyrido-2-benzimidazole and 2-quinol-2-benzimidazole as aglycons. The
comps. were prepared from the previously unknown heterocyclic precursors
and Hoffer's chlorosugar, yielding alpha anomers as the chief products.
X-ray crystal structures confirmed the geometry and showed that the
pyridine and benzimidazole ring systems deviated from coplanarity in the
solid state by 154° and 140°, resp. In methanol the comps.
I and II had absorption maxima at 360 and 370 nm, resp., and emission
maxima at 494 and 539 nm. Expts. revealed varied fluorescence responses
of the nucleosides to a panel of 17 monovalent, divalent, and trivalent
metal ions in methanol. One or both of the nucleosides showed significant
changes with 10 of the metal ions. The most pronounced spectral changes
for ligand-nucleoside I included red shifts in fluorescence (Au⁺, Ag⁺),
strong quenching (Cu²⁺, Hg²⁺, Pt²⁺), and substantial enhancements in
emission intensity coupled with red shifts (Ag⁺, Cd²⁺, Zn²⁺). The
greatest spectral changes for ligand-nucleoside II included a red shift in
fluorescence (Ag⁺), a blue shift (Cd²⁺), strong quenching (Pd²⁺, Pt²⁺),
and substantial enhancements in emission intensity coupled with a blue
shift (Zn²⁺). The comps. could be readily incorporated into
oligonucleotides, where an initial study revealed that they retained
sensitivity to metal ions in aqueous solution and demonstrated possible
cooperative sensing behavior with several ions. The two free nucleosides
alone can act as differential sensors for multiple metal ions, and they
are potentially useful monomers for contributing metal ion sensing
capability to DNA.

IT RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(fluorescent pyridobenzimidazole nucleosides DNA building blocks for
sensing metal ions)

RN 889664-41-9 CAPLUS
CN 1H-benzimidazol-6-amine, 1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-2-deoxy-
alpha-D-erythro-pentofuranosyl]-N,N-dimethyl-2-(2-pyridinyl)- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 889664-42-0 CAPLUS
CN 1H-benzimidazol-6-amine, 1-[5-O-[bis(4-methoxyphenyl)phenylmethyl]-3-O-

[[bis(1-methylethyl)amino](2-cyanoethoxy)phosphino]-2-deoxy- α -D-erythro-pentofuranosyl]-N,N-dimethyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STM

ACCESSION NUMBER: 2005-1354729 CAPLUS

DOCUMENT NUMBER: 144:88271

TITLE: Preparation of tricyclic thienopyridine compounds as IKK2 inhibitors

INVENTOR(S): Okamoto, Yoshinori; Hattori, Kazuyuki; Kubota, Hirokazu; Sato, Ippei; Kanayama, Takatoshi; Yokoyama, Kazuhiro; Terai, Yoshiya; Takeuchi, Masahiro

PATENT ASSIGNER(S): Astellas Pharma Inc., Japan; Kotobuki Pharmaceutical Co., Ltd.

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXX2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200513745	A1	20051229	WO 2005-JP11325	20050621
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, SE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPL. INFO.: JP 2004-183073 A 20040621

OTHER SOURCE(S): MARPAT 144:88271

GI


AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, SE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005215829 A1 20050901 AU 2005-215829 20050218
CA 2553879 AA 20050901 CA 2005-2553879 20050218
US 200522236 A1 20051006 US 2005-62305 20050218

PRIORITY APPL. INFO.: US 2004-546213 P 20040220
WO 2005-CA208 W 20050218

OTHER SOURCE(S): MARPAT 143:266920

GI



II

AB Title compds. [I: 1 of A, B = N, the other = C; 1 dotted line between 2 c atoms = double bond; dotted line between a C and an N atom = single bond; R1 = H, alkyl; R2 = H, alkyl, cyano, alkyl, alkenyl, cycloalkyl, (substituted) aryl, heterocyclyl; R3 = (halo)cycloalkyl; R4, R7 = H, alkyl, alkoxy, alkylthio, amino, halo; 1 of R5, R6 = CO2H, aminocarbonyl, (substituted) alkenyl, aryl, heterocyclyl; R8 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl; R9, R10 = alkyl; CR9R10 = atoms to form a (substituted) cycloalkyl, cycloalkenyl, heterocyclyl ring; were prepared for treatment of e.g. Hepatitis C virus (no data). Thus, title compound (II) was prepared via solution phase coupling reaction.

IT 863883-98-1P 863884-17-7P 863884-21-3P

863884-26-8P 863884-35-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indolylcarbamylaminomethylbenzimidazoles as viral polymerase inhibitors)

RM 863883-98-1 CAPLUS

CN 2-Propenoic acid, 3-[1-cyclobutyl-2-[1-[[[3-cyclopentyl-1-methyl-2-(2-pyridinyl)-1H-indol-6-yl]carbonyl]amino]cyclopentyl]-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = Q1, -NR3R3; Het = saturated heterocycle containing nitrogen;

R1 = alkyl, halo, haloalkyl, etc.; k = 0-3; when Het is morpholino group, k is 1-3; R2, R3 = H, alkyl, -alkylene-OR6, etc.; R6 = H, alkyl; X = -CR7R8-, -O-, -CO-, etc.; R7, R8 = H, alkyl, halo, etc.; m = 0-3; n = 0-3 such as 2Sm+nS5] were prepared. For example, reaction of tert-Bu 3-(4-cyano-3-thioxo-2,3,5,6,7,8-hexahydroisoquinolin-1-yl)piperidine-1-carboxylate, 4-g., prepared from cyanothioacetamide, with 2-bromoacetamide followed by treatment with HCl/dioxane afforded compound II-HCl [A = piperidin-3-yl; Y = H]. In IKK2 inhibition assays, the IC50 value of compound II-2HCl [A = piperazin-1-yl; Y = methyl] was 11 nM. Compds. I are claimed useful for the treatment of inflammation, autoimmune diseases.


IT

872137-36-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tricyclic thienopyridine compds. as IKK2 inhibitors for treatment of inflammation, autoimmune diseases)

RM

CN Thieno[2,3-c]isoquinoline-2-carboxamide, 1-amino-6,7,8,9-tetrahydro-5-(4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STM

ACCESSION NUMBER: 2005:962253 CAPLUS

DOCUMENT NUMBER: 143:266920

TITLE: Preparation of indolylcarbamylaminomethylbenzimidazole s as viral polymerase inhibitors

INVENTOR(S): Tsantrizos, Youla S.; Chabot, Catherine; Beaulieu, Pierre; Brochu, Christian; Poirier, Martin; Stammers, Timothy A.; Thavonekham, Bounkham; Rancourt, Jean

PATENT ASSIGNER(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co. K.G.

SOURCE: PCT Int. Appl., 177 pp.

CODEN: PIXX2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080388	A1	20050901	WO 2005-CA208	20050218
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, SE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				



RM 863884-17-7 CAPLUS

CN 2-Propenoic acid, 3-[1-cyclobutyl-2-[1-[[[3-cyclopentyl-1-methyl-2-(2-pyridinyl)-1H-indol-6-yl]carbonyl]amino]cyclopentyl]-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RM 863884-21-3 CAPLUS

CN 2-Propenoic acid, 3-[1-cyclobutyl-2-[1-[[[3-cyclopentyl-1-methyl-2-pyrazinyl-1H-indol-6-yl]carbonyl]amino]cyclopentyl]-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RM 863884-26-8 CAPLUS

CN 2-Propenoic acid, 3-[1-cyclobutyl-2-[1-[[[3-cyclopentyl-2-(3-furanyl)-1-


methyl-1H-indol-6-yl]carbonyl]amino]cyclobutyl]-1H-benzimidazol-6-yl]-, (2S)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863884-35-9 CAPLUS
CN 2-Propenoic acid, 3-[[1-cyclobutyl-2-[[1-[[[1-cyclopentyl-1-methyl-2-(3-pyridinyl)-1H-indol-6-yl]carbonyl]amino]cyclopentyl]-1H-benzimidazol-6-yl]-, (2S)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2005:33074 CAPLUS
DOCUMENT NUMBER: 142:114070
TITLE: Preparation of novel N-(heterobicycloalkane)-substituted indoles or hetero derivatives for treating or preventing CCR-3 receptor-related diseases
INVENTOR(S): Anderskewitz, Ralf; Martys, Dominik; Dollinger, Horst; Pouzet, Pascale; Birke, Franz; Bouysse, Thierry
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma GmbH & Co.KG, Germany
SOURCE: Eur. Pat. Appl., 23 pp.
CODEN: SPKXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

to be used for treating or preventing diseases related to the CCR-3 receptor. Thus, 4-FC6H4CF2(CH2)3Br was reacted with (azabicyclooctyl)benzimidazole II to give alkylated derivative III. The binding constant, K_i , for III was 10 nM.
IT 821786-86-1P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole deriv. for treating or preventing CCR-3 related diseases and binding affinity toward CCR-3 receptor)
RN 821786-86-1 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2-cyclopropyl-5-fluoro-1H-benzimidazol-1-yl)-8-[3-[(4-fluorophenyl)thio]propyl]-, monohydrochloride, (3-exo)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



• HCl

IT 821786-83-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (8-azabicyclo[3.2.1]oct-3-yl)-1H-benzimidazole deriv. for treating or preventing CCR-3 related diseases and binding affinity toward CCR-3 receptor)
RN 821786-83-8 CAPLUS
CN 8-Azabicyclo[3.2.1]octane, 3-(2-cyclopropyl-5-fluoro-1H-benzimidazol-1-yl)-8-(phenylmethyl)-, (3-exo)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2004:996210 CAPLUS
DOCUMENT NUMBER: 141:423302


EP 1496058	A1	20050112	EP 2003-15434	20030709
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, SE, HU, SK				
CA 2531749	AA	20050120	CA 2004-2531749	20040706
WO 2005005425	A1	20050120	WO 2004-EP7356	20040706
M: AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO				

EP 1648888 A1 20060426 EP 2004-740684 20040706
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
US 2005014782 A1 20050120 US 2004-886973 20040708
PRIORITY APPLN. INFO.: EP 2003-15434 A 20030709
US 2003-500513P P 20030905
WO 2004-EP7356 W 20040706

OTHER SOURCE(S): MARPAT 142:114070
OI



II



III

AB The title compds. I [A = C2-C8 alkylene optionally substituted with halide or OH; B = aryl, heteroaryl ring; R1 = aryl, heteroaryl, annulated heteroaryl, etc.; RS = C1-C6 alkyl, C1-C6 alkoxy, C1-C6 aralkyl, C3-C6 cycloalkyl, halide, NO2, etc.; X = H, CH, CR6; Y = CF2, NR4, O, S(O)n; n = 0, 1, 2; T, U, V, Z = independently (CH2)x, x = 0, 1, 2; W = C1-C3 alkylene, CH2-Z-CH2; Z = O, S, NR4; R4 = H, C1-C6 alkyl, C3-C8-cycloalkyl, (C3-C8-cycloalkyl)-C1-C6-alkyl, etc.; R6 = C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, OR3, SR3, cyano, COR3, SO2R3, aryl, etc.; R3 = H, C1-C6 alkyl, C3-C8-cycloalkyl, (C3-C8-cycloalkyl)-C1-C6-alkyl, etc.] were prepared

TITLE: Crystal structure of hepatitis C virus NS5B polymerase inhibitor binding pocket for drug design and screening
INVENTOR(S): Coulombe, Rene; Beaulieu, Pierre Louis; Jolicoeur, Eric; Kukolj, George; Laplante, Steven; Poupart, Marc-Andre
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG
SOURCE: PCT Int. Appl., 413 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004099241	A1	20041118	WO 2004-CA676	20040505
M: AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO				

AU 2004235848 A1 20041118 AU 2004-235848 20040505
CA 2522574 AA 20041118 CA 2004-2522574 20040505
EP 1625154 A1 20060215 EP 2004-731118 20040505
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
CN 1820022 A 20060816 CN 2004-80019473 20040505
US 2005003348 A1 20050106 US 2004-842046 20040507
PRIORITY APPLN. INFO.: US 2003-469604P P 20030509
WO 2004-CA676 W 20040505

AB The HCV NS5B polymerase, when complexed with certain inhibitors, adopts a conformation in which the finger loop region defined by amino acid residues 18 to 35 is displaced to expose a binding pocket defined generally by amino acid residues 32, 39, 395, 396, 424, 425, 428, 429, 492, 493, 494, 495, 496, 500 and 503. This newly exposed binding pocket defines a novel target in the search of further chemical entities which are capable of binding to HCV NS5B and modulating, or preferably inhibiting, the polymerase activity of HCV NS5B.

IT 491584-01-1
RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); PREP (Properties); ANST (Analytical study); BIOL (Biological study)
(crystal structure of hepatitis C virus NS5B polymerase inhibitor binding pocket for drug design and screening)

RN 491584-01-1 CAPLUS
CN 1H-Indole-3-carboxylic acid, 5-[[[4-[[[1-cyclohexyl-2-(3-furanyl)-1H-benzimidazol-5-yl]carbonyl]amino]-4-piperidinyl]carbonyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 31 CAPLUS COPYRIGHT 2006 ACS on STM
 ACCESSION NUMBER: 2004:799454 CAPLUS
 DOCUMENT NUMBER: 141:291229
 TITLE: Histone deacetylase inhibitors
 INVENTOR(S): Bressi, Jerome C.; Brown, Jason W.; Cao, Sheldon X.; Gangloff, Anthony R.; Jennings, Andrew J.; Stafford, Jeffrey A.; Vu, Phong H.; Xiao, Xiao-Yi
 PATENT ASSIGNER(S): Syrris, Inc., USA
 SOURCE: PCT Int. Appl., 276 pp.
 CODEN: PIXK2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004082638	A2	20040930	WO 2004-US8342	20040317
WO 2004082638	A3	20050506		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GR, OM, KE, LS, MW, MZ, SD, SE, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TG


CA 2518318	AA	20040930	CA 2004-2518318	20040317
US 2004254320	A1	20041216	US 2004-803575	20040317
US 2004266769	A1	20041230	US 2004-803344	20040317
US 2005137232	A1	20050623	US 2004-803580	20040317
EP 1608628	A2	20051228	EP 2004-757631	20040317

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, SE, HU, PL, SK
 CN 1787999 A 20060614 CN 2004-8001872 20040317
 JP 200620796 T2 20060914 JP 2006-507336 20040317
 OTHER SOURCE(S): MARPAT 141:291229
 AB Comps. that may be used to inhibit histone deacetylase are disclosed. Thus, 119 compts. were prepared which exhibited better than 1000 nM IC50 against HDAC1, HDAC2, HDAC6, and HDAC8 (suberanilohydroxamic acid showed an IC50 of 63 nM in this assay). Many of these compts. were 3-[3-(1-substituted-1H-benzimidazol-2-yl)phenyl]acrylic acids and N-hydroxy-3-[3-(1-substituted-1H-benzimidazol-2-yl)phenyl]acrylamides.


OTHER SOURCE(S): MARPAT 141:291229
 AB Comps. that may be used to inhibit histone deacetylase are disclosed. Thus, 119 compts. were prepared which exhibited better than 1000 nM IC50 against HDAC1, HDAC2, HDAC6, and HDAC8 (suberanilohydroxamic acid showed an IC50 of 63 nM in this assay). Many of these compts. were 3-[3-(1-substituted-1H-benzimidazol-2-yl)phenyl]acrylic acids and N-hydroxy-3-[3-(1-substituted-1H-benzimidazol-2-yl)phenyl]acrylamides.



RN 758690-62-9 CAPLUS
 CN Benzene sulfonamide, N-[6-ethoxy-1-(2-methylcyclohexyl)-2-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-5-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 758690-63-0 CAPLUS
 CN Benzene sulfonamide, N-[6-ethoxy-1-(2-methylcyclohexyl)-2-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-5-yl]-2,4,6-trimethyl- (9CI) (CA INDEX NAME)




RN 758690-64-1 CAPLUS

IT 758694-26-7
 RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (histone deacetylase inhibitors)
 RN 758694-26-7 CAPLUS
 CN 2-Propenamide, N-hydroxy-3-[3-[1-(1-phenylmethyl)-3-piperidinyl]-1H-benzimidazol-2-yl]phenyl- (9CI) (CA INDEX NAME)




L14 ANSWER 7 OF 31 CAPLUS COPYRIGHT 2006 ACS on STM
 ACCESSION NUMBER: 2004:603088 CAPLUS
 DOCUMENT NUMBER: 141:277557
 TITLE: Multistep parallel synthesis of substituted 5-aminobenzimidazoles in solution phase
 AUTHOR(S): Li, Li; Liu, Gang; Wang, Zhanguo; Yuan, Yunyun; Zhang, Chunxu; Tian, Hongyu; Wu, Xianghong; Zhang, Jing
 CORPORATE SOURCE: Institute of Materia Medica, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100050, Peop. Rep. China
 SOURCE: Journal of Combinatorial Chemistry (2004), 6(5), 811-821
 CODEN: JCCHEP; ISSN: 1520-4766
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:277557
 GI




AB An efficient solution-phase parallel synthesis of multisubstituted 5-aminobenzimidazoles, e.g. 1, is described. The two fluorine atoms of 1,5-difluoro-2,4-dinitrobenzene were sequentially and quant. replaced by nucleophiles. Simultaneous reduction of aromatic n-dinitro groups by Pd/C/HCOONH4 resulted in 2,4,5-benzenetriamines, which were continuously condensed with aldehydes to successfully construct the benzimidazole ring without addnl. oxidants. The free aromatic amino group was further modified by anhydrides, isocyanates, isothiocyanates, and sulfonyl chlorides. All the reactions involved here were highly effective in giving the desired products at room temperature. Four diversity points were introduced in the final


CN Benzene sulfonamide, N-[6-ethoxy-2-(4-ethoxy-3-methoxyphenyl)-1-(2-methylcyclohexyl)-1H-benzimidazol-5-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 758690-65-2 CAPLUS
 CN Benzene sulfonamide, 4-[(1,1-dimethylethyl)-N-[6-ethoxy-2-(4-ethoxy-3-methoxyphenyl)-1-(2-methylcyclohexyl)-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 758690-66-3 CAPLUS
 CN Benzene sulfonamide, N-[6-ethoxy-2-(4-ethoxy-3-methoxyphenyl)-1-(2-methylcyclohexyl)-1H-benzimidazol-5-yl]-2,4,6-trimethyl- (9CI) (CA INDEX NAME)




RN 758690-67-4 CAPLUS
 CN Benzene sulfonamide, N-[6-ethoxy-2-(4-methoxyphenyl)-1-(2-methylcyclohexyl)-1H-benzimidazol-5-yl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 758690-68-5 CAPLUS
 CN Benzenesulfonamide, 4-[[1,1-dimethylethyl]-N-[6-ethoxy-2-(4-methoxyphenyl)-1-(2-methylcyclohexyl)-1H-benzimidazol-5-yl]]- (9CI) (CA INDEX NAME)




RN 758690-69-6 CAPLUS
 CN Benzenesulfonamide, N-[6-ethoxy-2-(4-methoxyphenyl)-1-(2-methylcyclohexyl)-1H-benzimidazol-5-yl]-2,4,6-trimethyl- (9CI) (CA INDEX NAME)




RN 758690-70-9 CAPLUS
 CN Benzoic acid, 4-[6-ethoxy-5-[[[4-methoxyphenyl]sulfonyl]amino]-1-(2-methylcyclohexyl)-1H-benzimidazol-2-yl]]-, methyl ester (9CI) (CA INDEX NAME)



RN 758690-71-0 CAPLUS
 CN Benzoic acid, 4-[5-[[[4-(1,1-dimethylethyl)phenyl]sulfonyl]amino]-6-ethoxy-1-(2-methylcyclohexyl)-1H-benzimidazol-2-yl]]-, methyl ester (9CI) (CA INDEX NAME)



RN 758690-72-1 CAPLUS
 CN Benzoic acid, 4-[6-ethoxy-1-(2-methylcyclohexyl)-5-[[[2,4,6-trimethylphenyl]sulfonyl]amino]-1H-benzimidazol-2-yl]]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 8 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:487927 CAPLUS
 DOCUMENT NUMBER: 141:424144
 TITLE: Combinatorial synthesis of biheterocyclic benzimidazoles by microwave irradiation
 AUTHOR(S): Yeh, Wen-Bing; Lin, Mei-Jung; Sun, Chung-Ming
 CORPORATE SOURCE: Laboratory of Combinatorial Drug Design, National Tong Hwa University, Hualien, 974, Taiwan
 SOURCE: Combinatorial Chemistry and High Throughput Screening (2004), 7(3), 251-255
 CODEN: CCHSPU; ISSN: 1386-2073
 PUBLISHER: Bentham Science Publishers Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:424144
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Liquid phase synthesis of biheterocyclic benzimidazoles, e.g., 1, by controlled microwave irradiation was investigated. Polymer immobilized o-phenylenediamines was synthesized under microwave irradiation. The resulting PEG bound diamines was N-acylated with 4-fluoro-3-nitrobenzoic acid selectively in primary aromatic amino moiety. Nucleophilic aromatic substitution of amide was performed with various amines then cyclized to form the first benzimidazole scaffold, e.g., 11 (X = PEG), in acidic condition. Successive reduction, cyclization with isothiocyanates yielded


5-(benzimidazol-2-yl)benzimidazoles. The desired products were released from the polymer support to afford the tri-substituted bis-benzimidazoles in good yields and purity.

IT 796840-97-6P 796840-98-7P 796841-05-9P
 796841-06-0P
 RL: CPM (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of PEG-bound benzimidazolylphenylenediamines as biheterocyclic benzimidazole precursor via TFA-catalyzed cyclocondensation of PEG-bound (phenylenediaminecarbonyl)nitroanilines followed by nitro-reduction with zinc)


RN 796840-97-6 CAPLUS
 CN Poly(oxy-1,2-ethanediyl), α-[[[1-cyclopentyl-2-[3-nitro-4-[[[tetrahydro-2-furanyl]methyl]amino]phenyl]-1H-benzimidazol-5-yl]carbonyl]-ω-methoxy- (9CI) (CA INDEX NAME)




RN 796840-98-7 CAPLUS
 CN Poly(oxy-1,2-ethanediyl), α-[[[1-cyclopentyl-2-[3-nitro-4-[[[3-pyridinylmethyl]amino]phenyl]-1H-benzimidazol-5-yl]carbonyl]-ω-methoxy- (9CI) (CA INDEX NAME)



RN 796841-05-9 CAPLUS
 CN Poly(oxy-1,2-ethanediyl), α-[[[2-[3-amino-4-[[[tetrahydro-2-furanyl]methyl]amino]phenyl]-1-cyclopentyl-1H-benzimidazol-5-yl]carbonyl]-ω-methoxy- (9CI) (CA INDEX NAME)




RN 796841-06-0 CAPLUS
 CN Poly(oxy-1,2-ethanediyl), α-[[[2-[3-amino-4-[[[3-pyridinylmethyl]amino]phenyl]-1-cyclopentyl-1H-benzimidazol-5-yl]carbonyl]-ω-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 9 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:242529 CAPLUS
 DOCUMENT NUMBER: 140:375116
 TITLE: Focused microwave-assisted parallel synthesis of bis-benzimidazoles
 AUTHOR(S): Lin, Mei-Jung; Sun, Chung-Ming
 CORPORATE SOURCE: Department of Chemistry, National Dong Hwa University, Hualien, 974, Taiwan
 SOURCE: Synlett (2004), (4), 663-666
 CODEN: SYNLAS; ISSN: 0936-5214
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:375116
 GI




AB Combinatorial parallel synthesis of bis(benzimidazoles), e.g. I, by focused (mono-modal) microwave irradiation, is described. Polymer-immobilized o-phenylenediamines as a versatile template were synthesized under microwave irradiation. The resulting PBO-bound diamines were N-acylated with 4-fluoro-3-nitrobenzoic acid selectively on the primary aromatic amino moiety. The nucleophilic aromatic substitution of amides was performed with different amines, then cyclized to benzimidazoles under acidic condition. Successive reduction and cyclization with various aldehydes yielded 5-(benzimidazol-2-yl)benzimidazoles. The desired products were released from the polymer support to afford the tri-substituted bis-benzimidazoles in good yields and purity.


IT 684259-29-EP 684259-30-EP 684259-31-2P
684259-32-3P 684259-33-4P 684259-34-5P

RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)
(microwave-assisted combinatorial preparation of bis(benzimidazoles) via heterocyclization of PBO-supported (amino)nitrobenzamide/aminobenzoate followed by reduction, heterocyclization with aldehydes, and resin cleavage)


RN 684259-29-8 CAPLUS
CN [2,5'-Bi-1H-benzimidazole]-5-carboxylic acid, 1'-cyclopentyl-1-(2-furanylmethyl)-2'-phenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 684259-30-1 CAPLUS
CN [2,5'-Bi-1H-benzimidazole]-5-carboxylic acid, 1'-cyclopentyl-1-(2-furanylmethyl)-2'-[4-(methylthio)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 684259-31-2 CAPLUS
CN [2,5'-Bi-1H-benzimidazole]-5-carboxylic acid, 2'-cyclohexyl-1'-cyclopentyl-1-(2-furanylmethyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 684259-32-3 CAPLUS
CN [2,5'-Bi-1H-benzimidazole]-5-carboxylic acid, 1'-cyclopentyl-1-(2-furanylmethyl)-2'-(3-thienyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 684259-33-4 CAPLUS
CN [2,5'-Bi-1H-benzimidazole]-5-carboxylic acid, 1'-cyclopentyl-2'-[4-(methylthio)phenyl]-1-[3-(4-morpholinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 684259-34-5 CAPLUS
CN [2,5'-Bi-1H-benzimidazole]-5-carboxylic acid, 2'-(4-chlorophenyl)-1'-cyclopentyl-1-(2-furanylmethyl)-, methyl ester (9CI) (CA INDEX NAME)

cyclopentyl-1-[3-(4-morpholinyl)propyl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 10 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:855801 CAPLUS

DOCUMENT NUMBER: 139:350734

TITLE: Preparation of 1-(4-piperidinyl)benzimidazoles as

INVENTOR(S): Zeng, Qingbei; Aslanian, Robert G.; Berlin, Michael

Y.; Boyce, Christopher W.; Cao, Jianhua; Kozlovski,

Joseph A.; Mangiaracina, Pietro; McCormick, Kevin D.;

Mutahl, Mwangi W.; Rosenblum, Stuart B.; Shih,

Heng-Yang; Solomon, Daniel M.; Tom, Wing C.

SOURCE: Schering Corporation, USA

DOCUMENT TYPE: CODEN: PIXXD2

LANGUAGE: Patent

FAMILY ACC. NUM. COUNT: English

PATENT INFORMATION: 2

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2003088967 A1 20031030 WO 2003-US11672 20030416

M: AS, AG, AL, AM, AT, AU, A2, BA, BB, BO, BR, BY, BZ, CA, CH, CN,

CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GR, HR, HU,

ID, IL, IN, IS, JP, KR, KZ, LC, LR, LT, LU, LV, MA, MD,

MG, MK, MN, MX, MY, NI, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG,

SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM,

RW: GN, GM, KE, LB, MG, ME, SD, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NR, SN, TD, TG

CA 2481940 AA 20031030 CA 2003-2481940 20030416

AU 2003223627 A1 20031103 AU 2003-223627 20030416

US 2004097483 A1 20040520 US 2003-417391 20030416

US 7105505 B2 20060912 20030416

EP 1499316 A1 20050126 EP 2003-719766 20030416

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,



IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BO, CZ, EE, HU, SK

BR 2003009348 A 20050301 BR 2003-9348 20030416

CN 1658874 A 20050824 CN 2003-813779 20030416

JP 2005529116 T2 20050929 JP 2003-585719 20030416

ZA 2004007984 A 20051018 ZA 2004-7984 20041004
NO 2004005002 A 20050118 NO 2004-5002 20041117
PRIORITY APPL. INFO.: US 2002-373731P P 20020418
US 2002-373467P P 20020418
OTHER SOURCE(S): MARPAT 139:350734
OI




AB The title comds. [I; R1 = (un)substituted benzimidazolyl or a derivative thereof; R2 = (un)substituted aryl or heteroaryl; M1, M2 = CR3, N; X = a bond, alkylene; Y = CO, CS, SO2, etc.; Z = a bond, alkylene, CO, etc.; R3 = H, halo, alkyl, etc.; R12 = alkyl, OH, alkoxy, etc.; R13 = alkyl, alkoxy, OH, etc.; a, b = 0-2; n, p = 1-3; r = 0-3; with the proviso] which are histamine H3 antagonists, were prepared E.g., a multi-step synthesis of II which showed Ki of 1 nM in rHu H3 binding assay, was given. Also disclosed are pharmaceutical comds. comprising the comds. of formula I and methods of treating various diseases or conditions, such as allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the comds. I. Also disclosed are methods of treating said diseases or conditions using the comds. of formula I in combination with an H1 receptor antagonist.


IT 618893-71-OP 618893-72-1P 618893-85-6P
618893-01-9P 618893-02-OP 618893-03-1P
618893-04-2P 618893-06-4P 618893-08-6P
618893-10-OP 618893-12-2P 618893-14-4P
618893-16-6P 618893-18-8P 618893-20-2P
618893-22-4P 618893-24-6P 618893-26-8P
618893-27-9P 618893-29-1P 618893-31-5P
618893-35-9P 618893-37-1P 618893-38-2P
618893-40-6P 618893-46-2P 618893-48-4P
618893-50-8P 618893-52-OP 618893-54-2P
618893-56-4P 618893-59-7P 618893-61-1P
618893-63-3P 618893-65-5P 618893-67-7P
618893-68-8P 618893-69-9P 618893-71-3P
618893-73-5P 618893-75-7P 618893-77-9P
618893-79-1P 618893-81-5P 618893-82-6P
618893-83-7P 618893-85-9P 618893-86-OP
618893-87-1P 618893-89-3P 618893-91-7P

618893-92-8P 618893-93-9P 618893-94-0P
 618893-95-1P 618893-96-2P 618893-97-3P
 618893-98-4P 618894-00-1P 618894-01-2P
 618894-02-3P 618894-04-5P 618894-06-7P
 618894-07-8P 618894-09-0P 618894-11-4P
 618894-13-6P 618894-15-8P 618894-17-0P
 618894-19-2P 618894-21-6P 618894-23-8P
 618894-25-0P 618894-27-2P 618894-28-3P
 618894-29-4P 618894-30-7P 618894-31-8P
 618894-32-9P 618894-33-0P 618894-34-1P
 618894-35-2P 618894-36-3P 618894-37-4P
 618894-38-5P 618894-39-6P 618894-40-9P
 618894-41-0P 618894-42-1P 618894-54-5P
 618894-55-6P 618894-61-4P 618894-63-6P
 618894-70-5P 618894-71-6P 618894-72-7P
 618894-73-8P 618894-74-9P 618894-75-0P
 618894-76-1P 618894-77-2P 618894-79-4P
 618894-80-7P 618894-81-8P 618894-82-9P
 618894-83-0P 618894-84-1P 618894-87-4P
 618894-88-5P 618894-89-6P 618894-90-9P
 618894-91-0P 618894-94-3P 618894-95-4P
 618894-96-5P 618894-97-6P 618894-98-7P
 618895-42-4P 618895-43-5P 618895-44-6P
 618895-45-7P 618895-49-1P 618895-50-4P
 618895-51-5P 618895-52-6P 618895-53-7P
 618895-54-8P 618895-56-0P 618895-57-1P
 618895-70-8P 618895-71-9P 618895-72-0P
 618895-73-1P 618895-74-2P 618895-75-3P
 618895-77-5P 618895-78-6P 618895-79-7P
 618895-80-0P 618895-81-1P 618895-83-3P
 618895-84-4P 618895-85-5P 618895-86-6P
 618895-87-7P 618895-88-8P 618895-90-2P
 618895-91-3P 618895-96-8P 618895-98-0P
 618895-99-1P 618896-17-6P 618896-19-8P
 618896-21-2P 618896-23-4P 618896-25-6P
 618896-37-0P 618896-46-1P 618896-47-2P
 618896-54-1P 618896-55-2P 618896-56-3P
 618896-57-4P 618896-60-9P 618896-61-0P
 618896-62-1P 618896-66-5P 618896-67-6P
 618896-68-7P 618896-76-7P 618896-92-7P
 618896-94-9P 618896-96-1P 618897-29-3P
 618897-30-6P 618897-31-7P 618897-32-8P
 618897-33-9P 618897-34-0P 618897-35-1P
 618897-36-2P 618897-38-4P 618897-40-8P
 618897-41-9P 618897-42-0P 618897-52-2P
 618897-53-3P 618897-54-4P 618897-55-5P
 618897-56-6P 618897-57-7P 618897-58-8P
 618897-62-4P 618897-63-5P 618897-64-6P
 618897-65-7P 618897-66-8P 618897-67-9P
 618897-68-0P 618897-70-4P 618897-71-5P
 618897-74-8P 618897-89-5P 618897-90-8P
 618897-97-5P 618898-04-7P 618898-29-6P
 618898-60-5P 618898-62-7P 618898-66-1P
 618898-68-3P 618898-70-7P 618898-71-8P
 618898-72-9P 618898-73-0P 618898-74-1P
 618898-75-2P 618898-90-1P 618898-92-3P
 618898-93-4P 618899-07-3P 618899-08-4P
 618899-09-5P 618899-10-8P 618899-22-2P
 618899-28-8P 618899-29-9P 618899-30-2P
 618899-31-3P 618899-32-4P 618899-40-4P
 618899-41-5P 618899-46-0P 618899-47-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1-(4-piperidinyl)benzimidazole as histamine H3 antagonists)



RN 618893-03-1 CAPLUS
 CN Piperidine, 1-([1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl)-4-(6-fluoro-2-(tetrahydro-2-furanyl)-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618893-04-2 CAPLUS
 CN Piperidine, 1-([1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl)-4-(5-fluoro-2-(5-oxo-2-pyrrolidinyl)-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618893-06-4 CAPLUS
 CN Piperidine, 1-([1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl)-4-(5-fluoro-2-(5-oxo-4-imidazolidinyl)-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)


RN 618892-71-0 CAPLUS
 CN Piperidine, 1-([1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl)-4-(5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618892-72-1 CAPLUS
 CN Piperidine, 1-([1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl)-4-(5-(2-pyridinyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618892-85-6 CAPLUS
 CN Piperidine, 1-([1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl)-4-(5-chloro-2-cyclohexyl-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618893-01-9 CAPLUS
 CN Piperidine, 1-([1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl)-4-(6-fluoro-2-(tetrahydro-2H-pyran-4-yl)-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618893-02-0 CAPLUS
 CN Piperidine, 1-([1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl)-4-(5-fluoro-2-(tetrahydro-2H-pyran-4-yl)-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 618893-08-6 CAPLUS
 CN Piperidine, 1-([1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl)-4-(5-bromo-2-(tetrahydro-2-furanyl)-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618893-10-0 CAPLUS
 CN Piperidine, 1-([1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl)-4-(5-fluoro-2-(tetrahydro-3-furanyl)-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618893-12-2 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(tetrahydro-2-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-14-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2,4-difluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-16-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3,5-difluorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-18-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(4-fluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-20-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3,4-difluorophenyl)-6,7-difluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-22-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-chloro-2-(4-fluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-24-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-fluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-26-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(3,5-difluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-27-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3,4-difluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-29-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(4-fluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-31-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-phenyl-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-35-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(2-fluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-37-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(3,4-difluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-38-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-chlorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-40-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-hydroxyphenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-46-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-48-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3,5-dichlorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-50-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(4-chlorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-52-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-chloro-2-(4-chlorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-54-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-methoxyphenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-56-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-(trifluoromethyl)phenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-59-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(3,5-dichlorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-61-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-ethoxy-3-fluorophenyl)-5-methyl-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-63-3 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-65-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-ethoxy-2-(3,5-dichlorophenyl)-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 618893-67-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-ethoxy-3-fluorophenyl)-5-methyl-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618893-68-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-69-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[3,5-bis(trifluoromethyl)phenyl]-5-bromo-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-71-3 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-ethoxy-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)


RN 618893-73-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(1-oxido-2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-75-7 CAPLUS
CN Piperidine, 4-[2-(2-amino-3-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 618893-77-9 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[(4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618893-79-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-81-5 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-82-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-83-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-pyrazinyl-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-85-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[7-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-86-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-87-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-pyrazinyl-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618893-89-3 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-pyrazinyl-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-91-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-92-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)


RN 618893-93-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-94-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-ethoxy-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-95-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(6-methyl-2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-96-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-97-3 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[5-bromo-2-(1-oxido-2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618893-99-5 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-00-1 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[5-chloro-2-(4-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-01-2 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[2-(4-chloro-2-pyridinyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-02-3 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[2-(4-pyrimidinyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618894-04-5 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-06-7 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[2-(4-chloro-2-pyridinyl)-6,7-difluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-07-8 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[6,7-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)


NAME)




RN 618894-09-0 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[2-(1,2-dihydro-2-oxo-3-pyridinyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-11-4 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[2-(4-chloro-2-pyridinyl)-7-fluoro-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-13-6 CAPLUS
CN Piperidine, 4-[2-(2-amino-4-pyridinyl)-5-fluoro-1H-benzimidazol-1-yl]-1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 618894-15-8 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-17-0 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[2-(2-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-19-2 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[2-(1H-pyrrrol-2-yl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-21-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(3-thienyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-23-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(3-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-25-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618894-27-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-thienyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-28-3 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-29-4 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-30-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-thienyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-31-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6,7-difluoro-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-32-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-33-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-ethoxy-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618894-34-1 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[5-fluoro-2-(3-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-35-2 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[5-bromo-2-(1H-pyrrol-2-yl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-36-3 CAPLUS


CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[5-fluoro-2-(1H-pyrrol-2-yl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-37-4 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-38-5 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[7-fluoro-2-(5-methyl-3-isoxazolyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-39-6 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[5-fluoro-2-(5-(4-fluorophenyl)-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-40-9 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[5-fluoro-2-(2-methyl-3-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-41-0 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[2-(5-(1,1-dimethylethyl)-2-methyl-3-furanyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-42-1 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl)carbonyl]-4-[5-fluoro-2-(3-methyl-2-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-54-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-morpholinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618894-55-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-methylsulfonyl)-1-piperazinyl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-61-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-(trifluoromethyl)sulfonyl)-1-piperazinyl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-63-6 CAPLUS
CN 4-Piperidinecarboxamide, 1-[1-[1-[(2-amino-4-pyridinyl)methyl]-4-


piperidinyl]carbonyl]-4-piperidinyl]-5-fluoro-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 618894-70-5 CAPLUS
CN Piperidine, 4-[2-(6-amino-3-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618894-71-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[7-fluoro-2-(2-pyridinyl)-5-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-72-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-73-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-74-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-hydroxy-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-75-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-76-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-methyl-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618894-77-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-79-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2,6-dimethyl-3-furanyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-80-7 CAPLUS



CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4,5-dimethyl-2-furanyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-81-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[5-methyl-2-(trifluoromethyl)-3-furanyl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-82-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(tetrahydro-2,2-dimethyl-2H-pyran-4-yl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-83-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-[5-(trifluoromethyl)-2-furanyl]-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-84-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618894-87-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-2-methyl-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-88-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(3-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-89-6 CAPLUS



CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-90-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-thiomorpholinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-91-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(1-piperidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-94-3 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-methyl-1-piperazinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618894-95-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-3-hydroxy-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-96-5 CAPLUS
CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-97-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-morpholinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618894-98-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618895-43-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-43-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-44-6 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-pyrazinyl-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-45-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-49-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[3,4-difluorophenyl]-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-50-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-51-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-pyrazinyl-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-52-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-chloro-2-(4-fluorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618895-53-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-54-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-chloro-2-(3,5-dichlorophenyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-56-0 CAPLUS


CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-chloro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)






RN 618895-57-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[6-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-70-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-71-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2,4-difluorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-72-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3,4-difluorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-73-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(3-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-74-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-pyrazinyl-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-75-3 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-77-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-78-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-79-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5,7-difluoro-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-80-0 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[(4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618895-81-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5,6-difluoro-2-pyrazinyl-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-83-3 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-84-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-pyrazinyl-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-85-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618895-86-6 CAPLUS
CN Piperidine, 1-([1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl)-4-[5-fluoro-2-(3-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-87-7 CAPLUS
CN Piperidine, 1-([1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl)-4-[2-(3,4-difluorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-88-8 CAPLUS
CN Piperidine, 1-([1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl)-4-[2-(2,4-difluorophenyl)-5-fluoro-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-90-2 CAPLUS
CN Piperidine, 1-([1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl)-4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-91-3 CAPLUS
CN Piperidine, 1-([1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl)-4-[2-(5-methyl-3-isoxazolyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-96-8 CAPLUS
CN Piperidine, 1-([1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl)-4-[5-fluoro-2-(3-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618895-98-0 CAPLUS
CN Piperidine, 1-([1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl)-4-[5-fluoro-2-(3-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618895-99-1 CAPLUS
CN Piperidine, 1-([1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl)-4-[5-fluoro-2-(3-furanyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)





RN 618896-17-4 CAPLUS
CN Piperidine, 1-([1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl)-4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-19-8 CAPLUS
CN Piperidine, 1-([1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl)-4-[5-fluoro-2-(4-morpholinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-21-2 CAPLUS
CN Piperidine, 1-([1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl)-4-[5-fluoro-2-(4-morpholinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-23-4 CAPLUS
CN Piperidine, 1-([1-[(2-amino-3-pyridinyl)methyl]-4-piperidinyl]carbonyl)-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-25-6 CAPLUS
CN Piperidine, 4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[(1H-imidazo[4,5-b]pyridin-7-yl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618896-37-0 CAPLUS
CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-46-1 CAPLUS
CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-47-2 CAPLUS
CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-54-1 CAPLUS
CN Piperidine, 1-[[1-[(6-methoxy-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-55-2 CAPLUS
CN Piperidine, 4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[(6-methoxy-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618896-56-3 CAPLUS
CN Piperidine, 4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[(6-methoxy-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618896-57-4 CAPLUS
CN Piperidine, 1-[[1-[(4-fluoro-1-[(5-fluoro-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-60-9 CAPLUS
CN Piperidine, 4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[(3-pyridazinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618896-61-0 CAPLUS
CN Piperidine, 4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[(4-pyridazinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618896-62-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-methyl-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618896-66-5 CAPLUS
CN Piperidine, 1-[[1-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-67-6 CAPLUS
CN Piperidine, 1-[[1-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618896-68-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[[2-[[[2R,6S]-2,6-dimethyl-4-morpholinyl]-5-fluoro-1H-benzimidazol-1-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 618896-76-7 CAPLUS
CN Piperidine, 1-[[1-[[5-((6-amino-4-pyrimidinyl)methyl)-4-fluoro-4-piperidinyl]carbonyl]-4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)]]




RN 618896-92-7 CAPLUS
CN Piperidine, 1-[[1-[[5-((dimethylamino)methyl)-2-furanyl)methyl]-4-piperidinyl]carbonyl]-4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)]]




RN 618896-94-9 CAPLUS
CN Piperidine, 1-[[1-[[5-((aminopyrazinyl)methyl)-4-fluoro-4-piperidinyl]carbonyl]-4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)]]




RN 618896-96-1 CAPLUS
CN Piperidine, 1-[[1-[[5-((aminomethyl)-2-furanyl)methyl]-4-piperidinyl]carbonyl]-4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)]]




RN 618897-29-3 CAPLUS
CN 2-Pyrimidinamine, 4-[[4-[[4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]cyclohexyl]methyl]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 618897-30-6 CAPLUS
CN 2-Pyrimidinamine, 5-[[4-[[4-[[5-fluoro-2-(4-pyrimidinyl)-1H-benzimidazol-1-yl]-1-piperidinyl]amino]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 618897-31-7 CAPLUS
CN 2-Pyrimidinamine, 5-[[4-[[4-[[5-fluoro-2-(3-furanyl)-1H-benzimidazol-1-yl]-1-piperidinyl]amino]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 618897-32-8 CAPLUS
CN 2-Pyrimidinamine, 5-[[4-[[4-[[5-fluoro-2-(tetrahydro-2-furanyl)-1H-benzimidazol-1-yl]-1-piperidinyl]amino]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 618897-33-9 CAPLUS
CN 2-Pyrimidinamine, 5-[[4-[[4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-piperidinyl]amino]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 618897-34-0 CAPLUS
CN 2-Pyrimidinamine, 5-[[4-[[4-[[5-fluoro-2-(3-pyridinyl)-1H-benzimidazol-1-yl]-1-piperidinyl]amino]-1-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 618897-35-1 CAPLUS
CN Piperazine, 1-[[1-[[2-amino-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-4-methyl- (9CI) (CA INDEX NAME)




RN 618897-36-2 CAPLUS
CN Piperazine, 1-[[1-[[2-amino-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 618897-38-4 CAPLUS
CN Piperazine, 1-((2-amino-4-pyridinyl)methyl)-4-[[4-[5-chloro-2-(2,4,6-trifluorophenyl)-1H-benzimidazol-1-yl]-1-piperidinyl]carbonyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 618897-40-8 CAPLUS
CN Piperazine, 1-((1-[[5-(aminomethyl)-2-furanyl]methyl]-4-fluoro-4-piperidinyl]carbonyl)-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618897-41-9 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-[[2-[(methylsulfonyl)amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-42-0 CAPLUS
CN Piperidine, 1-[[1-[[2-[bis(methylsulfonyl)amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618897-52-2 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-(2-furanylmethyl)-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618897-53-3 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(1H-pyrazol-2-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-54-4 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(2-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-55-5 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-56-6 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-(3-furanylmethyl)-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618897-57-7 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(2-thiazolylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-58-8 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(1,2,3-thiadiazol-4-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-62-4 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(2-furanylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-63-5 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(1H-pyrrol-2-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-64-6 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(2-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-65-7 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-66-8 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-furanylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-67-9 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(2-thiazolylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-68-0 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(1,2,3-thiadiazol-4-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-70-4 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618897-71-5 CAPLUS
CN Piperidine, 1-[[1-[[2-[[[ethylamino]carbonyl]amino]-4-pyridinyl]methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618897-74-8 CAPLUS
CN Piperazine, 1-[[2-amino-5-pyrimidinyl]methyl]-4-[[4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-89-5 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(1H-pyrazol-3-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-90-8 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-(1H-pyrazol-3-ylmethyl)-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618897-97-5 CAPLUS
CN Piperidine, 1-[[1-[[5-[(dimethylamino)methyl]-2-furanyl]methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618898-04-7 CAPLUS
CN Piperidine, 1-[[1-[[2-amino-5-pyrimidinyl]methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-methoxy-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618898-29-6 CAPLUS
CN Piperidine, 1-[[1-[[2-amino-5-pyrimidinyl]methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-hydroxy-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618898-60-5 CAPLUS
CN Piperidine, 1-[[1-(3-furanyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618898-62-7 CAPLUS
CN Piperidine, 4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-66-1 CAPLUS
CN Piperidine, 4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-68-3 CAPLUS
CN Piperidine, 1-[[1-[[2-amino-5-pyrimidinyl]methyl]-4-piperidinyl]carbonyl]-4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618898-70-7 CAPLUS
CN Piperidine, 4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-furanyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-71-8 CAPLUS
CN Piperidine, 4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-furanyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-72-9 CAPLUS
CN Piperidine, 4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-73-0 CAPLUS
CN Piperidine, 1-[[1-[[2-amino-5-pyrimidinyl]methyl]-4-piperidinyl]carbonyl]-4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618898-74-1 CAPLUS
CN Piperidine, 4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-furanyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-75-2 CAPLUS
CN Piperidine, 4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-90-1 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(2-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-92-3 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(3-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-93-4 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(1-methyl-1H-pyrrol-3-yl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 618899-07-3 CAPLUS
CN Piperidine, 4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-08-4 CAPLUS
CN Piperidine, 1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-09-5 CAPLUS
CN Piperidine, 4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-


pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-10-8 CAPLUS
CN Piperidine, 4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-22-2 CAPLUS
CN Piperidine, 4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-26-8 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-29-9 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(2-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-30-2 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(3-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-31-3 CAPLUS
CN Piperidine, 4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-32-4 CAPLUS
CN Piperidine, 1-[[1-(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-40-4 CAPLUS
CN Piperidine, 4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-41-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)



RN 618899-46-0 CAPLUS
CN Piperidine, 4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-47-1 CAPLUS
CN Piperidine, 4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




IT 618899-48-2P 618899-49-3P 618899-52-8P
618899-54-0P 618899-55-1P 618899-58-4P
618899-59-5P 618899-65-7P 618899-86-8P
618899-87-9P 618899-88-0P 618899-91-5P
618899-92-6P 618900-01-9P 618900-05-3P
618900-06-4P 618900-08-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of 1-(4-piperidinyl)benzimidazoles as histamine H3 antagonists)


RN 618899-48-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-49-3 CAPLUS
CN Piperidine, 4-[5-bromo-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-52-8 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-fluoro-1-(1H-pyrrol-3-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-54-0 CAPLUS
CN Piperidine, 4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-55-1 CAPLUS
CN Piperidine, 4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-58-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-(methylsulfonyl)-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-59-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-85-7 CAPLUS
CN Piperidine, 4-[5-(methylsulfonyl)-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-86-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[4-methyl-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-87-9 CAPLUS
CN Piperidine, 4-[4-methyl-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-88-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[4-methyl-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)




RN 618899-91-5 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-piperidinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 618899-92-6 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(phenylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618900-01-9 CAPLUS
CN Piperidine, 4-[5,6-difluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 618900-05-3 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-[(1-methyl-1H-pyrrol-3-yl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)


1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 11 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STM
ACCESSION NUMBER: 2003:737580 CAPLUS
DOCUMENT NUMBER: 139:261298
TITLE: Preparation of imidazole and benzimidazole derivatives that inhibit the interaction of ligands with RAGE
INVENTOR(S): Mjalli, Adnan M. M.; Andrews, Robert C.; Gopalaswamy, Ramesh; Hari, Anitha; Avor, Kwesi; Qabaja, Ghassan; Guo, Xiao-Chuan; Gupta, Suparna; Jones, David R.; Chen, Xin
PATENT ASSIGNER(S): Transtech Pharma, Inc., USA
SOURCE: PCT Int. Appl., 462 pp.
CODEN: PIKXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003075921	A2	20030918	WO 2003-US6749	20030305
WO 2003075921	A3	20031204		
M: AE, AO, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KR, KP, KS, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, IL, IN, KE, NE, NG, NO, OM, PG, PY, RE, RW, SD, SN, TD, TO				
CA 2476594	AA	20030918	CA 2003-2476594	20030305
AU 2003217943	A1	20030922	AU 2003-217943	20030305
US 2004082542	A1	20040429	US 2003-382203	20030305
EP 1482931	A2	20041208	EP 2003-713918	20030305
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1633290	A	20050629	CN 2003-805204	20030305
JP 2005525378	T2	20050825	JP 2003-574195	20030305
PRIORITY APPLN. INFO.:			US 2002-361983P	P 20020305
			WO 2003-US6749	M 20030305
OTHER SOURCE(S):		MARPAT 139:261298		
GI				




RN 618900-06-4 CAPLUS
CN Piperidine, 4-[5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(1H-pyrrol-3-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618900-08-6 CAPLUS
CN Piperidine, 4-[5-chloro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-1-[[1-(1H-pyrrol-3-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



IT 618900-58-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-(4-piperidinyl)benzimidazoles as histamine H3 antagonists)
RN 618900-58-6 CAPLUS
CN Carbamic acid, 4-[[4-[[4-(5-fluoro-2-(2-pyridinyl)-1H-benzimidazol-1-yl]-



AB Title compds. and analogs I [wherein A = O, S, or NR2; R1 and R2 = independently H or (un)substituted (hetero)aryl, (cyclo)alkyl, heterocyclyl, alkenyl, alkynyl, alkylene(hetero)aryl, alkylene heterocyclyl, alkylene cycloalkyl, etc.; R3 and R4 = independently H, halo, OH, CN, CONH2, CO2H, or (un)substituted (hetero)aryl, (cyclo)alkyl, heterocyclyl, alkenyl, alkynyl, alkylene(hetero)aryl, alkylene heterocyclyl, alkylene cycloalkyl, etc.; and pharmaceutically acceptable salts thereof] were prepared as modulators of the interaction between the receptor for advanced glycosylated end products (RAGE) and its ligands, such as advanced glycosylated end products (AGEs), S100/calgranulin/EN-RAGE, beta-amyloid, and amphotericin. For example, 1-BOC-4-[2-(4-amino-3-butylaminophenoxy)ethyl]piperazine was condensed with 3-hydroxybenzaldehyde to give the hydroxybenzimidazole. Coupling with cyclohexylmethyl bromide in the presence of NaH in THF afforded II. In binding studies employing S100b as the RAGE ligand, five hundred fifty-one invention compds. exhibited binding with IC50 values of < 10 μM. Thus, I and their pharmaceutical compds. are useful for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE, including acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis (no date).
IT 603145-50-2P, N-[3-[[2-(4-(benzyloxy)phenyl]-3-cyclopentyl-3H-benzimidazol-5-yl)oxy]propyl]-N,N-diethylamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(RAGE modulator; preparation of imidazole and benzimidazole RAGE modulators for treatment of inflammation, diabetes, tumors, and other conditions)
RN 603145-50-2 CAPLUS
CN 1-Propanamine, 3-[[1-cyclopentyl-2-(4-(phenylmethoxy)phenyl)-1H-benzimidazol-6-yl]oxy]-N,N-diethyl- (9CI) (CA INDEX NAME)



L14 ANSWER 12 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:539807 CAPLUS
DOCUMENT NUMBER: 139:69267
TITLE: Preparation of 2-benzimidazolylamines as ORL1-receptor agonists for the treatment of pain and inflammatory diseases
INVENTOR(S): Ito, Punitaka
PATENT ASSIGNER(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 33 pp.
CODEN: EPXIXW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1069124	A1	20010117	EP 2000-305981	20000714
EP 1069124	B1	20040512		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6340681	B1	20020122	US 2000-606921	20000629
JP 2001048879	A2	20010220	JP 2000-209374	20000711
JP 3276111	B2	20020422		
JP 2001039974	A2	20010213	JP 2000-211264	20000712
BR 2000002796	A	20010403	BR 2000-2796	20000714
AT 266657	B	20040515	AT 2000-305981	20000714
PT 1069124	T	20040930	PT 2000-305981	20000714
SE 2119272	T3	20041201	SE 2000-305981	20000714
CA 2314008	AA	20010116	CA 2000-2314008	20000717
			WO 1999-181290	W 19990716

PRIORITY APPLN. INFO.:
OTHER SOURCE(S): MARPAT 139:69267
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [R1, R2 = H, halo, OH, etc.; R3, R4 = H, halo-alkyl, substituted alkyl, i.e., OH, alkoxy, alkyl-S, etc.; R5 = phenyl, substituted cycloalkyl, i.e., H, halo, OH, etc.], and their pharmaceutically acceptable salts were prepared. For example, N-alkylation of N-methylpiperazine by chlorobenzimidazolyl II, e.g., prepared from 1,3-dihydro-1-(4-piperidinyl)-2H-benzimidazol-2-one in 2-steps, afforded 2-benzimidazolylamine III in 15% yield. In selective affinity studies of opioid receptors, i.e., ORL1, μ , κ and δ , some examples of compds. I exhibited good ORL1-receptor agonist activity. Compds. I are claimed useful as analgesics.

IT 548793-41-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of 2-benzimidazolylamines as ORL1-receptor agonists for the treatment of pain and inflammatory diseases)
RN 548793-41-8 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




IT 548793-36-8P 548793-37-9P 548793-38-0P
548793-39-1P 548793-40-4P 548793-42-6P
548793-43-7P 548793-44-8P 548793-45-9P
548793-46-0P 548793-56-4P 548793-59-2P
548793-60-8P 548793-61-9P 548793-68-6P
548793-69-7P 548793-70-0P 548793-71-1P
548793-72-2P 548793-73-3P 548793-74-4P
548793-75-5P 548793-76-6P 548793-78-8P
548793-79-9P 548793-80-2P 548793-81-3P
548793-82-4P 548793-83-5P 548793-84-6P
548793-87-9P 548793-88-0P 548793-89-1P
548793-90-4P 548793-91-5P 548793-92-6P
548793-93-7P 548793-94-8P 548793-95-9P
548793-96-0P 548793-97-1P 548793-98-2P
548794-00-9P 548794-04-3P 548794-06-5P
548794-07-6P 548794-08-7P 548794-09-8P
548794-13-4P 548794-14-5P 548794-15-6P
548794-17-8P 548794-18-9P 548794-23-6P
548794-24-7P 548794-25-8P 548794-26-9P
548794-27-0P 548794-28-1P 548794-34-9P
548794-41-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of 2-benzimidazolylamines as ORL1-receptor agonists for the treatment of pain and inflammatory diseases)
RN 548793-36-8 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 548793-37-9 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclohexylmethyl)-4-piperidinyl]-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 548793-38-0 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cycloheptylmethyl)-4-piperidinyl]-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 548793-39-1 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclopentylmethyl)-4-piperidinyl]-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 548793-40-4 CAPLUS
CN 1H-Benzimidazole, 2-(4-methyl-1-piperazinyl)-1-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 548793-42-6 CAPLUS


CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 548793-43-7 CAPLUS
CN 3-Pyrrolidinol, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 548793-44-8 CAPLUS
CN 3-Piperidinemethanol, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 548793-45-9 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 548793-46-0 CAPLUS
CN 1-Piperazineethanamine, 4-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 548793-58-4 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(4-phenyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 548793-59-5 CAPLUS
CN Piperazine, 1-acetyl-4-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 548793-60-8 CAPLUS
CN [1,4'-Bipiperidin]-4-amine, 1'-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 548793-61-9 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-[4-[[1-(1-pyrrolidinylmethyl)cyclopentyl]methyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)



RN 548793-68-6 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(hexahydro-1(2H)-azocinyl)- (9CI) (CA INDEX NAME)




RN 548793-69-7 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)




RN 548793-70-0 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 548793-71-1 CAPLUS
CN 1H-Benzimidazole, 2-[4-[(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-1-[1-(cyclooctylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 548793-72-2 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(3,6-dihydro-1(2H)-pyridinyl)- (9CI) (CA INDEX NAME)




RN 548793-73-3 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-[4-(2-methoxyphenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 548793-74-4 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-[4-(4-fluorophenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 548793-75-5 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-[4-(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 548793-76-6 CAPLUS
CN 1-Piperazineethanol, 4-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 548793-78-8 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 548793-79-9 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(3-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 548793-80-2 CAPLUS

CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(3,5-dimethyl-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 548793-81-3 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl


RN 548793-82-4 CAPLUS
CN 4-Piperidinol, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 548793-83-5 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(4-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 548793-84-6 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(cyclohexylmethyl)-4-piperidinyl]-2-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 548793-87-9 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(hexahydro-1H-azepin-1-yl)- (9CI) (CA INDEX NAME)




RN 548793-88-0 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 548793-89-1 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 548793-90-4 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-[4-(2-fluorophenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 548793-91-5 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)- (9CI) (CA INDEX NAME)




RN 548793-92-6 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-[4-[(2E)-3-phenyl-2-propenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 548793-93-7 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 548793-94-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 548793-95-9 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(3,5-dimethyl-4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 548793-96-0 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(5-ethyl-2-methyl-1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 548793-97-1 CAPLUS
CN 4-Piperidineethanol, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 548793-98-2 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-[4-(2-methoxyphenyl)-1-piperidinyl]- (9CI) (CA INDEX NAME)




RN 548794-00-9 CAPLUS
CN 3-Piperidinecarboxamide, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 548794-04-3 CAPLUS
CN Carbamic acid, 1-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-3-pyrrolidinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 548794-06-5 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-[4-[4-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 548794-07-6 CAPLUS
CN 1H-Benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-[4-[3-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 548794-08-7 CAPLUS
CN 1H-Benzimidazole, 2-[4-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl]-1-[1-(cyclooctylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 548794-09-8 CAPLUS
CN Quinoline, 4-[4-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-1-piperazinyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 548794-13-4 CAPLUS
CN 3-Piperidinecarboxamide, 1-[1-[(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-N,N-diethyl- (9CI) (CA INDEX NAME)




RN 548794-14-5 CAPLUS
CN 1H-Benzimidazole, 1-[1-[(cyclooctylmethyl)-4-piperidinyl]-2-[4-[2-nitro-4-(trifluoromethyl)phenyl]-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 548794-15-6 CAPLUS
CN 1-Piperazinecarboxaldehyde, 4-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 548794-17-8 CAPLUS
CN 1H-Benzimidazole, 1-[1-[(cyclooctylmethyl)-4-piperidinyl]-2-[4-ethyl-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 548794-18-9 CAPLUS
CN 2-Piperazineethanol, 4-[1-[(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-1-ethoxy- (9CI) (CA INDEX NAME)




RN 548794-23-6 CAPLUS
CN 1H-Benzimidazole, 1-[1-[(cyclooctylmethyl)-4-piperidinyl]-2-[2,6-dimethyl-4-morpholinyl]- (9CI) (CA INDEX NAME)




RN 548794-24-7 CAPLUS
CN 1H-Benzimidazole, 1-[1-[(cyclooctylmethyl)-4-piperidinyl]-2-[4-(2-ethoxyphenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 548794-25-8 CAPLUS
CN 1H-Benzimidazole, 1-[1-[(cyclooctylmethyl)-4-piperidinyl]-2-[4-(3,4-dichlorophenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 548794-26-9 CAPLUS
CN 1H-Benzimidazole, 1-[1-[(cyclooctylmethyl)-4-piperidinyl]-2-[4-(3,5-dimethylphenyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 548794-27-0 CAPLUS
CN 1H-Benzimidazole, 1-[1-[(cyclooctylmethyl)-4-piperidinyl]-2-[4-(diphenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 548794-28-1 CAPLUS
CN 1H-Benzimidazole, 2-[4-(2-chlorophenyl)-1-piperazinyl]-1-[1-(cyclooctylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 548794-34-9 CAPLUS
CN 1H-benzimidazole, 1-[1-(cyclooctylmethyl)-4-piperidinyl]-2-(4,5-dihydro-2,4-dimethyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 548794-41-8 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[1-[1-(cyclooctylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 13 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STM

ACCESSION NUMBER: 2003:454117 CAPLUS

DOCUMENT NUMBER: 139:36439

TITLE: Preparation of 2-pyridinone AMPA receptor antagonists for the treatment of demyelinating disorders and neurodegenerative diseases

INVENTOR(S): Smith, Terence

PATENT ASSIGNER(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 229 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

suppressing action to calcium influx into nerve cells induced by AMPA with IC50 values ranging from 0.01 μ M to 9.5 μ M. Thus, I and compns. thereof are useful for the treatment of demyelinating disorders and neurodegenerative diseases.


IT 380921-52-8P, 3-[1-[1-(1-Benzylpiperidin-4-yl)benzimidazol-2-yl]-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-59-5P, 3-[2-(2-Cyanophenyl)-5-[1-[1-(1-Benzylpiperidin-4-yl)benzimidazol-2-yl]-1-phenyl-1,2-dihydropyridin-2-one 380921-71-1P, 3-[1-(1-Piperidin-4-yl)benzimidazol-2-yl]-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one 380921-72-2P, 3-[2-(2-Cyanophenyl)-5-[1-(1-piperidin-4-yl)benzimidazol-2-yl]-1-phenyl-1,2-dihydropyridin-2-one 380921-92-6P, 3-[2-(2-Cyanophenyl)-5-[1-(1-methylpiperidin-4-yl)benzimidazol-2-yl]-1-phenyl-1,2-dihydropyridin-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(AMPA receptor antagonist; preparation of pyridinone AMPA receptor antagonists for treatment of demyelinating disorders and neurodegenerative diseases)


RN 380921-52-8 CAPLUS

CN [2,3'-Bipyridin]-6'-(1'H)-one, 1'-phenyl-5'-[1-[1-(phenylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 380921-59-5 CAPLUS

CN Benzonitrile, 2-[1,2-dihydro-2-oxo-1-phenyl-5-[1-[1-(phenylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2003047577	A2	20030612	WO 2002-GB5542	20021206	
WO 2003047577	A3	20030724			
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, GM, ML, MR, NE, SN, TD, TO					
CA 2469076	AA	20030612	CA 2002-2469076	20021206	
AU 2002347365	A1	20030617	AU 2002-347365	20021206	
EP 1465626	A2	20041013	EP 2002-783299	20021206	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002014705	A	20041123	BR 2002-14705	20021206	
JP 2005515995	T3	20050602	JP 2003-548832	20021206	
CN 1738618	A	20060222	CN 2002-827926	20021206	
ZA 2004004330	A	20050907	ZA 2004-4330	20040101	
NO 2004002298	A	20040906	NO 2004-2298	20040603	
US 2006100249	A1	20060511	US 2005-497518	20050209	
PRIORITY APPLN. INFO.:				GB 2001-29260	20011206
OTHER SOURCE(S):				WO 2002-GB5542	A
G1				WO 2002-GB5542	W




AB Compns. comprising title compds. I [wherein Q = NH, O, or S; R1-R5 = independently H, halo, alkyl, or X; X = a bond, O, S, CO, SO, SO2, NR6, NR7CO, CONR8, NR9CH2, CH2NR10, CH2CO, COCH2, NR11SOO-2, SOO-2NR12, CH2SOO-2, SOO-2CH2, CH2O, OCH2, NR13CONR14, NR15CONR16, or (un)substituted alkylene, alkenylene, or alkynylene; A = (un)substituted cycloalkyl, cycloalkenyl, heterocyclyl, or (hetero)aryl; R6-R16 = independently H, alkyl, or alkoxy; with provisos; and salts and hydrates thereof] and an immunomodulatory, immunosuppressive, or an antiinflammatory agent are disclosed. Examples include the preparation of over 400 invention compds. and ten biol. assays. For instance, coupling of 5-(2-pyridyl)-3-bromo-2-methoxyphenyl with 2-(2-cyanophenyl)-1,3,2-dioxaborinane in the presence of Cs2CO3 in DMF gave 3-(2-cyanophenyl)-5-(2-pyridyl)-2-methoxyphenyl, which was converted to the 2(1H)-pyridone using NaI and TMSCl in MeCN. Reaction with a suspension of phenylboronic acid, Cu(OAc)2, and TEA in CH2Cl2 provided II. The latter in combination with interferon β reduced the severity of paralysis and weight loss during exptl. allergic encephalomyelitis (EAE) in rats compared to either I or interferon β alone. In addition, nearly 300 example compds. were tested and demonstrated

RN 380921-71-1 CAPLUS
CN [2,3'-Bipyridin]-6'-(1'H)-one, 1'-phenyl-5'-[1-[4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 380921-72-2 CAPLUS

CN Benzonitrile, 2-[1,2-dihydro-2-oxo-1-phenyl-5-[1-(4-piperidinyl)-1H-benzimidazol-2-yl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 380921-92-6 CAPLUS

CN Benzonitrile, 2-[1,2-dihydro-5-[1-(1-methyl-4-piperidinyl)-1H-benzimidazol-2-yl]-2-oxo-1-phenyl-3-pyridinyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN


ACCESSION NUMBER: 2002:10123 CAPLUS
DOCUMENT NUMBER: 136:64091
TITLE: Method and system for predicting pharmacokinetic properties
INVENTOR(S): Hattori, Kazunari; Shimada, Kaore; Uchiyama, Mamoru
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 27 pp.
CODEN: EPXXDM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1167969	A2	20020102	EP 2001-304648	20010525
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2003069698	A1	20030410	US 2001-876767	20010607
JP 2003014728	A2	20030115	JP 2001-179774	20010614
PRIORITY APPLN. INFO.:			US 2000-211864P	P 20000614


AB This invention provides a method for predicting pharmacokinetic properties of mols. comprising the steps of: (a) preparing 3D-structures of mols. used as a training set; (b) constructing a 2D-fingerprint by counting the number of structural descriptors that potentially relate to a pharmacokinetic property, either manually or automatically using internally developed macro; wherein said structural descriptors consist of predefined 20 to 80 atoms/fragments or substructures; (c) analyzing the obtained 2D-fingerprint by a statistical anal. method to correlate with the pharmacokinetic property of the mol. to yield a quant. structure-property relation (QSPR) model; and (d) calculating the pharmacokinetic property of a trial mol. using the above obtained QSPR model. A system for this invention is also provided. According to this method and system, it is possible to predict pharmacokinetic properties of mols. prior to synthesis, without labor-intensive and time-consuming experimentation.

IT 258286-77-0 258286-79-2 258286-84-9
258287-25-1 258287-29-5 258287-68-2
258288-00-5 258288-26-5 258288-50-5
384329-46-8 384329-49-1 384329-50-4
RL: PCT (Pharmacokinetics); PRP (Properties); BIOL (Biological study) (method and system for predicting pharmacokinetic properties)


RN 258286-77-0 CAPLUS
CN 1H-Benzimidazole, 2-(4-methyl-1-piperazinyl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 258286-79-2 CAPLUS
CN 1H-Benzimidazole, 2-(4-methyl-1-piperazinyl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 258286-84-9 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 258287-25-1 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 258287-29-5 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 258287-68-2 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 258288-00-5 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 258288-26-5 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-methylcycloheptyl)-4-piperidinyl]-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 258288-50-5 CAPLUS
CN 4-Piperidinamine, 1-[1-(1-ethenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 384329-46-8 CAPLUS
CN 4-Piperidinamine, 1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 384329-49-1 CAPLUS
CN 4-Piperidinamine, 1-[1-(1-methylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 384329-50-4 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-methylcycloheptyl)-4-piperidinyl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)




L14 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2001:923769 CAPLUS
DOCUMENT NUMBER: 136:53682
TITLE: Preparation of 1,2-dihydropyridinone compounds and use thereof as AMPA receptor and kainite receptor inhibitors
INVENTOR(S): Nagato, Satoshi; Ueno, Kohshi; Kawano, Koki; Norimine, Yoshihiko; Ito, Koichi; Hanada, Takahisa; Ueno, Masataka; Amino, Hiroyuki; Ogo, Makoto; Hatakeyama, Shinji; Urawa, Yoshio; Naka, Hiroyuki; Groom, Anthony John; Rivers, Lesanne; Smith, Terence
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 284 pp.
CODEN: P1XXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096308	A1	20011220	WO 2001-JP4857	20010608
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MM, NZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, QA, OM, GW, ML, MR, NE, SN, TD, TO				
AU 2001062723	A5	20011224	AU 2001-62723	20010608
CA 2412172	AA	20021206	CA 2001-2412172	20010608
EP 1300396	A1	20030409	EP 2001-936920	20010608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011596	A	20040302	BR 2001-11596	20010608
NZ 522773	A	20050624	NZ 2001-522773	20010608
RU 2265015	C2	20051127	RU 2003-100533	20010608
ZA 2002009270	A	20050603	ZA 2002-9270	20021114
US 2004023973	A1	20040205	US 2002-296719	20021126
US 6949571	B2	20050927		
MO 2002005955	A	20030212	MO 2002-5955	20021311
US 2005245581	A1	20051103	US 2005-174514	20050706
			JP 2000-175966	A 20000612
			GB 2000-22483	A 20000913
			WO 2001-JP4857	W 20010608
			US 2002-296719	A3 20021126


PRIORITY APPLN. INFO.:
GI

OTHER SOURCE(S):
MARPAT 136:53682
GI




AB Title compds. [I; Q = NH, O, S; R1, R2, R3, R4, R5 each independently = H, halo, C1-6 alkyl-XA; X = single bond, C1-6 alkylene; A = C6-14 aromatic carbocyclic, C6-14 aromatic heterocyclic], salts, hydrates, and 3-(2-cyanophenyl)-4-(2-pyridyl)-2-methoxypyridine, exhibiting excellent inhibitory activities against AMPA receptor and/or kainite receptor, are prepared. Thus, the title compound II was prepared and orally tested effective as anti-AMPA-induced-spasm agent in male ddY mouse and in vitro


anti-AMPA-induced nerve cell calcium influx.
IT 380921-52-8P 380921-59-5P 380921-71-1P
380921-72-2P 380921-92-6P
RL: PAC (Pharmacological activity); SPM (Synthetic preparation); THU (Therapeutic use); BIOB (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1,2-dihydropyridine-2-one compds. and use thereof as AMPA receptor and kainite receptor inhibitors)
RN 380921-52-8 CAPLUS
CN [2,3'-Bipyridin]-6'-(1'H)-one, 1'-phenyl-5'-[1-[1-(phenylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 380921-59-5 CAPLUS
CN Benzonitrile, 2-[1,2-dihydro-2-oxo-1-phenyl-5-[1-[1-(phenylmethyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 380921-71-1 CAPLUS
CN [2,3'-Bipyridin]-6'-(1'H)-one, 1'-phenyl-5'-[1-(4-piperidinyl)-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 380921-72-3 CAPLUS
CN Benzonitrile, 2-[1,2-dihydro-2-oxo-1-phenyl-5-[1-(4-piperidinyl)-1H-benzimidazol-2-yl]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 380921-92-6 CAPLUS
CN Benzonitrile, 2-[1,2-dihydro-5-[1-(1-methyl-4-piperidinyl)-1H-benzimidazol-2-yl]-2-oxo-1-phenyl-3-pyridinyl]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2001:228903 CAPLUS
DOCUMENT NUMBER: 134:266308
TITLE: Benzimidazole derivatives and combinatorial libraries thereof, and their biological activity
INVENTOR(S): Leng, Hengyuan; Pei, Yasheng
PATENT ASSIGNEE(S): Trega Biosciences, Inc., USA
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGES: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021634	A1	20010329	WO 2000-US20942	20000801
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1214330	A1	20020619	EP 2000-950920	20000801
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PRIORITY APPLN. INFO.:			US 1999-401004	A 19990921
			WO 2000-US20942	W 20000801

OTHER SOURCE(S):
MARPAT 134:266308
GI




AB The invention relates to novel benzimidazole derive. I [R1-R4 = H, halo, (protected) OR, cyano, (un)substituted alkyl(en/yn)yl, alkoxy, aryl, heterocyclyl, carbamoyl, etc.; R5 = H, (un)substituted alkyl, Ph, phenylalkyl, CO2H, amino, heterocyclyl, etc.; R6 = -O-M-E, wherein M = bond, (un)substituted phenylene, cycloalkylene, arylene, heterocyclene, etc.; D = (un)substituted (cyclo/phenyl)alk(en/yn)ylene, phenylene, NH, etc.; E = bond, groups given for D; R7, R8 = H, resin, (un)substituted alkyl, Ph, heterocyclyl, cycloalk(en)yl, sulfonyl or carbonyl derive.; with provisos requiring that one of R1-R4 = (un)substituted COM2 when R6 = CH2]. The invention further relates to combinatorial libraries containing two or more such compds., as well as methods of preparing them. The compds.

are potentially useful due to biol. activity. For instance, a library of 36,288 such benzimidazole derivs. was prepared from 3 arrays of: 48 aromatic or heteroatom, aldehydes; 27 amino acids or diamines; and 28 amines. The synthetic method involved: (1) coupling of an N-protected amino acid component to an amine resin, or a coupling of a diamine component using CDI; (2) deprotection; (3) N-acylation of the supported amine with 4-fluoro-3-nitrobenzoic acid; (4) amidation of the supported acid with an amine component; (5) SnCl₂ reduction of the nitro group to an amine; (6) cyclocondensation of the supported diamine with an aldehyde component; and (7) cleavage from the support with HF. An exemplary compound is II, derived from 4-fluoro-3-nitrobenzoic acid and: BOC-glycine, 2-methyl-1-(3-methylphenyl)piperazine and 4-pyridinecarboxaldehyde. Three bioassays useful for I are described: a melanocortin receptor assay, an antimicrobial screen, and a penile erection assay in rats (vs. HP 228 as control).

IT 331819-10-4P, trans-1-(4-Ureidocyclohexyl)-2-(2,3-dichlorophenyl)-5-[(4-methylhomopiperazin-1-yl)carbonyl]-1H-benzimidazole
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 RN 331819-10-4 CAPLUS
 CN 1H-1,4-Diazepine, 1-[[1-[trans-4-[(aminocarbonyl)amino]cyclohexyl]-2-(2,3-dichlorophenyl)-1H-benzimidazol-5-yl]carbonyl]hexahydro-4-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2000:117042 CAPLUS
 DOCUMENT NUMBER: 132:151821
 TITLE: Preparation of 2-substituted-1-piperidylbenzimidazoles as ORL1 receptor agonists.
 INVENTOR(S): Ito, Fumitaka; Noguchi, Hirohide; Kondo, Hiroshi
 PATENT ASSIGNEE(S): Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.
 SOURCE: PCT Int. Appl., 127 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000008013	A2	20000217	WO 1999-181239	19990705
WO 2000008013	A3	20000323		

piperidinyl]benzimidazole (preparation given) was stirred with MeNH₂ in MeOH in an autoclave at 110° for 6 h to give N-methyl-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-amine.


IT 258286-77-0P 258286-79-2P 258286-80-5P
 258286-84-9P 258286-87-2P 258286-88-3P
 258287-00-2P 258287-07-9P 258287-08-0P
 258287-09-1P 258287-19-3P 258287-20-6P
 258287-23-9P 258287-24-0P 258287-25-1P
 258287-26-2P 258287-27-3P 258287-28-4P
 258287-29-5P 258287-30-8P 258287-37-5P
 258287-38-6P 258287-39-7P 258287-40-0P
 258287-59-1P 258287-60-4P 258287-61-5P
 258287-62-6P 258287-63-7P 258287-64-8P
 258287-67-1P 258287-68-2P 258287-69-3P
 258287-73-9P 258287-74-0P 258287-75-1P
 258287-76-2P 258287-77-3P 258287-78-4P
 258287-79-5P 258287-83-1P 258287-84-2P
 258287-85-3P 258287-86-4P 258287-87-5P
 258287-88-6P 258287-89-7P 258288-00-5P
 258288-01-6P 258288-03-8P 258288-04-9P
 258288-22-1P 258288-24-3P 258288-26-5P
 258288-28-7P 258288-32-3P 258288-33-4P
 258288-40-1P 258288-42-5P 258288-50-5P
 258288-51-6P 258288-56-1P 258288-57-2P
 258289-05-1P 258289-06-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2-substituted-1-piperidylbenzimidazoles as ORL1 receptor agonists)

RN 258286-77-0 CAPLUS
 CN 1H-Benzimidazole, 2-(4-methyl-1-piperazinyl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 258286-79-2 CAPLUS
 CN 1H-Benzimidazole, 2-(4-methyl-1-piperazinyl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 258286-80-5 CAPLUS


M: AR, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TW, TR, TT, UA, UG, US, UZ, VB, VU, ZA, ZW
 RN: GA, GM, KE, LS, MW, SD, SE, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CO, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TO

TM 513424	B	20021211	TW 1999-88110899	19990628
CA 2339621	AA	20000217	CA 1999-2339621	19990705
CA 2339621	C	20050405		
AU 9943859	A1	20000228	AU 1999-43859	19990705
AU 749166	B2	20020620		
EP 1102762	A2	20010530	EP 1999-926688	19990705
EP 1102762	B1	20021113		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO				
TR 200100403	T2	20010723	TR 2001-200100403	19990705
BR 9912778	A	20010925	BR 1999-12778	19990705
BR 200100075	A	20020617	BR 2001-75	19990705
JP 2002522431	B2	20020723	JP 2000-563646	19990705
JP 3367945	T2	20030120		
AT 227716	B	20021115	AT 1999-926688	19990705
PT 1102762	T	20030228	PT 1999-926688	19990705
ES 2185357	T3	20030416	ES 1999-926688	19990705
NZ 509299	A	20030530	NZ 1999-509299	19990705
US 6172067	B1	20010109	US 1999-169208	19990805
ZA 2001000900	A	20020603	ZA 2001-900	20010201
HR 2001000589	A1	20020228	HR 2001-89	20010202
HR 200100029	B1	20020430		
NO 2001000603	A	20010405	NO 2001-603	20010205
BO 105301	A	20011231	BO 2001-105301	20010301
US 2003109549	A1	20030612	US 2002-283604	20021030

PRIORITY APPLN. INFO.:


OTHER SOURCE(S): MARPAT 132:151821

OI




AB Title compds. [I; R = (substituted) mono-, di-, tri-, or tetracycloalkyl; A = alkyl, haloalkyl, alkenyl, alkynyl, (substituted) phenylethyl, aryl, heteroaryl, heterocyclyl; Y = H, halo, amino, SH, (substituted) alkyl-M, cycloalkyl-M, alkenyl-M, alkyl-NH-alkyl-M, dialkyl-N-alkyl-M, aryl-M, heterocyclyl-M, arylalkyl-M, etc.; M = bond, O, S, NH S, SO, SO₂, etc.; Z1-Z4 = H, halo, alkyl, haloalkyl, alkoxy, alkylsulfonyl, alkylcarbonyl, CO₂H, amino, H₂NCO, Ph, naphthyl, etc.], were prepared as ORL1 receptor agonists (no date). Thus, 2-chloro-1-[1-(1-phenylcycloheptyl)-4-



CN 1H-Benzimidazole, 1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 258286-84-9 CAPLUS
 CN 1H-Benzimidazole, 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 258286-87-2 CAPLUS
 CN 1-Piperidinecarboximidamide, 4-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 258286-88-3 CAPLUS
 CN 1-Piperazinecarboximidamide, 4-[1-[1-(1-methylcyclooctyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 258287-00-2 CAPLUS
CN 1H-Benzimidazole, 2-((4-methyl-1-piperazinyl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl])- trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 258287-07-9 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(1-pyrrolidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 258287-08-0 CAPLUS
CN 1H-Benzimidazole, 2-(4-morpholinyl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 258287-09-1 CAPLUS
CN 1H-Benzimidazole, 2-(4-morpholinyl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 258287-19-3 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 258287-20-6 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 258287-23-9 CAPLUS
CN 1H-Benzimidazole, 2-cyclohexyl-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 258287-24-0 CAPLUS
CN 1H-Benzimidazole, 2-cyclohexyl-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 258287-25-1 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 258287-26-2 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(1-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 258287-27-3 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(4-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)

(phenylmethyl)-1-piperazinyl]- (9CI) (CA INDEX NAME)




RN 258287-28-4 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(4-phenylmethyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 258287-29-5 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 258287-30-8 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 258287-37-5 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(4-fluorophenyl)cycloheptyl]-4-piperidinyl]-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 258287-38-6 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(4-fluorophenyl)cycloheptyl]-4-piperidinyl]-2-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 258287-39-7 CAPLUS
CN 1H-Benzimidazole, 2-[4-methyl-1-piperazinyl]-1-[1-(1-phenylcyclooctyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 258287-40-0 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 258287-59-1 CAPLUS
CN Piperazine, 1-acetyl-4-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 258287-60-4 CAPLUS
CN Piperazine, 1-acetyl-4-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 258287-61-5 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(4-phenyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




RN 258287-62-6 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(4-phenyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 258287-63-7 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




RN 258287-64-8 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(4-pyridinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 258287-67-1 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 258287-68-2 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




RN 258287-69-3 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-methylcycloonyl)-4-piperidinyl]-2-(4-methyl-1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl


RN 258287-73-9 CAPLUS
CN 1H-Benzimidazole, 4-fluoro-2-(4-methyl-1-piperazinyl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 258287-74-0 CAPLUS
CN 1H-Benzimidazole, 5-fluoro-2-(4-methyl-1-piperazinyl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 258287-75-1 CAPLUS
CN 1H-Benzimidazole, 5-fluoro-2-(4-methyl-1-piperazinyl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 258287-76-2 CAPLUS
CN 1H-Benzimidazole, 6-fluoro-2-(4-methyl-1-piperazinyl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 258287-77-3 CAPLUS
CN 1H-Benzimidazole, 6-fluoro-2-(4-methyl-1-piperazinyl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 258287-78-4 CAPLUS
CN 1H-Benzimidazole, 2-(4-methyl-1-piperazinyl)-1-[1-(1-phenylcyclohexyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 258287-79-5 CAPLUS
CN 1H-Benzimidazole, 2-(4-methyl-1-piperazinyl)-1-[1-(1-phenylcyclohexyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 258287-83-1 CAPLUS
CN 4-Piperidinone, 1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 258287-84-2 CAPLUS
CN 4-Piperidinone, 1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 258287-85-3 CAPLUS
CN 4-Piperidinol, 1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 258287-86-4 CAPLUS
CN 4-Piperidinol, 1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 258287-87-5 CAPLUS
CN 4-Piperidinone, 1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, oxime (9CI) (CA INDEX NAME)



RN 258287-88-6 CAPLUS
CN 4-Piperidinone, 1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, oxime, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 258287-87-5
CNF C30 H39 N5 O




CM 2

CRN 110-17-8
CNF C4 H4 O4

Double bond geometry as shown.




RN 258287-89-7 CAPLUS
CN 4-Piperidinamine, 1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 258288-00-5 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 258288-01-6 CAPLUS
CN 1H-Benzimidazole, 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-(1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 258288-03-8 CAPLUS
CN 1-Piperidinecarboximidamide, 4-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 258288-04-9 CAPLUS
CN 1-Piperazinecarboximidamide, 4-[1-[1-(1-methylcyclooctyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 258288-22-1 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-methylcycloheptyl)-4-piperidinyl]-2-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 258288-24-3 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-methylcycloheptyl)-4-piperidinyl]-2-(4-piperidinyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 258288-26-5 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-methylethyl)cycloheptyl]-4-piperidinyl]-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 258288-28-7 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-methylethyl)cycloheptyl]-4-piperidinyl]-2-(1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




● 3 HCl

RN 258288-32-3 CAPLUS
CN 4-Piperidinamine, 1-[1-[1-(1-phenyl-4-cyclohepten-1-yl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 258288-33-4 CAPLUS
CN 4-Piperidinamine, 1-[1-[1-(1-phenyl-4-cyclohepten-1-yl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 258288-40-3 CAPLUS
CN 4-Piperidinamine, 1-[1-[1-(1-methylethyl)cycloheptyl]-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 258288-43-5 CAPLUS
CN 4-Piperidinamine, 1-[1-[1-(1-methylethyl)cycloheptyl]-4-piperidinyl]-1H-benzimidazol-2-yl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 258288-50-5 CAPLUS
CN 4-Piperidinamine, 1-[1-[1-(1-ethenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 258288-51-6 CAPLUS
CN 4-Piperidinamine, 1-[1-[1-(1-ethenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 258288-56-1 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-phenyl-4-cyclohepten-1-yl)-4-piperidinyl]-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 258288-57-2 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-phenyl-4-cyclohepten-1-yl)-4-piperidinyl]-2-(1-piperazinyl)-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

RN 258289-05-3 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)





RN 258289-06-4 CAPLUS
CN 1H-Benzimidazole, 4-fluoro-2-(4-methyl-1-piperazinyl)-1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-, trihydrochloride (9CI) (CA INDEX NAME)




●3 HCl

IT 258288-83-4P 258288-88-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 2-substituted-1-piperidylbenzimidazoles as ORL1 receptor agonists)

RN 258288-83-4 CAPLUS
CN 1H-Benzimidazole, 1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-2-(1-phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 258288-88-9 CAPLUS
CN Carbamic acid, {1-[1-[1-(1-phenylcycloheptyl)-4-piperidinyl]-1H-benzimidazol-2-yl]-4-piperidinyl}-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




DOCUMENT NUMBER: 129:148993
 TITLE: Preparation and formulation of m- (heteroaryloxy)alkanamines as serotonin reuptake inhibitors and 5-HT1A receptor ligands
 INVENTOR(S): Audie, James E.; Hibeckman, David J.; Krushinski, Joseph H., Jr.; Mabry, Thomas E.; Nissen, Jeffrey S.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.; Wong, David T.
 PATENT ASSIGNER(S): Eli Lilly Co., USA
 SOURCE: U.S., 67 pp., Cont.-in-part of U. S. Ser. No. 373,823, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5789402	A	19980804	US 1995-471121	19950606
CN 1178530	A	19980408	CN 1996-192598	19960111
PRIORITY APPL. INFO.:			US 1995-373823	B2 19950117
OTHER SOURCE(S):		MARPAT 129:148993		

GI



AB Title compds. [I; R1 = (CH2)RCHXCH2(CH3)R; r = 0-4; s = 0-1; D = a residue which combines with the carbon atoms to which it is attached to complete a pyrrolyl group; X = H, Ph, OH, MeO; R = (un)substituted piperazino, piperidino, etc.] were prep'd as serotonin reuptake inhibitors and 5-HT1A receptor ligands (no data). Thus, refluxing of (8)-(+)-4-(oxiranylmethoxy)-1H-indole with 4-amino-1-benzylpiperidine in MeOH gave (2S)-(-)-I [R1 = CH2CH(OH)CH2R, R = 1-benzyl-4-piperidinylamino].
 IT 180157-24-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of heteroaryloxy alkanamines having effects on serotonin-related systems)
 RN 180157-24-8 CAPLUS
 CN 1-Piperidineethanol, n-[(1H-indol-4-yloxy)methyl]-4-(2-phenyl-1H-benzimidazol-1-yl)-, (aS)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
 CM 1
 CRN 180157-23-7
 CMF C29 H30 N4 O2
 Absolute stereochemistry. Rotation (-).




CM 2
 CRN 144-62-7
 CMF C2 H2 O4



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L14 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1998:260235 CAPLUS
 DOCUMENT NUMBER: 129:49317
 TITLE: Synthesis of biologically active derivatives of xanthine and benzimidazole
 AUTHOR(S): Khaliullin, F. A.; Kataev, V. A.; Alekhin, S. K.; Volkova, S. S.; Nasyrov, Kh. M.; Strokin, Yu. V.
 CORPORATE SOURCE: Bashk. Gos. Med. Univ., Ufa, Russia
 SOURCE: Bashkirekii Khimicheskii Zhurnal (1997), 4(4), 59-62
 CODEN: BKHFUJ; ISSN: 0869-8406
 PUBLISHER: Izdatel'stvo "Reaktiv"
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 AB A study was done of reactions of amines with products of xanthines or benzimidazoles alkylation by epithiochlorohydrin. 2-Amino-substituted 1-(3-thienyl)benzimidazoles were synthesized from 1-(3-thienyl)-2-chlorobenzimidazole. 8-Amino-substituted deriva. were formed from 8-bromo-1,3-dimethyl-7-(1-oxothietanyl-3)- and 8-bromo-1,3-dimethyl-7-(1,1-dioxothietanyl-3)xanthines. 2-Amino-substituted 2,3-dihydrothiazolo[3,2-e]benzimidazoles were synthesized from 2-methylsulfonyl-1-(2,3-epithiopropyl)benzimidazole. Immunotropic and anti-inflammatory activities of the synthesized compds. were discovered.
 IT 208577-07-5P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of biol. active deriva. of xanthine and benzimidazole)
 RN 208577-07-5 CAPLUS
 CN 1H-Benzimidazole, 2-(4-phenyl-1-piperazinyl)-1-(3-thienyl)- (9CI) (CA INDEX NAME)



L14 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1998:25697 CAPLUS
 DOCUMENT NUMBER: 128:294709
 TITLE: Heterocycloxyalkanamines having effects on serotonin-related systems
 INVENTOR(S): Hibeckman, David J.; Krushinski, Joseph H., Jr.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.
 PATENT ASSIGNER(S): Eli Lilly and Co., USA
 SOURCE: U.S., 65 pp., Cont.-in-part of U.S. Ser. No. 373,823, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5741789	A	19980421	US 1995-467434	19950606
CN 1178530	A	19980408	CN 1996-192598	19960111
US 6172073	B1	20010109	US 1998-49837	19980327
PRIORITY APPL. INFO.:			US 1995-373823	B2 19950117
OTHER SOURCE(S):		MARPAT 128:294709	US 1995-467434	A3 19950606

GI



AB A series of heterocycloxy-substituted alkanamines I [m = 0-4; n = 0-1; D = a atoms to complete fused pyrrolo, imidazolo, pyrido, pyrazino, pyridazino, or pyrimido nucleus (only pyrido is claimed); X = H, Ph, OH, OMe; R = H or Ph when m = 0; R = certain (un)substituted cyclic, bicyclic, and alicyclic amino groups] are effective pharmaceuticals for the treatment of conditions related to or affected by the reuptake of serotonin and by the serotonin 1A receptor (no data). Some I show a unique combination of 5-HT1A receptor activity and serotonin reuptake inhibition. I are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression and other conditions for which serotonin reuptake inhibitors are used. Over 200 synthetic examples and 7 standard formulation examples are given. In the only example of a claimed compound (quinoline-derived, D = pyrido), reaction of (R)-5-(oxiranylmethoxy)quinoline with 6-chloro-2-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole in EtOH gave the preferred compound II in 87% yield.
 IT 180157-24-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of heterocycloxyalkanamines as serotonin 1A antagonists and reuptake inhibitors)
 RN 180157-24-8 CAPLUS

CN 1-Piperidineethanol, n-[(1H-indol-4-yloxy)methyl]-4-(2-phenyl-1H-benzimidazol-1-yl)-, (aS)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
 CM 1
 CRN 180157-23-7
 CMF C29 H30 N4 O2
 Absolute stereochemistry. Rotation (-).



CM 2
 CRN 144-62-7
 CMF C2 H2 O4




REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1997:344806 CAPLUS
 DOCUMENT NUMBER: 127:34133
 TITLE: Heterocycloxyalkanamines having effects on serotonin-related systems
 INVENTOR(S): Audie, James E.; Hibeckman, David J.; Krushinski, Joseph H., Jr.; Mabry, Thomas E.; Nissen, Jeffrey S.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.; Wong, David T.
 PATENT ASSIGNER(S): Eli Lilly and Company, USA
 SOURCE: U.S., 65 pp., Cont.-in-part of U.S. Ser. No. 373,823, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 6
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5627196	A	19970506	US 1995-468948	19950606
CN 1178530	A	19980408	CN 1996-192598	19960111
PRIORITY APPL. INFO.:			US 1995-373823	B2 19950117
OTHER SOURCE(S):		MARPAT 127:34133		


GI



● HCl

RN 185056-26-2 CAPLUS
CN Propanamide, 2-amino-N-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinylethyl]-2-methyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 185056-50-2 CAPLUS
CN Propanamide, 2-amino-2-methyl-N-[4-phenyl-1-[[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]butyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 185056-55-7 CAPLUS
CN 4-Piperidinecarboxamide, N-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinylethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 185056-62-6 CAPLUS
CN 4-Piperidinecarboxamide, N-[2-[4-(2-cyclopropyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(2-naphthalenylmethyl)-2-oxoethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 185056-64-8 CAPLUS
CN 4-Piperidinecarboxamide, N-[1-(2-naphthalenylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinylethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 185056-73-9 CAPLUS
CN Butanamide, 2-amino-N-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinylethyl]-3-methyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 185056-77-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-methyl-N-[1-(2-naphthalenylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinylethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 185056-80-8 CAPLUS
CN Propanamide, 2-amino-2-methyl-N-[2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(phenylmethyl)ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 185961-75-5 CAPLUS
CN Propanamide, 2-amino-N-[1-[(6-fluoro-1H-indol-3-yl)methyl]-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

IT 185057-43-6P 185058-28-OP 185058-33-7P
185058-93-9P 185059-01-2P 185059-08-9P
185059-10-3P 185059-11-4P 185059-29-4P
185059-37-4P 185962-11-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of growth hormone-releasing dipeptides)
RN 185057-43-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(phenylmethyl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 185058-28-0 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 185058-33-7 CAPLUS
CN Carbamic acid, [2-[[[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 185058-93-9 CAPLUS
CN Carbamic acid, [1,1-dimethyl-2-oxo-2-[[[4-phenyl-1-[[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]butyl]amino]ethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 185059-01-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 185059-08-9 CAPLUS
CN 1H-Benzimidazole, 2-cyclopropyl-1-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 185059-10-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[2-[4-(2-cyclopropyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(2-naphthalenylmethyl)-2-oxoethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 185059-11-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-[2-naphthalenylmethyl]-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 185059-29-4 CAPLUS
CN Carbamic acid, [3-[[[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]-1,1-dimethyl-3-oxopropyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 185059-37-4 CAPLUS
CN Carbamic acid, [1,1-dimethyl-2-oxo-2-[(2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]ethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185962-11-2 CAPLUS
CN Carbamic acid, [2-[[1-[(6-fluoro-1H-indol-3-yl)methyl]-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L14 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1997:26293 CAPLUS
DOCUMENT NUMBER: 126:60362
TITLE: Preparation of heterocyclic dipeptide derivatives

INVENTOR(S): which promote release of growth hormone
Carpino, Philip A.; Jardine DeSilva, Paul A.; Lofker, Bruce A.; Ragan, John A.
PATENT ASSIGNEE(S): Pfizer, Inc., USA
SOURCE: PCT Int. Appl., 158 pp.
CODEN: P1XXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9635713	A1	19961114	WO 1995-18333	19950508
W: CA, FI, JP, MX, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9654554	A1	19961212	AU 1996-54554	19960528
PRIORITY APPL. INFO.:				
WO 1995-18333 A 19950508				
WO 1995-18410 A 19950529				

OTHER SOURCE(S): MARPAT 126:60362
OI




AB Title compds. I [Z = COCR1R2cLCOANR4R5; L = NR6, O, CH2; W = H; W and X = benzo fusion optionally substituted with 1-3 R3a, TR3b, or R12; Y = H, C1-6 alkyl, C3-10 cycloalkyl, aryl optionally substituted with 1-3 R3a, R3b, or R12; X = OR2, R5OMN(Aryl), R8R9NCO, R2bO2C, optionally substituted carbocyclic or heterocyclic ring; R1 = optionally substituted C1-10 alkyl, aryl, etc.; R2c = H, C1-6 alkyl, C3-7 cycloalkyl; CH1R3c = optionally substituted C3-8 ring; R2 = H, C1-6 alkyl, C3-7 cycloalkyl; R2a = H, C1-6 alkyl; R2b = H, C1-8 alkyl, C1-8 halogenated alkyl, C3-8 cycloalkyl, alkylaryl, aryl; R3a, R12 = independently H, halo, Me, OMe, CF3; T = bond, phenylene, 5- or 6-membered heterocycle containing 1-3 hetero atoms; R3b = H, CONR8R9, SO2NR8R9, CO2H, CO2(C1-6 alkyl), NR2SO2R9, NR2CONR8R9, NR2SO2NR8R9, NR2COR9, imidazolyl, thiazolyl, tetrazolyl; R4, R5 = independently H, optionally substituted C1-6 alkyl; R6 = H, C1-6 alkyl; R6CR2c = C3-8 ring; R5O = optionally substituted morpholino, piperazino, C3-7 cycloalkyl, C1-6 alkyl; M = CO, SO2; A = bond, Z1(CH2)2XCR7R7a(CH2)2; Z1 = NR2, O, bond; R7, R7a = independently H, CF3, Ph, optionally substituted C1-6 alkyl; R8 = H, optionally substituted C1-6 alkyl; R9 = H, optionally substituted C1-6 alkyl, Ph, thiazolyl, imidazolyl, furyl, thienyl, are growth hormone releasing peptide mimics. Heterocyclic dipeptide deriva. I are useful for the treatment and prevention of osteoporosis. Thus, condensation of Boc-D-Ser(CH2Ph)-OH (Boc = Me3CO2C) with 4-(2-oxo-1-benzimidazol-1-yl)piperidine, followed by deprotection, coupling with BocHRCMe2CO2H, and deprotection with HCl gave dipeptide amide salt II.

IT 185056-64-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation and growth hormone releasing activity of heterocyclic dipeptide)

deriva.)
RN 185056-64-8 CAPLUS
CN 4-Piperidinecarboxamide, N-[1-(2-naphthalenylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 185055-90-7P 185056-26-2P 185056-49-9P
185056-50-2P 185056-55-7P 185056-62-6P
185056-73-9P 185056-77-3P 185056-80-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and growth hormone releasing activity of heterocyclic dipeptide deriva.)

RN 185055-90-7 CAPLUS
CN 4-Piperidinecarboxamide, N-[2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(phenylmethyl)ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 185056-26-2 CAPLUS
CN Propanamide, 2-amino-N-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-methyl-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 185056-49-9 CAPLUS
CN Propanamide, 2-amino-N-[1-[(6-fluoro-1H-indol-3-yl)methyl]-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185056-50-2 CAPLUS
CN Propanamide, 2-amino-2-methyl-N-[4-phenyl-1-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]butyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 185056-55-7 CAPLUS
CN 4-Piperidinecarboxamide, N-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinylethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 185056-62-6 CAPLUS
CN 4-Piperidinecarboxamide, N-[2-[4-(2-cyclopropyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(2-naphthalenylmethyl)-2-oxoethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 185056-73-9 CAPLUS
CN Butanamide, 3-amino-N-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinylethyl]-3-methyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 185056-77-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-methyl-N-[1-(2-naphthalenylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinylethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 185056-80-8 CAPLUS
CN Propanamide, 2-amino-2-methyl-N-[2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(phenylmethyl)ethyl]-, monohydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl


IT 185057-43-6P 185058-28-0P 185058-33-7P
185058-92-8P 185058-93-9P 185059-01-2P
185059-08-9P 185059-10-3P 185059-11-4P
185059-29-4P 185059-37-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and growth hormone releasing activity of heterocyclic dipeptide derive.)

RN 185057-43-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(phenylmethyl)ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 185058-28-0 CAPLUS
CN 1H-Benzimidazole, 2-phenyl-1-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 185058-33-7 CAPLUS
CN Carbamic acid, [2-[[1-[(4-fluoro-1H-indol-3-yl)methyl]-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinylethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 185058-92-8 CAPLUS
CN Carbamic acid, [2-[[1-[(4-fluoro-1H-indol-3-yl)methyl]-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinylethyl]amino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 185058-93-9 CAPLUS
CN Carbanic acid, [1,1-dimethyl-2-oxo-2-[[4-phenyl-1-[[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]butyl]amino]ethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185059-01-2 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 185059-08-9 CAPLUS
CN 1H-Benzimidazole, 2-cyclopropyl-1-[1-(phenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185059-37-4 CAPLUS
CN Carbanic acid, [1,1-dimethyl-2-oxo-2-[[2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(phenylmethyl)ethyl]amino]ethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L14 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:15489 CAPLUS
DOCUMENT NUMBER: 126:74755
TITLE: Preparation and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and analogs as 5-HT1A receptor ligands
INVENTOR(S): Krushinski, Joseph H., Jr.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: U.S., 63 pp., Cont.-in-part of U.S. Ser. No. 383,823, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 576321	A	19961119	US 1995-468900	19950606
CA 2210220	AA	19960725	CA 1996-2210220	19960111
WO 9622290	A1	19960725	WO 1996-US41	19960111

W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, DE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LV, MD, MG, MK, MN, MW,




RN 185059-10-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[2-[4-(2-cyclopropyl-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(2-naphthalenylmethyl)-2-oxoethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 185059-11-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[1-(2-naphthalenylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]carbonyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185059-29-4 CAPLUS
CN Carbanic acid, [3-[[[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]ethyl]amino]-1,1-dimethyl-3-oxopropyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

MX, NO, NZ, PL, RO, RU, SD, SO, SI, SK, TJ, TM, TR, TT, UA, UO, US, US
RW: KR, LS, MW, SD, SZ, UG, BP, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9646516 A1 19960807 AU 1996-46516 19960111
AU 718875 B2 20000420
BR 9607077 A 19971118 BR 1996-7077 19960111
CN 1178530 A 19980408 CN 1996-192598 19960111
JP 10512861 T2 19981208 JP 1996-522282 19960111
EP 722941 A2 19960724 EP 1996-300286 19960115
EP 722941 A3 20000412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
NO 9703281 A 19970908 NO 1997-3281 19970715
FI 9703024 A 19970716 FI 1997-3024 19970716
PRIORITY APPL. INFO.: US 1995-373823 B2 19950117
US 1995-468900 A 19950606
WO 1996-US41 W 19960111
OTHER SOURCE(S): MARPAT 126:74755
OI




AB Title compds. [I; A = atoms to complete an N-containing heterocyclic ring; R1 = (CH2)2CHCH2CH2CH2SR; R = alkylamino, azinylamino, N-attached heterocyclyl, etc.; R2 = H, OH, OMe, Ph; R = 0-4; n = 0-1] were prepared as 5-HT1A receptor ligands (no data). Thus, (S)-4-oxiranylmethoxy-1H-indole was aminated by 4-amino-1-benzylpiperidine to give title compound (S)-II.
IT 180157-24-BP
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRP (Preparation); USES (Uses)
[preparation and formulation of 4-(3-amino-2-hydroxypropoxy)indoles and analogs as 5-HT1A receptor ligands]
RN 180157-24-B CAPLUS
CN 1-Piperidineethanol, α-[[[1-(1H-indol-4-yl)oxy]methyl]-4-(2-phenyl-1H-benzimidazol-1-yl)-, (aS)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180157-23-7
CMF C29 H30 N4 O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 144-62-7
CMF C2 H2 O4



L14 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1996:509758 CAPLUS
DOCUMENT NUMBER: 125:168021
TITLE: Preparation of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A receptor antagonists and partial agonists
INVENTOR(S): Audia, James E.; Hibschman, David J.; Krushinski, Jr Joseph H.; Mabry, Thomas E.; Nissen, Jeffrey S.; Rasmussen, Kurt; Rocco, Vincent P.; Schaus, John M.; Thompson, Dennis C.; Wong, David T.
PATENT ASSIGNER(S): Eli Lilly and Co., USA
SOURCE: Eur. Pat. Appl., 112 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 722941	A2	19960724	EP 1996-300286	19960115
EP 722941	A3	20000412		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5576321	A	19961119	US 1995-468900	19950606
PRIORITY APPLN. INFO.: US 1995-373823 A 19950117				
US 1995-468900 A 19950606				
OTHER SOURCE(S): MARPAT 125:168021				
GI				



AB The title compds. [I; R = O-4; s = O-1; D = pyrrolo, imidazo, etc.; X = H,


Ph; R = piperazino, piperidinyl, morpholino, etc.], useful for alleviating the symptoms of nicotine and tobacco withdrawal, and for the treatment of depression, anxiety, hypertension, etc., were prepared and formulated. Thus, refluxing of indole II with 4-amino-1-benzylpiperidine in MeOH for 18 h afforded 78% desired product III. In general, compds. I are effective at 20-25 mg/day.

IT 180157-24-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of 3-(4-indolyloxy)-2-hydroxypropanamines as serotonin 1A receptor antagonists and partial agonists)
RN 180157-24-8 CAPLUS
CN 1-Piperidineethanol, α -[(1H-indol-4-yloxy)methyl]-4-(2-phenyl-1H-benzimidazol-1-yl)-, (oS)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180157-23-7
CMF C29 H30 N4 O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 144-62-7
CMF C2 H2 O4




L14 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1995:833943 CAPLUS
DOCUMENT NUMBER: 123:305897
TITLE: Metabolism of pimobendan in long-term human hepatocyte culture: in vivo-in vitro comparison
AUTHOR(S): Pahernik, S. A.; Schmid, J.; Sauter, T.; Schildberg, F. W.; Koebe, H.-G.
CORPORATE SOURCE: Chirurgische Klinik, Ludwig-Maximilians-Universitaet Muenchen, Munich, D-81366, Germany
SOURCE: Xenobiotica (1995), 25(8), 811-23
CODEN: XENOBH; ISSN: 0049-8254
PUBLISHER: Taylor & Francis
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The aim of this study was to investigate further the potential of a new hepatocyte culture based on the hypothesis that liver cells in an appropriate in vitro environment (immobilizing gel technique) maintain high metabolic activity comparable with that in vivo. Pimobendan (UD-CO

115), a pyridazinone derivative, is a cardiotonic vasodilator that increases myocardial contractility through calcium sensitization and relaxation of vascular smooth muscle, probably due to phosphodiesterase inhibition. In man, pimobendan is O-demethylated to UD-CO 212. This latter is metabolized to O- and N-glucuronides. Pimobendan itself is also glucuronidated to a N-glucuronide. Human hepatocytes immobilized in collagen gel were incubated with pimobendan to investigate their metabolic activity in the long-term and to compare the results in the data from clin. trials. ¹⁴C-labeled pimobendan was incubated at two concns. (10 and 100 μ M) at day 3, 11 and 22 of culture, and samples were analyzed after 4, 24 and 48-h incubation. Metabolic patterns were evaluated by HPLC with radioactivity-, and diode array-, and mass spectral-detection. In vitro, pimobendan was O-demethylated and subsequently O-glucuronidated. The rate of metabolism of pimobendan could be maintained to this culture system for >3 wk. However, the relative amount of a putative N-glucuronide under in vitro conditions was lower than in vivo.


IT 170125-53-8 170125-54-9
RL: BSU (Biological study, unclassified); MPM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(biotransformation of pimobendan in human hepatocyte culture)
RN 170125-53-8 CAPLUS
CN β -D-Glucopyranuronic acid, 1-deoxy-1-[2-(4-methoxyphenyl)-5-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170125-54-9 CAPLUS
CN β -D-Glucopyranuronic acid, 1-deoxy-1-[2-(4-hydroxyphenyl)-5-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L14 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1993:124534 CAPLUS
DOCUMENT NUMBER: 118:124534
TITLE: Preparation of 2-(imidazolylpiperidino)benzimidazoles and analogs as 5-HT receptor ligands
INVENTOR(S): Jegham, Samir; Defosse, Gerard; Purcell, Thomas; Schoemaker, Johannes
PATENT ASSIGNER(S): Synthelabo S. A., Fr.
SOURCE: Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 507650	A1	19921007	EP 1992-400780	19920323
EP 507650	B1	19960522		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
FR 2674855	A1	19921009	FR 1991-4009	19910403
FR 2674855	B1	19940114		
AT 138375	E	19960615	AT 1992-400780	19920323
CA 2064924	AA	19921004	CA 1992-2064924	19920402
NO 9201281	A	19921005	NO 1992-1281	19920402
AU 9213989	A1	19921008	AU 1992-13989	19920402
AU 646332	B2	19940217		
CN 1065459	A	19921021	CN 1992-102327	19920402
JP 05112563	A2	19930507	JP 1992-80690	19920402
JP 07088378	B4	19950927		
HU 62573	A2	19930528	HU 1992-1116	19920402
HU 5280030	A	19940118	US 1992-862376	19920402
PRIORITY APPLN. INFO.: FR 1991-4009 A 19910403				
OTHER SOURCE(S): MARPAT 118:124534				
GI				




AB Title compds. [I; R = H, F; R¹ = H, (cyclo)alkyl; X = O, S, NR₃; R₃ = H, (cyclo)alkyl, Ph, pyridyl, etc.] were prepared. Thus, 1-(4-pyridyl)-1-propanone was converted in 2 steps to 2-amino-1-(4-pyridyl)-1-propanone which was cyclized with KSCN and the product converted in 2 steps to 4-(5-methyl-1H-imidazol-4-yl)piperidine. The latter was condensed with 2-chloro-1-(1-methylethyl)-1H-benzimidazole (preparation given) to give I (R = H, R¹ = Me, X = NCHMe₂). I gave \geq 50% inhibition of serotonin-induced bradycardia in rats at 10 μ g/kg i.v.

IT 146365-95-9P 146365-96-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as 5-HT receptor ligand)
RN 146365-95-9 CAPLUS
CN 1H-Benzimidazole, 1-cyclopropyl-2-(4-(5-methyl-1H-imidazol-4-yl)-1-piperidinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CH 1


CRN 146365-94-8
CMP C19 H23 N5




CH 2

CRN 110-17-8
CMP C4 H4 O4

Double bond geometry as shown.



RN 146365-96-0 CAPLUS
CN 1H-Benzimidazole, 1-cyclopropyl-2-[4-(1H-imidazol-4-yl)-1-piperidinyl]- (9CI) (CA INDEX NAME)



L14 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1979:54975 CAPLUS
DOCUMENT NUMBER: 90:54975
TITLE: 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives
INVENTOR(S): Raeymaekers, Alfons H. M.; Van Geider, Josephus L. H.; Boeckx, Gustaaf M.; Van Hemeldonck, Lodewijk L.
PATENT ASSIGNER(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: Ger. Offen., 68 pp.
CODEN: GWKXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2813523	A1	19781005	DE 1978-2813523	19780329
US 4179505	A	19791218	US 1978-866882	19780104
CA 1119597	A1	19820309	CA 1978-298497	19780308
SE 7803057	A	19781001	SE 1978-3057	19780316
FR 2385713	A1	19781027	FR 1978-7675	19780316
FR 2385713	B1	19831223		

ES 468077	A1	19790901	ES 1978-468077	19780320
AU 7834313	A1	19790927	AU 1978-34313	19780320
AU 517661	B2	19810820		
BE 865110	A2	19790921	BE 1978-186107	19780321
GB 1598278	A	19810916	GB 1978-11524	19780322
GB 7801358	A	19781001	DK 1978-1358	19780328
IL 54373	A1	19820331	IL 1978-54373	19780328
FI 7800954	A	19781001	FI 1978-954	19780329
NL 7803312	A	19781003	NL 1978-3312	19780329
NO 7801078	A	19781003	NO 1978-1078	19780329
JP 53141287	A2	19781208	JP 1978-35366	19780329
JP 63035591	B4	19880805		
ZA 7801789	A	19791128	ZA 1978-1789	19780329
PL 118310	B1	19810930	PL 1978-205650	19780329
AT 7802209	A	19820115	AT 1978-2209	19780329
AT 368136	B	19820910		
SU 986297	A3	19821230	SU 1978-2595004	19780329
HU 22951	O	19820728	HU 1978-JA815	19780330
HU 180477	B	19830328		
US 4243806	A	19810106	US 1979-48216	19790613
			US 1977-782651	A 19770330
			US 1978-866882	A 19780104


PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 90:54975


Q1




AB The benzimidazole deriva. I [R = R1 = thienyl, pyridyl, Ph optionally substituted by R, NO2, alkyl, alkoxy; R2 = H, alkyl, cycloalkyl, aralkyl, (esterified or etherified) hydroxy- or mercaptoalkyl, haloalkyl; R3 = R2, R4R5 = bond; R6R7 = O, R8 = H; n = 1, 2] and their salts were prepared for use as antihistaminics at 0.0025-0.16 mg/mL in vitro and as antianaphylactics at 2.5 mg/kg in vivo. Thus, II (prepared by the reaction of 4,3-Cl(OM)C6H3CH2Cl with 1-(diphenylmethyl)piperazine, followed by N-alkylation and reduction) reacted with MeC(OR)3 in HOAc to give I (R = R1 = Ph, R2 = Pr, R3 = H, R4R5 = bond, n = 1).
IT 68741-41-3P 68741-42-4P 68741-50-4P
68741-51-5P 68741-59-3P 68741-60-6P
RL: SPN (Synthetic preparation): PREP (Preparation)
RN 68741-41-3 CAPLUS
CN 1H-Benzimidazole, 1,2-dicyclopropyl-5-[[4-(diphenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 68741-42-4 CAPLUS
CN 1H-Benzimidazole, 1-cyclopropyl-2-[4-(1H-imidazol-4-yl)-1-piperidinyl]methyl- (9CI) (CA INDEX NAME)




RN 68741-50-4 CAPLUS
CN 1H-Benzimidazole, 2-cyclopropyl-1-cyclopropyl-5-[[4-(diphenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 68741-51-5 CAPLUS
CN 1H-Benzimidazole, 1,2-dicyclopropyl-5-[[4-(diphenylmethyl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)






RN 68741-59-3 CAPLUS
CN 1H-Benzimidazole, 1-cyclopropyl-5-[[4-(diphenylmethyl)-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)




RN 68741-60-6 CAPLUS
CN 1H-Benzimidazole, 1-cyclopropyl-5-[[4-(diphenylmethyl)-1-piperazinyl]methyl]-2-phenyl- (9CI) (CA INDEX NAME)



L14 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1978:608915 CAPLUS
DOCUMENT NUMBER: 89:208915
TITLE: Psychotropic agents. 3. 4-(4-Substituted piperidinyl)-1-(4-fluorophenyl)-1-butanones with potent neuroleptic activity
AUTHOR(S): Sato, Makoto; Arimoto, Masahiro; Ueno, Katsujiro; Kojima, Hiroshi; Yamasaki, Terukiyo; Sakurai, Takeo; Kasahara, Akira
CORPORATE SOURCE: Res. Inst., Daiichi Seiyaku Co., Ltd., Tokyo, Japan
JOURNAL OF MEDICINAL CHEMISTRY (1978), 21(11), 1116-20
CODEN: JMCMAJ; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
Q1



AB I [R = C(CO2H), C(COMe), and N], II, III, and IV synthesized by cyclocondensation reactions of substituted 4-(2-aminooanilino)piperidines were tested for neuroleptic activity. 4-[[4-(2,3-Dihydro-2-thioxo-1H-benzimidazol-1-yl)-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone [57648-21-2] was the most potent with activity almost equal to the reference drugs, benperidol and haloperidol. Structure-activity relationships are discussed.
IT 68336-70-9P
RL: SPN (Synthetic preparation): PREP (Preparation)
(preparation and tranquilizing activity of)
RN 68336-70-9 CAPLUS
CN 1-Butanone, 1-(4-fluorophenyl)-4-[4-(2-phenyl-1H-benzimidazol-1-yl)-1-piperidinyl]-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

L14 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1968:114917 CAPLUS
 DOCUMENT NUMBER: 68:114917
 TITLE: Thiazolylbenzimidazole glycosides as biocides
 PATENT ASSIGNEE(S): Chimetron S.a r.l.
 SOURCE: Fr., 4 pp.
 CODEN: FRXIAK
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1476535		19670414	FR 1965-16429	19650510


GI For diagram(s), see printed CA issue.
 AB The title compds. are active as fungicides, nematocides, anthelmintics, insecticides, bactericides, and antiviral agents. Thus, 20.1 g. 2-(4-thiazolyl) benzimidazole in 250 ml. alc. was treated with 6.8 g. NaOEt, followed by addition of 27.2 g. HgCl₂ in 200 ml. 50% aqueous alc., and the mixture heated at 80° for 30 min. Chloromercuric compound was filtered off, suspended in xylene, and refluxed for 6 hrs. with 31 g. tri-O-acetyl-D-ribofuranosyl chloride to give I (R = tri-O-acetyl-D-ribofuranosyl), hydrolysis of which with NH₃-saturated MeOH gave I (R = D-ribofuranosyl). The propionate and benzoate were prepared similarly were prepared the following I (R given): tri-O-benzoyl-D-ribofuranosyl; tri-O-acetyl-D-glucopyranosyl; tri-O-acetyl-D-xylopyranosyl; tri-O-acetyl-D-mannopyranosyl; D-glucopyranosyl; D-xylopyranosyl; D-mannopyranosyl. Also prepared were II (R = tri-O-acetyl-D-ribofuranosyl), II (R = ribofuranosyl), III (R = tri-O-acetylribofuranosyl), III (R = ribofuranosyl), IV (R = tri-O-acetylribofuranosyl), and IV (R = ribofuranosyl).
 IT 20250-70-8P 20250-79-7P 20250-82-2P
 RL: SPN (Synthetic preparation); PRP (Preparation) (preparation of)
 RN 20250-70-8 CAPLUS
 CN Benzimidazole, 1-D-ribofuranosyl-2-(4-thiazolyl)-, 2',3',5'-tribenzoate (8CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 20250-79-7 CAPLUS
 CN Benzimidazole, 2-(4-methyl-2-phenyl-5-thiazolyl)-1-D-ribofuranosyl-, 2',3',5'-triacetate (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 20250-82-2 CAPLUS
 CN Benzimidazole, 2-(4-methyl-2-phenyl-5-thiazolyl)-1-D-ribofuranosyl-, (8CI) (CA INDEX NAME)

Absolute stereochemistry.



==> LOG HOLD
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	ENTRY	TOTAL
171.29	642.08	

CA SUBSCRIBER PRICE ENTRY -23.25 SESSION -41.25
 SESSION WILL BE HELD FOR 60 MINUTES
 STN INTERNATIONAL SESSION SUSPENDED AT 12:47:13 ON 25 SEP 2006
 Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sespta1623zct

PASSWORD:

*** RECONNECTED TO STN INTERNATIONAL ***
 SESSION RESUMED IN FILE 'CAPLUS' AT 13:01:01 ON 25 SEP 2006
 FILE 'CAPLUS' ENTERED AT 13:01:01 ON 25 SEP 2006
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY 171.29	SESSION 642.08
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY -23.25	SESSION -41.25

==> S 2-PHENOXYPHENYL BENZIMIDAZOLE
 8886193 2
 2569 PHENOXYPHENYL
 1 PHENOXYPHENYL
 2570 PHENOXYPHENYL
 (PHENOXYPHENYL OR PHENOXYPHENYL)
 23436 BENZIMIDAZOLE
 5914 BENZIMIDAZOLE
 24796 BENZIMIDAZOLE
 (BENZIMIDAZOLE OR BENZIMIDAZOLE)
 L15 0 2-PHENOXYPHENYL BENZIMIDAZOLE
 (2 (M) PHENOXYPHENYL (M) BENZIMIDAZOLE)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY 177.60	SESSION 648.39
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY -23.25	SESSION -41.25

FILE 'REGISTRY' ENTERED AT 13:01:50 ON 25 SEP 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8
 DICTIONARY FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>


==> S 2-PHENOXYPHENYL BENZIMIDAZOLE
 20951928 2
 0 PHENOXYPHENYL BENZIMIDAZOLE
 L16 0 2-PHENOXYPHENYL BENZIMIDAZOLE
 (2 (M) PHENOXYPHENYL BENZIMIDAZOLE)

==> S PHENOXYPHENYL BENZIMIDAZOLE
 0 PHENOXYPHENYL BENZIMIDAZOLE
 L17 0 PHENOXYPHENYL BENZIMIDAZOLE

==> Uploading C:\Program Files\Stnexp\Queries\HeP C FUSED RING COMPOUNDS 2.str

L16 STRUCTURE UPLOADED

==> D L18
 L18 HAS NO ANSWERS
 L18 STR



} SIMPLE SPECIES?

Structure attributes must be viewed using STN Express query preparation.

==> S L18
 SAMPLE SEARCH INITIATED 13:06:30 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 175 TO ITERATE

100.0% PROCESSED 175 ITERATIONS 4 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 2707 TO 4293
 PROJECTED ANSWERS: 4 TO 200

L19 4 SEA SSS SAM L18

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY 17.80	SESSION 666.19
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

CA SUBSCRIBER PRICE ENTRY SESSION
0.00 -41.25

FILE 'CAPLUS' ENTERED AT 13:06:41 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PS) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 24 Sep 2006 (20060924/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

>> S L19
L20 3 L19

>> D 1-3 IBIB ABS HITSTR

L20 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:


LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003050320	A1	20030313	US 2001-939374	20010824
US 6770666	B2	20040803		
WO 2001047883	A1	20010705	WO 2000-JP9181	20001222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MP, MZ, NC, NE, NG, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001247550	A2	20010911	JP 2000-391904	20001225
ZA 2001001393	A	20040715	ZA 2003-1393	20020626
US 2004097438	A1	20040520	US 2003-615329	20030708

CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[3-fluoro-4-[(phenylmethoxy)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 347167-46-8 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[3-[(2-chloro-4-pyridinyl)methoxy]phenoxy]phenyl]-1-cyclohexyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000254	A1	20030103	WO 2002-JP6405	20020626
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MP, MZ, NC, NE, NG, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 200323846	A2	20030730	JP 2002-185241	20020625
CA 2423800	AA	20030325	CA 2002-2423800	20020626

PRIORITY APPLN. INFO.:

JP 1999-369008	A 19991227
WO 2000-JP9181	A2 20001222
JP 2000-391904	A 20001225
JP 2001-193786	A 20010626
US 2001-939374	A3 20010824

OTHER SOURCE(S): MARPAT 138:238181
OI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds. I [the dotted line in rings B1 and B2 indicates a single or double bond; G1 = N, CR1; G2 = N, CR2; G3 = N, CR3; G4 = N, CR4; G5, G6, G8, G9 = C, N; G7 = O, S, CR7, etc.; R1-R4 = H, NO2, etc.; ring Cy = (unsubstituted cycloalkyl ring, etc.; ring A = Ph, cycloalkyl, etc. R5, R6 = H, halo, etc.; X = H, CN, etc.; R7 = H, alkyl] are prepared and formulated. Compds. I showed HCV polymerase inhibitory activity (data given). E.g., a multi-step synthesis of II.HCl, starting from 2-bromo-5-nitrotoluene and Me 2-(2-fluoro-4-hydroxyphenyl)-1-cyclohexylbenzimidazole-5-carboxylate, was given.

IT 347166-25-0P 347166-46-7P 347166-92-1P
347167-46-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C)

RN 347166-25-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(phenylmethoxy)phenoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 347166-48-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(2-phenoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 347166-92-1 CAPLUS

BR 2002005684	A	20030617	BR 2002-5684	20020626
EP 1400241	A1	20040324	EP 2002-743728	20020626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001393	A	20040715	ZA 2003-1393	20030626
TR 200300544	T1	20050822	TR 2003-544	20020626
US 2004082635	A1	20040429	US 2003-344997	20030218
NO 2003000832	A	20030422	NO 2003-832	20030221
PRIORITY APPLN. INFO.:				
JP 2001-193786	A	20010626		
JP 2001-351537	A	20011116		
NO 2002-JP6405	M	20020626		

OTHER SOURCE(S): MARPAT 138:66657
OI




AB Fused cyclic compds. represented by the following general formula [I] or pharmaceutically acceptable salts thereof and remedies for hepatitis C containing these compds.: I wherein each symbol is as defined in the description. Because of having an effect against hepatitis C virus (HCV) based on an HCV polymerase inhibitory effect, these compds. are useful as remedies or preventives for hepatitis C.

IT 347166-25-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(fused cyclic compds. as hepatitis C virus polymerase inhibitors and antiviral agents)

RN 347166-25-0 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(phenylmethoxy)phenoxy]phenyl]- (9CI) (CA INDEX NAME)




IT 347166-48-7P 347166-92-1P 347167-46-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(fused cyclic compds. as hepatitis C virus polymerase inhibitors and antiviral agents)

RN 347166-48-7 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-[(2-phenoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)


phenoxyphenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 347166-92-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[3-fluoro-4-(phenylmethoxy)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 347167-46-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-{3-[(2-chloro-4-pyridinyl)methoxy]phenoxy}phenyl]-1-cyclohexyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:489367 CAPLUS

DOCUMENT NUMBER: 135:76874

TITLE: Preparation of heterocyclic compounds as remedies for hepatitis C

INVENTOR(S): Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito

PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan


SOURCE: PCT Int. Appl., 438 pp.

DOCUMENT TYPE: CODEN: PIXXD2
Patent

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047883	A1	20010705	WO 2000-JP9181	20001222
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RD, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CO, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2363274	AA	20010705	CA 2000-2363274	20001222
EP 1162196	A1	20011212	EP 2000-967728	20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008525	A	20020102	BR 2000-8525	20001222
TR 200103147	T1	20020621	TR 2001-3147	20001222
NZ 514403	A	20021025	NZ 2000-514403	20001222
AU 763356	B2	20030717	AU 2001-24017	20001222
RU 2223761	C2	20040220	RU 2001-126283	20001222
CN 1623984	A	20050608	CN 2004-10055872	20001222
NO 2001004134	A	20011022	NO 2001-4134	20010824
US 2003050320	A1	20030313	US 2001-939374	20010824
US 6770666	B2	20040803		
ZA 2001007870	A	20020925	ZA 2001-7870	20010928
US 2004097438	A1	20040520	US 2003-615329	20030708
PRIORITY APPLN. INFO.:				
JP 1999-369008 A 19991227				
WO 2000-JP9181 W 20001222				
JP 2000-391904 A 20001225				
JP 2001-193786 A 20010826				
US 2001-939374 A3 20010824				

OTHER SOURCE(S): MARPAT 135:76874
GI



AB The title compds. I [the dotted line in rings B1 and B2 indicates a single or double bond; G1 = N, CR1; G2 = N, CR2; G3 = N, CR3; G4 = N, CR4; G5, G6, G8, G9 = C, N; G7 = O, etc.; R1 - R4 = H, nitro, etc.; ring Cy = (un)substituted cycloalkyl ring, etc.; ring A = C3-C8 cycloalkyl, etc. R5, R6 = H, halo, etc.; X = H, cyano, etc.] are prepared The benzimidazole derivative II in vitro showed IC50 of 0.011 µM against hepatitis C virus polymerase. A formulation is given.

IT 347166-25-0P 347166-48-7P 347166-92-1P


347167-46-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic compds. as remedies for hepatitis C)


RN 347166-25-0 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-{3-(phenylmethoxy)phenoxy}phenyl]- (9CI) (CA INDEX NAME)




RN 347166-48-7 CAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[4-{2-(phenoxyphenoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 347166-92-1 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 1-cyclohexyl-2-[3-fluoro-4-(phenylmethoxy)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 347167-46-8 CAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-{3-[(2-chloro-4-pyridinyl)methoxy]phenoxy}phenyl]-1-cyclohexyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

==> FILE REQ			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
	ENTRY	SESSION	
FULL ESTIMATED COST	15.79	681.98	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL	
CA SUBSCRIBER PRICE	ENTRY	SESSION	
	-2.25	-43.50	

FILE 'REGISTRY' ENTERED AT 13:07:14 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8
DICTIONARY FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8

New CAS Information Use Policies, enter HELP USA8TERMS for details.

TS/CA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprope.html>

Uploading C:\Program Files\Stnexp\Queries\HeP C FUSED RING COMPOUNDS.STR




chain nodes :
10 12 13
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
8-10 9-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-10 9-13
exact bonds :
8-9
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:Atom 13:Atom
Generic attributes :
10:
Saturation : Unsaturated
Type of Ring System : Monocyclic
13:
Saturation : Saturated

L21 STRUCTURE UPLOADED

=> D L21
L21 HAS NO ANSWERS
L21 STR



G1 C.N

Structure attributes must be viewed using STN Express query preparation.

=> S L21
SAMPLE SEARCH INITIATED 13:07:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1079415 TO ITERATE


0.2% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 21534102 TO 21642498
PROJECTED ANSWERS: 9401 TO 12187

L23 1 SEA 555 SAM L21

=> D

L22 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 844892-33-7 REGISTRY
ED Entered STN: 10 Mar 2005
CN 1H-Benzimidazole-5-carboxylic acid, 2-[4-[[4'-chloro-4-(3-oxo-4-morpholinyl)](1,1'-biphenyl)-2-yl]methoxy]-2-fluorophenyl]-1-cyclohexyl-mono-hydrochloride (9CI) (CA INDEX NAME)
MF C37 H33 Cl F N3 O5 . Cl H
SR CA
LC STN Files: CA, CAPIUS
CRN (845460-31-3)



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPIUS (1907 TO DATE)

=> LOG HOLD
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 2.78 684.76
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE 0.00 -43.50

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:08:24 ON 25 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:seepal623act

PASSWORD:

***** RECONNECTED TO STN INTERNATIONAL *****
SESSION RESUMED IN FILE 'REGISTRY' AT 13:10:35 ON 25 SEP 2006
FILE 'REGISTRY' ENTERED AT 13:10:35 ON 25 SEP 2006
COPYRIGHT (C) 2006 American Chemical Society (ACS)

COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 2.78 684.76
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE 0.00 -43.50


Uploading C:\Program Files\Stnexp\Queries\HeP C FUSED RING COMPOUNDS.STR

chain nodes :
10 12 13
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
8-10 9-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-10 9-13
exact bonds :
8-9
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:Atom 13:Atom
Generic attributes :
10:
Saturation : Unsaturated
Type of Ring System : Monocyclic
13:
Saturation : Saturated

L23 STRUCTURE UPLOADED

=> D L23
L23 HAS NO ANSWERS
L23 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L23
SAMPLE SEARCH INITIATED 13:11:10 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2210 TO ITERATE

SEARCH
DIDN'T
RUN

(TOO MANY VARIABLES)

IMIDAZO [4,5-b] PYRIDINES
SEARCHED

90.5% PROCESSED 2000 ITERATIONS 10 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE **COMPLET**
BATCH **COMPLET**
PROJECTED ITERATIONS: 41381 TO 47019
PROJECTED ANSWERS: 22 TO 420

L24 10 SEA SSS SAM L23

--> D 1-
YOU HAVE REQUESTED DATA FROM 10 ANSWERS - CONTINUE? Y/(N):N

--> D 10

L24 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2006 ACS on STN
RN 618895-28-7 REGISTRY
SD Entered STN: 20 Nov 2003
CN Piperidine, 1-[[1-(2-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-
[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA
INDEX NAME)
MP C28 H34 N8 O2
SR CA
LC STN File: CA, CAPLUS, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

--> S L21 SSS FULL
FULL SEARCH INITIATED 13:11:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 21577644 TO ITERATE

---Logging off of STN---

0.9% PROCESSED 199851 ITERATIONS 17 ANSWERS
END

1.8% PROCESSED 385391 ITERATIONS 48 ANSWERS
SEARCH ENDED BY USER
SEARCH TIME: 00.00.30

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: 21577644 TO 21577644
PROJECTED ANSWERS: 2532 TO 2642

L35 48 SEA SSS FUL L21

--> Executing the logoff script...

--> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.50	854.48
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	0.00	-43.50

STN INTERNATIONAL LOGOFF AT 13:12:18 ON 25 SEP 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:Y

LOGINID:####1623zct

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 4 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 5 MAY 11 KOREAPAT updates resume
NEWS 6 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 7 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and
USPATFULL/USPAT2
NEWS 8 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS
NEWS 9 JUN 02 The first reclassification of IPC codes now complete in
INPADOC
NEWS 10 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and
and display fields
NEWS 11 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12 JUL 11 CHEMSAFE reloaded and enhanced
NEWS 13 JUL 14 PSTA enhanced with Japanese patents
NEWS 14 JUL 19 Coverage of Research Disclosure reinstated in DWPI
NEWS 15 AUG 09 INSPEC enhanced with 1998-1998 archive
NEWS 16 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 17 AUG 30 CA(EN)/CAPLUS(EN) Austrian patent law changes
NEWS 18 SEP 11 CA/CAPLUS enhanced with more pre-1907 records

NEWS 19 SEP 21 CA/CAPLUS fields enhanced with simultaneous left and right
truncation

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 13:12:48 ON 25 SEP 2006

--> D HIS

(FILE 'HOME' ENTERED AT 13:12:48 ON 25 SEP 2006)

FILE REQ	SINCE FILE ENTRY	TOTAL SESSION
COST IN U.S. DOLLARS	0.21	0.21
FULL ESTIMATED COST		

FILE 'REGISTRY' ENTERED AT 13:13:03 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGTERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8
DICTIONARY FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8

New CAS Information Use Policies, enter HELP USAGTERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

--> Uploading C:\Program Files\Stnexp\Queries\HeP C FUSED RING COMPOUNDS.etr




chain nodes :
10 12 13
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
8-10 9-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-10 9-13
exact bonds :
8-9
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:Atom 13:Atom
Generic attributes :
10:
Saturation : Unsaturated
Type of Ring System : Monocyclic
13:
Saturation : Saturated

L1 STRUCTURE UPLOADED


--> D L1
L1 HAS NO ANSWERS
L1 STR




Structure attributes must be viewed using STN Express query preparation.

--> S L1
SAMPLE SEARCH INITIATED 13:13:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2210 TO ITERATE


.....




RN 618895-11-7 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-methoxyphenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618895-12-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-ethoxy-5-fluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-13-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-14-0 CAPLUS
CN Piperidine, 4-[2-(2-amino-3-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


INDEX NAME)




RN 618895-15-1 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-chloro-2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-16-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-pyrimidinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-17-3 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-18-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(6-methyl-2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-19-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-20-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618895-21-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)





RN 618895-22-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-24-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(5-(1,1-dimethylethyl)-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-27-5 CAPLUS
CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[(5-(4-fluorophenyl)-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 618895-28-6 CAPLUS
CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-[(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 618895-29-7 CAPLUS
CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)ethyl]-4-piperidinyl]carbonyl]-4-[2-[(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 618895-30-0 CAPLUS
CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-hydroxy-4-piperidinyl]carbonyl]-4-[2-[(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 618895-31-1 CAPLUS
CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-phenyl-4-piperidinyl]carbonyl]-4-[2-[(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 618895-32-2 CAPLUS
CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-[(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]]- (9CI) (CA INDEX NAME)






RN 618895-33-3 CAPLUS
CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-[(3-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 618895-34-4 CAPLUS
CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]]- (9CI) (CA INDEX NAME)






RN 618895-35-5 CAPLUS
CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-[(2,4-difluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 618895-36-6 CAPLUS
CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-[(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]]- (9CI) (CA INDEX NAME)




RN 618895-37-7 CAPLUS
CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2,4-difluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-58-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-pyrimidinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-59-3 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-60-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-61-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(4-pyrimidinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-64-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-4-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-68-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-ethoxy-5-fluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-69-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-89-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-92-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618895-94-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-05-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-15-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-27-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2,5-dimethyl-3-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-29-0 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3-methyl-2-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-31-4 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(3-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-39-2 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(5-methyl-3-furanyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-40-5 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2,4-difluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-41-6 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(4-pyrimidinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-43-8 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(3,4-difluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-45-0 CAPLUS
CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-48-3 CAPLUS
CN Piperidine, 1-[[1-[(6-amino-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-52-9 CAPLUS
CN Piperidine, 1-[[1-[(6-methoxy-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)






RN 618896-53-0 CAPLUS
CN Piperidine, 1-[[1-[(4-fluoro-1-[(6-methoxy-3-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-58-5 CAPLUS
CN Piperidine, 1-[[1-[(3,6-dichloro-4-pyridazinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-59-6 CAPLUS
CN Piperidine, 1-([1-((2-amino-5-pyrimidinyl)methyl)-4-fluoro-4-piperidinyl]carbonyl)-4-(2-(2,4-difluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 618896-64-3 CAPLUS
CN Piperidine, 1-([1-((1,6-dihydro-6-oxo-3-pyridinyl)methyl)-4-piperidinyl]carbonyl)-4-(2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 618896-65-4 CAPLUS
CN Piperidine, 1-([1-((1,6-dihydro-6-oxo-3-pyridinyl)methyl)-4-fluoro-4-piperidinyl]carbonyl)-4-(2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 618896-72-3 CAPLUS
CN Piperidine, 1-([4-fluoro-1-(2-furanylmethyl)-4-piperidinyl]carbonyl)-4-(2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 618896-73-4 CAPLUS
CN Piperidine, 1-([4-fluoro-1-(3-furanylmethyl)-4-piperidinyl]carbonyl)-4-(2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 618896-74-5 CAPLUS
CN Piperidine, 1-([4-fluoro-1-(2-thienylmethyl)-4-piperidinyl]carbonyl)-4-(2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 618896-75-6 CAPLUS
CN Piperidine, 1-([4-fluoro-1-(3-thienylmethyl)-4-piperidinyl]carbonyl)-4-(2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 618896-77-8 CAPLUS
CN Piperidine, 1-([1-((6-amino-4-pyrimidinyl)methyl)-4-fluoro-4-piperidinyl]carbonyl)-4-(2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 618896-78-9 CAPLUS
CN Piperidine, 4-(2-(2,4-difluorophenyl)-3H-imidazo[4,5-b]pyridin-3-yl)-1-([4-fluoro-1-(3-thienylmethyl)-4-piperidinyl]carbonyl)- (9CI) (CA INDEX NAME)




RN 618896-81-4 CAPLUS
CN Piperidine, 1-([4-fluoro-1-(2-thiazolylmethyl)-4-piperidinyl]carbonyl)-4-(2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 618896-82-5 CAPLUS
CN Piperidine, 1-([4-fluoro-1-(1H-pyrrol-3-ylmethyl)-4-piperidinyl]carbonyl)-4-(2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 618896-83-6 CAPLUS
CN Piperidine, 1-([4-fluoro-1-(1H-pyrazol-3-ylmethyl)-4-piperidinyl]carbonyl)-4-(2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl)]- (9CI) (CA INDEX NAME)




RN 618896-84-7 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-((1,2,3-thiadiazol-4-yl)methyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-85-8 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-((5-(methylthio)-2-thienyl)methyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-86-9 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-((4-thiazolylmethyl)-4-piperidinyl)carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618896-87-0 CAPLUS
CN Piperidine, 1-[[1-[(3,5-dimethyl-4-isoxazolyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-88-1 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-((5-methyl-3-isoxazolyl)methyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-90-5 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-((1,2,4-oxadiazol-3-yl)methyl)-4-


piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618896-91-6 CAPLUS
CN Acetamide, N-4-[[4-fluoro-4-[[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-piperidinyl]carbonyl]-1-piperidinyl]methyl]-2-thiazolyl]- (9CI) (CA INDEX NAME)




RN 618896-95-0 CAPLUS
CN Piperidine, 1-[[1-[[5-(aminomethyl)-2-furanyl]methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618896-97-2 CAPLUS


CN Piperidine, 1-[[4-fluoro-1-((2-methyl-4-thiazolyl)methyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618897-37-3 CAPLUS
CN Piperidine, 1-[[8-[(2-amino-5-pyrimidinyl)methyl]-8-azabicyclo[3.2.1]oct-3-yl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-43-1 CAPLUS
CN Piperidine, 1-[[1-[[5-[(dimethylamino)methyl]-2-furanyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-44-2 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-((1H-tetrazol-5-yl)methyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-


(9CI) (CA INDEX NAME)




RN 618897-45-3 CAPLUS
CN Piperidine, 4-[[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(1H-pyrrol-2-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-46-4 CAPLUS
CN Piperidine, 4-[[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(2-thiazolylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-47-5 CAPLUS
CN Piperidine, 4-[[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(3-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-48-6 CAPLUS
CN Piperidine, 1-[[1-(2-furanyl)amino]-4-piperidinyl]carbonyl]-4-[[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1- (9CI) (CA INDEX NAME)




RN 618897-49-7 CAPLUS
CN Piperidine, 4-[[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(2-thienylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-50-0 CAPLUS
CN Piperidine, 1-[[1-(3-furanyl)amino]-4-piperidinyl]carbonyl]-4-[[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1- (9CI) (CA INDEX NAME)




RN 618897-51-1 CAPLUS
CN Piperidine, 4-[[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(1,2,3-thiadiazol-4-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-59-9 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-[[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1- (9CI) (CA INDEX NAME)




RN 618897-60-2 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-(1H-1,2,3-triazol-4-ylmethyl)-4-piperidinyl]carbonyl]-4-[[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1- (9CI) (CA INDEX NAME)




RN 618897-61-3 CAPLUS
CN Piperidine, 4-[[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[[1-(1H-tetrazol-5-ylmethyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-72-6 CAPLUS
CN Piperidine, 1-[[1-(2-amino-5-pyrimidinyl)methyl]-4-piperidinyl]carbonyl]-4-[[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1- (9CI) (CA INDEX NAME)




RN 618897-73-7 CAPLUS
CN Piperazine, 1-[[2-amino-5-pyrimidinyl)methyl]-4-[[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-75-9 CAPLUS
CN Piperidine, 1-[[1-[[5-[(dimethylamino)methyl]-2-furanyl]methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-76-0 CAPLUS
CN Piperazine, 1-[[2-amino-5-pyrimidinyl]methyl]-4-[[4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618897-77-1 CAPLUS
CN Piperidine, 1-[[1-[[2-amino-5-pyrimidinyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(1-oxido-2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-78-2 CAPLUS
CN Piperidine, 1-[[1-[[2-(1-piperidinyl)-5-thiazolyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-79-3 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-[[2-(1-piperidinyl)-5-thiazolyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-80-6 CAPLUS
CN Piperidine, 1-[[1-[[2-(4-morpholinyl)-5-thiazolyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-81-7 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-[[2-(4-morpholinyl)-5-thiazolyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-82-8 CAPLUS
CN Piperidine, 1-[[1-[[2-amino-5-pyrimidinyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(3-methyl-2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-83-9 CAPLUS
CN Piperidine, 1-[[1-[[2-amino-5-pyrimidinyl]methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(3-methyl-2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-84-0 CAPLUS
CN Piperidine, 1-[[1-[[2-(4-morpholinyl)-5-thiazolyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-85-1 CAPLUS
CN Piperidine, 1-[[1-[[2-(4-morpholinyl)-5-thiazolyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-86-2 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-[[2-(4-morpholinyl)-5-thiazolyl]methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-88-4 CAPLUS
CN Piperidine, 1-[[1-[(1H-pyrazol-3-ylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-91-9 CAPLUS
CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[(1H-pyrrol-3-ylmethyl)-4-piperidinyl]carbonyl- (9CI) (CA INDEX NAME)




RN 618897-92-0 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-[(1H-pyrrol-3-ylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618897-98-6 CAPLUS
CN Piperidine, 4-fluoro-1-[(4-pyridinyl)carbonyl]-4-[4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-piperidinyl]carbonyl- (9CI) (CA INDEX NAME)




RN 618897-99-7 CAPLUS
CN Piperidine, 1-[[1-[(5-nitro-3-thienyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-00-3 CAPLUS
CN Piperidine, 1-[[1-[(5-amino-3-thienyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-01-4 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-[(5-nitro-3-thienyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-02-5 CAPLUS
CN Piperidine, 1-[[1-[(5-amino-3-thienyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-11-6 CAPLUS
CN Piperazine, 1-[[2-amino-5-pyrimidinyl)methyl]-4-[[1-fluoro-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-12-7 CAPLUS
CN Piperidine, 1-[[4-fluoro-1-[(5-nitro-2-furanyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-13-8 CAPLUS
CN Piperidine, 1-[[1-[(5-nitro-2-furanyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-14-9 CAPLUS
CN Piperidine, 1-[[1-[(2-amino-5-pyrimidinyl)methyl]-4-hydroxy-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-21-8 CAPLUS
CN Piperidine, 1-[(1-(cyclohexylmethyl)-4-piperidinyl)carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618898-24-1 CAPLUS
CN Piperidine, 1-[(1-(cyclohexylmethyl)-4-fluoro-4-piperidinyl)carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-27-4 CAPLUS
CN Piperidine, 1-[(1-[(5-amino-2-furanyl)methyl]-4-fluoro-4-piperidinyl)carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-28-5 CAPLUS
CN Piperidine, 1-[(1-[(2-amino-5-pyrimidinyl)methyl]-3-hydroxy-4-piperidinyl)carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)


piperidinyl)carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-40-1 CAPLUS
CN Piperidine, 1-[(1-[(3-amino-2-thienyl)methyl]-4-piperidinyl)carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-45-6 CAPLUS
CN Piperidine, 1-[(1-[(3-amino-2-thienyl)methyl]-4-piperidinyl)carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-50-3 CAPLUS
CN Piperidine, 1-[(1-[(benzo[b]thien-2-yl)methyl]-4-fluoro-4-piperidinyl)carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-56-9 CAPLUS
CN Piperidine, 4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[(1-(4-pyridazinylmethyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-78-5 CAPLUS
CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[(1-(4-pyridazinylmethyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-79-6 CAPLUS
CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[(1-(2-pyridinylmethyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 618898-80-9 CAPLUS
CN Piperidine, 1-[(4-fluoro-1-(2-pyridinylmethyl)-4-piperidinyl)carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-81-0 CAPLUS
CN Piperidine, 1-[(4-fluoro-1-(3-pyridinylmethyl)-4-piperidinyl)carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-82-1 CAPLUS
CN Piperidine, 1-[(4-fluoro-1-(4-pyridinylmethyl)-4-piperidinyl)carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618898-83-2 CAPLUS
CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[(1-(3-pyridinylmethyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 618899-73-3 CAPLUS
CN Piperidine, 1-[(1-[3-(2-amino-4-pyridinyl)propyl]-4-piperidinyl)carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618899-94-8 CAPLUS
CN Piperidine, 1-[(1-(phenylmethyl)-4-piperidinyl)carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618899-96-0 CAPLUS
CN Piperidine, 1-[(1-[4-fluoro-1-(phenylmethyl)-4-piperidinyl]carbonyl)-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618900-00-8 CAPLUS
CN Piperidine, 1-[(1-[4-(4-piperidinylmethyl)-4-piperidinyl]carbonyl)-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618900-03-1 CAPLUS
CN Piperidine, 4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-[(1-(2-thienylsulfonyl)-4-piperidinyl)carbonyl]- (9CI) (CA INDEX NAME)





RN 618900-04-2 CAPLUS
CN Piperidine, 1-[(1-[5-isoxazolylmethyl)-4-piperidinyl]carbonyl)-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 618900-29-1 CAPLUS
CN Piperidine, 1-[(1-ethyl-4-piperidinyl)carbonyl]-4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)




IT 618900-27-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 1-(4-piperidinyl)benzimidazoles as histamine H3 antagonists)
RN 618900-27-1 CAPLUS
CN Piperidine, 4-[2-(5-methyl-3-isoxazolyl)-3H-imidazo[4,5-b]pyridin-3-yl]-1-(4-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)



IT 618900-73-5P 618900-79-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-(4-piperidinyl)benzimidazoles as histamine H3 antagonists)
RN 618900-73-5 CAPLUS
CN Piperidine, 1-[(1-[4-fluoro-4-piperidinyl]carbonyl)-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 618900-79-1 CAPLUS
CN Piperidine, 1-[(1-[4-fluoro-4-piperidinyl]carbonyl)-4-[2-(1-oxido-2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:261620 CAPLUS
DOCUMENT NUMBER: 138:287673
TITLE: Preparation of phenylbenzimidazole compounds useful for treating hepatitis C virus
INVENTOR(S): Priestley, Eldon Scott; Decicco, Carl P.; Hudyma, Thomas W.; Zheng, Xiaofan
PATENT ASSIGNER(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXX2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026587	A2	20030403	WO 2002-US30989	20020926
WO 2003026587	A3	20031106		

W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CY, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GR, GM, GU, HK, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,


LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RD, RU, SD, SE, SO, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

RN: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, SF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO

US 2003134853 A1 20030717 US 2002-259041 20020926
EP 1429759 A2 20040623 EP 2002-773657 20020926
R: AT, BE, CH, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, NL, SE, MC, PT, SI, SD, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

PRIORITY APPLN. INFO.:
US 2001-324874P P 20010926
US 2002-259041 B1 20020926
WO 2002-US30989 W 20020926


OTHER SOURCE(S):
MARPAT 138:287673
GI




AB Compds. of formula I [Q = CH, N; R1 = tetrazolyl, MeCONHSO2, PhCONHSO2, etc.; R2 = CH2-aryl, CHPh2, etc.; R3 = cycloalkyl] are prepared which are useful in treating viral hepatitis C. Thus, II was prepared and had an IC50 of 0.14 μ M against HCV NS5B RdRp (RNA-dependent RNA polymerase).

IT 503857-63-4P 503857-64-SP 503857-65-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylimidazopyridine compds. for treating hepatitis C viral infection)

RN 503857-63-4 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-cyano-2-[[4-[3-cyclohexyl-6-(1H-tetrazol-5-yl)-3H-imidazo[4,5-b]pyridin-2-yl]phenoxy]methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 503859-39-0 CAPLUS
CN 1H-Tetrazole-1-propanenitrile, 5-[3-cyclohexyl-2-(4-hydroxyphenyl)-3H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)




L6 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:5773 CAPLUS
DOCUMENT NUMBER: 138:66657
TITLE: Fused cyclic compounds and medicinal use thereof
INVENTOR(S): Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito
PATENT ASSIGNER(S): Japan Tobacco Inc., Japan
SOURCE: PCT Int. Appl., 603 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000254	A1	20030103	WO 2002-JP6405	20020626
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MX, MY, NZ, OM, PH, PL, PT, RD, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO				
JP 2003212846	A2	20030730	JP 2002-185241	20020625
CA 2423800	AA	20030325	CA 2002-2423800	20020626
BR 2002005684	A	20030617	BR 2002-5684	20020626



RN 503857-64-5 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, 4'-chloro-2-[[4-[3-cyclohexyl-6-(1H-tetrazol-5-yl)-3H-imidazo[4,5-b]pyridin-2-yl]phenoxy]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 503857-65-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-6-carboxamide, 2-[4-[(4'-chloro-4-methoxy[1,1'-biphenyl]-2-yl)methoxy]phenyl]-3-cyclohexyl-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



IT 503859-38-9P 503859-39-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylimidazopyridine compds. for treating hepatitis C viral infection)

RN 503859-38-9 CAPLUS
CN 1H-Tetrazole-1-propanenitrile, 5-[3-cyclohexyl-2-[[4-[(1,1-dimethylethyl)dimethylsilyl]oxy]phenyl]-3H-imidazo[4,5-b]pyridin-6-yl]- (9CI) (CA INDEX NAME)

EP 1400241 A1 20040324 EP 2002-743728 20020626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
ZA 2003001393 A 20040715 ZA 2003-1393 20020626
TR 200300544 T1 20050822 TR 2003-544 20020626
US 2004002635 A1 20040429 US 2003-344997 20030218
NO 2003000832 A 20030422 NO 2003-832 20030221
JP 2001-193786 A 20010626
JP 2001-351537 A 20011116
WO 2002-JP6405 W 20020626


PRIORITY APPLN. INFO.:
MARPAT 138:66657
OTHER SOURCE(S):
GI



AB Fused cyclic compds. represented by the following general formula (I) or pharmaceutically acceptable salts thereof and remedies for hepatitis C containing these compds.: I wherein each symbol is as defined in the description. Because of having an effect against hepatitis C virus (HVC) based on an HCV polymerase inhibitory effect, these compds. are useful as remedies or preventives for hepatitis C.

IT 480462-66-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(fused cyclic compds. as hepatitis C virus polymerase inhibitors and antiviral agents)

RN 480462-66-6 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid, 2-[4-[(4'-chloro-4-methoxy[1,1'-biphenyl]-2-yl)methoxy]phenyl]-3-cyclohexyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS ON STN


ACCESSION NUMBER: 2002:51438 CAPLUS
DOCUMENT NUMBER: 136:118447
TITLE: Preparation of benzimidazolecarboxylates and related compounds as viral polymerase inhibitors
INVENTOR(S): Beaulieu, Pierre Louis; Fasel, Guilres; Gillard, James; Kukoli, George; Austel, Volkhard
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 322 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004425	A2	20020117	WO 2001-CA989	20010704
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GR, GU, HR, HU, ID, IL, IN, IS, JP, KR, KG, KP, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TO				
US 2002065418	A1	20020530	US 2001-898297	20010703
US 6448281	B2	20020910		
CA 241718	AA	20020117	CA 2001-2412718	20010704
EP 1301487	A2	20030416	EP 2001-951274	20010704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004502761	T2	20040129	JP 2002-509292	20010704
US 6479508	B1	20021112	US 2001-995099	20011127
CA 2439176	AA	20020912	CA 2002-2439176	20020306
WO 2002070739	A2	20020912	WO 2002-CA323	20020306
WO 2002070739	A3	20030530		
W: AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GD, GE, GR, GU, HR, HU, ID, IL, IN, IS, JP, KR, KG, KP, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HK, HR, HU, ID, IL, IN, IS, JP, KR, KG, KP, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
EP 1370682	A2	20031217	EP 2002-712681	20020306
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520839	T2	20040715	JP 2002-570761	20020306
NZ 528644	A	20050527	NZ 2002-528644	20020306
US 200323816	A1	20031218	US 2002-238282	20020910
US 6794404	B2	20040921		
US 2004110126	A1	20040610	US 2004-471164	20040205
US 2004224955	A1	20041111	US 2004-851710	20040521
PRIORITY APPL. INFO.:			US 2000-216084P	P 20000706
			US 2001-274374P	P 20010308
			US 2001-281343P	P 20010405
			US 2001-898297	A3 20010703
			WO 2001-CA989	W 20010704
			US 2001-995099	A3 20011127
			WO 2002-CA323	W 20020306
			US 2002-238282	A1 20020910
OTHER SOURCE(S):		MARPAT 136:118447		

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9638471	A1	19961205	WO 1995-18410	19950529
W: CA, FI, JP, MX, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2220055	AA	19961205	CA 1995-2220055	19950529
CA 2220055	C	20010424		
EP 828754	A1	19960518		
EP 828754	B1	20050202	EP 1995-918123	19950529
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
JP 10510511	T2	19981013	JP 1995-511175	19950529
JP 3133073	B2	20010205	JP 1996-511175	19950529
AT 268444	E	20050215	AT 1995-918123	19950529
ES 2235171	T3	20050701	ES 1995-918123	19950529
NO 9602162	A	19961202	NO 1996-2162	19960528
AU 9654554	A1	19961212	AU 1996-54554	19960528
CN 1143647	A	19970226	CN 1996-107637	19960528
US 5936089	A	19990810	US 1997-973268	19971126
FI 9704368	A	19971128	FI 1997-4368	19971128
PRIORITY APPL. INFO.:			WO 1995-18323	A 19950508
			WO 1995-18410	W 19950529
OTHER SOURCE(S):		MARPAT 126:104431		

GI



AB Title compds. I [2 = COC(R1)R2C(=O)N(R3)R4; L = NR6, O, CH2; W = H; W and X = benzo fusion substituted with 0-3 R3a, TR3b, or R12; Y = H, C1-6 alkyl, C4-10 cycloalkyl, aryl-K, phenyl-(C1-6alkyl)-K, thienyl-(C1-6 alkyl)-K substituted with 0-3 R3a, R3b, or R12; K = bond, O, S(O)m, NR2a, X = OR2, R5OM(R1), R8R9MCO, R2bO2C, (un)substituted carbo- or heterobicyclic ring; R1 = (un)substituted C1-10 alkyl, aryl, etc.; R2c = H, C1-6 alkyl, C3-7 cycloalkyl; CR1R3c = (un)substituted C3-8 ring; R2 = H, C1-6 alkyl, C3-7 cycloalkyl; R3a = H, C1-6 alkyl; R3b = H, C1-8 alkyl, C1-8 halogenated alkyl, C3-8 cycloalkyl, alkylaryl, aryl; R3a, R12 = independently H, halo, Me, OMe, CF3; T = bond, phenylene, 5- or 6-membered heterocycle containing 1-3 hetero atoms; R3b = H, CONR8R9, SO2R8R9, CO2H, CO2(C1-6 alkyl), NR2SO2R9, NR2CONR8R9, NR2SO2NR8R9, NR2COR9, imidazolyl, thiazolyl, tetrazolyl; R4, R5 = independently H, (un)substituted C1-6 alkyl; R6 = H, C1-6 alkyl; R6CR2c = C3-8 ring; R5O = (un)substituted morpholino, piperazino, C3-7 cycloalkyl, C1-6 alkyl; W = CO, SO2; A = bond, Z1(CH2)2XCR7R7a(CH2)2; Z1 = NR2, O, bond; R7, R7a = independently H, CF3, Ph, (un)substituted C1-6 alkyl; R8 = H, (un)substituted C1-6 alkyl; R9 = H, (un)substituted C1-6 alkyl, Ph, thiazolyl, imidazolyl, furyl, thienyl, are growth hormone releasing peptide mimics. Heterocyclic dipeptide derive. I are useful for the treatment and prevention of osteoporosis (no data). Thus, condensation of Boc-D-Ser(CH2Ph)-OH (Boc = Me3CO2C) with 4-(2-oxo-1-benzimidazolyl)piperidine, followed by

GI




AB Title compds. [I; X = CH, N; Y = O, S; Z = OH, NH2, NMeR3, NHR3, OR3, 5-6 membered (substituted) heterocyclyl; A = N, COR7, CR5; R5 = H, halo, alkyl; R7 = H, alkyl; X and A are not both N; R6 = H, halo, alkyl, OR7; R7 = H, alkyl; R1 = (substituted) hetero(bicyclic), Ph, phenylalkyl, alkyl, phenylalkenyl, cycloalkyl, alkyl, CF3; R2 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, bicyclicalkyl, adamantyl, Ph, pyridyl; R3 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, alkenyl, cycloalkylalkenyl, arylalkenyl, dialkylamino, heterocyclyl, etc.; n = 0, 1, were prepared. Thus, Me 3-amino-4-cyclohexylaminobenzoate (preparation given), 2-pyridinecarboxaldehyde, and Oxone were stirred in DMF to give 80% Et 1-cyclohexyl-2-pyridin-2-yl-1H-benzimidazole-5-carboxylate, which was saponified with aqueous NaOH in MeOH to give 91% 1-cyclohexyl-2-pyridin-2-yl-1H-benzimidazole-5-carboxylic acid. The latter inhibited hepatitis C virus RNA dependent polymerase (NS5B) with IC50 = 1-5 μM.

IT 390814-90-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzimidazolecarboxylates and related compds. as viral polymerase inhibitors)

RN 390814-90-1 CAPLUS
CN L-Tryptophan, N-[(1-cyclohexyl-2-yl-1H-benzimidazole-5-carboxylate)-5-carboxyl]-5-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L6 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:94071 CAPLUS
DOCUMENT NUMBER: 126:104431
TITLE: Preparation of heterocyclic dipeptide derivatives which promote release of growth hormone
INVENTOR(S): Carpino, Philip A.; Jardine DaSilva, Paul A.; Lefker, Bruce A.; Ragan, John A.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent

deprotection, coupling with BocHCHMeCO2H, and deprotection with HCl gave dipeptide amide salt II.

IT 185056-48-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of growth hormone-releasing dipeptides)

RN 185056-48-8 CAPLUS
CN Propanamide, 2-amino-N-[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinylethyl]-2-methyl-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

IT 185058-91-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of growth hormone-releasing dipeptides)

RN 185058-91-7 CAPLUS
CN Carbamic acid, [2-[[[1-(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinylethylamino]-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethylethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L6 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:16293 CAPLUS
DOCUMENT NUMBER: 126:60362

TITLE: Preparation of heterocyclic dipeptide derivatives which promote release of growth hormone
 INVENTOR(S): Carpino, Philip A.; Jardine DaSilva, Paul A.; Lefker, Bruce A.; Ragan, John A.
 PATENT ASSIGNER(S): Pfizer, Inc., USA
 SOURCE: PCT Int. Appl., 158 pp.
 CODEN: PIXX22
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9635713	A1	19961114	WO 1995-18333	19950508
W: CA, FI, JP, MX, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9654554	A1	19961212	AU 1996-54554	19960528
PRIORITY APPLN. INFO.:			WO 1995-18333	A 19950508
			WO 1995-18410	A 19950529

OTHER SOURCE(S): MARPAT 126:60362
 OI




AB Title compds. I (Z = COCR1R2COCNRR4R5; L = NR6, O, CH2; W = H; W and X = benzo fusion optionally substituted with 1-3 R3a, TR3b, or R12; Y = H, C1-6 alkyl, C3-10 cycloalkyl, aryl optionally substituted with 1-3 R3a, R3b, or R12; X = OR2, R5OR6(Aryl), R8R9NCO, R2BO2C, optionally substituted carbocyclic or heterocyclic ring; R1 = optionally substituted C1-10 alkyl, aryl, etc.; R2c = H, C1-6 alkyl, C3-7 cycloalkyl; CR1R3c = optionally substituted C3-8 ring; R2 = H, C1-6 alkyl, C3-7 cycloalkyl; R2a = H, C1-6 alkyl; R2b = H, C1-8 halogenated alkyl, C3-8 cycloalkyl, alkylaryl, aryl; R3a, R12 = independently H, halo, Me, OMe, CF3; T = bond, phenylene, 5- or 6-membered heterocycle containing 1-3 hetero atoms; R3b = H, CONRR9, SO2RR9, CO2(C1-6 alkyl), NR2SO2RR9, NR2CONRR9, NR2SO2NR9, NR2COR9, imidazolyl, thiazolyl, tetrazolyl; R4, R5 = independently H, optionally substituted C1-6 alkyl; R6 = H, C1-6 alkyl; R6CR2c = C3-8 ring; R50 = optionally substituted morpholino, piperazino, C3-7 cycloalkyl, C1-6 alkyl; M = CO, SO2; A = bond, 21(CH2)XCR1R2A(CH2)Y; Z1 = NR2, O, bond; R7, R7a = independently H, CF3, Ph, optionally substituted C1-6 alkyl; R8 = H, optionally substituted C1-6 alkyl; R9 = H, optionally substituted C1-6 alkyl, Ph, thiazolyl, imidazolyl, furyl, thienyl, are growth hormone releasing peptide mimics. Heterocyclic dipeptide derivs. I are useful for the treatment and prevention of osteoporosis. Thus, condensation of Boc-D-Ser(CH2Ph)-OH (Boc = Me3CO2C) with 4-(2-oxo-1-benzimidazolyl)piperidine, followed by deprotection, coupling with BocNHMe2CO2H, and deprotection with HCl gave dipeptide amide salt II.

IT 185056-48-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and growth hormone releasing activity of heterocyclic dipeptide

deriva.)
 RN 185056-48-8 CAPLUS
 CN Propanamide, 2-amino-N-[1-[(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]ethyl]-2-methyl-, dihydrochloride, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

IT 185058-91-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and growth hormone releasing activity of heterocyclic dipeptide derivs.)
 RN 185058-91-7 CAPLUS
 CN Carbamic acid, [2-[(1-[(1H-indol-3-ylmethyl)-2-oxo-2-[4-(2-phenyl-3H-imidazo[4,5-b]pyridin-3-yl)-1-piperidinyl]ethyl]amino)-1,1-dimethyl-2-oxoethyl]-, 1,1-dimethyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



FILE REG	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	58.92	226.07
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION

CA SUBSCRIBER PRICE -6.75 -6.75

FILE 'REGISTRY' ENTERED AT 13:18:44 ON 25 SEP 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8
 DICTIONARY FILE UPDATES: 24 SEP 2006 HIGHEST RN 908332-13-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UQ/regprops.html>

Uploading C:\Program Files\Stnexp\Queries\HeP C FUSED RING COMPOUNDS.ctr




chain nodes :
 10 12 13
 ring nodes :
 1 2 3 4 5 6 7 8 9
 chain bonds :
 8-10 9-13
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
 exact/norm bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-10 9-13
 exact bonds :
 8-9
 isolated ring systems :
 containing 1 :

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 12:Atom 13:Atom
 Generic attributes :
 10:
 Saturation : Unsaturated
 Type of Ring System : Monocyclic
 13:
 Saturation : Saturated

L7 STRUCTURE UPLOADED

== D L7
 L7 HAS NO ANSWERS
 L7 STR



Structure attributes must be viewed using STN Express query preparation.

== S L7
 SAMPLE SEARCH INITIATED 13:19:17 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 39931 TO ITERATE
 5.0% PROCESSED 2000 ITERATIONS 2 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01
 FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 786685 TO 810555
 PROJECTED ANSWERS: 419 TO 1177

L8 2 SEA SSS SAM L7

== S L7 SSS FULL
 FULL SEARCH INITIATED 13:19:28 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 797527 TO ITERATE

100.0% PROCESSED 797527 ITERATIONS 175 ANSWERS
 SEARCH TIME: 00.00.16

L9 175 SEA SSS FUL L7

FILE CAPLUS	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	167.38	393.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-6.75

FILE 'CAPLUS' ENTERED AT 13:20:07 ON 25 SEP 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

INDOLES SEARCHED

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 24 Sep 2006 (20060924/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

-- S L9
L10 18 L9

-- S L10 NOT L5
L11 17 L10 NOT L5

-- D 1-17 IBIS ABS HITSTR

L11 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:851092 CAPLUS

DOCUMENT NUMBER: 145:271642

TITLE: Preparation of indoles for prevention or treatment of Hepatitis C virus (HCV) infection.

INVENTOR(S): Karp, Gary Mitchell; Hwang, Peter Seongwoo; Takasugi, James Jan; Ren, Hongyu; Wilde, Richard Gerald; Turpoff, Anthony Allan; Arefolov, Alexander; Chen, Guangming; Campbell, Jeffrey Allen

PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 328pp., Cont.-in-part of U.S. Ser. No. 160,961.

CODEN: USXXCO


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006189606	A1	20060824	US 2006-331180	20060113
WO 2006039831	A1	20060223	WO 2005-US24881	20050714
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VE, VN, YU, ZA, ZM, ZW				
RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:				
		US 2004-587487P	P 20040714	
		US 2004-634979P	P 20041213	
		US 2005-645586P	P 20050124	
		US 2005-665349P	P 20050328	
		US 2005-675440P	P 20050428	
		US 2005-180961	A2 20050714	




RN 906642-12-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 906642-56-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 906642-58-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 906643-06-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

01

WO 2005-US24881 A2 20050714



AB Title compds. [I; X = NO2, cyano, CHO, (substituted) aryl, heteroaryl, CO2R, etc.; R = alkyl; Y = haloalkyl, halo, benzofuryl, benzothienyl, dibenzofuryl, naphthyl, indolyl, etc.; Z = (substituted) alkyl, alkylene, aryl, etc.; R = H, halo, alkoxy; R1 = H, OH, halo, haloalkyl, NO2, heteroaryl, heterocyclyl, etc.; R2 = H, NO2, halo, OH, alkyl, haloalkyl, amino, alkoxy, amide, heteroaryl, etc.; R1R2 = OCH2O, OCH2CH2O; R3 = H, CH2COOR; with proviso], were prepared Thus, reacting 2-(4-amino-3-fluorophenyl)-1-ethyl-6-methoxy-1H-indole-3-carbonitrile with Pr chloroformate afforded 634 II. Compds. I were tested in an HCV-PV screen for viral RNA reduction and for the selectivity for HCV IRES-driven translation using cellular IRES-mediated translation assays (data given).


IT 876742-27-7P 876742-30-2P 906642-12-4P 906642-56-6P 906642-58-8P 906643-06-9P 906643-54-7P 906643-77-4P 906643-78-5P 906643-79-6P 906643-80-9P 906643-93-4P 906644-13-1P 906644-14-2P 906644-21-1P 906644-22-2P 906644-24-4P 906644-25-5P 906644-26-6P 906644-27-7P 906644-28-8P 906647-02-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of indoles for prevention or treatment of Hepatitis C virus infection)


RN 876742-27-7 CAPLUS

CN 1H-Indole-3-carbonitrile, 1-cyclobutyl-6-(difluoromethoxy)-2-[4-(2-oxo-1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 876742-30-2 CAPLUS


CN Cyclopropenesulfonamide, N-[4-(3-cyano-1-cyclobutyl-6-(difluoromethoxy)-1H-indol-2-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 906643-54-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 906643-77-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 906643-78-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 906643-79-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 906643-80-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 906643-93-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 906644-13-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 906644-14-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 906644-21-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 906644-23-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Rotation (+).




RN 906644-24-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 906644-25-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 906644-26-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 906644-27-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 906644-28-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 906647-02-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



IT 906644-46-0P 906644-47-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of indoles for prevention or treatment of Hepatitis C virus
infection)
RN 906644-46-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 906644-47-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



L11 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:167821 CAPLUS
DOCUMENT NUMBER: 144:254002
TITLE: Preparation of indoles for prevention or treatment of
Hepatitis C virus (HCV) infection.
INVENTOR(S): Hwang, Peter Seongwoo; Takasugi, James; Ren, Hongyu;
Wilde, Richard Gerald; Turpoff, Anthony; Arefolov,
Alexander; Karp, Gary Mitchell; Chen, Guangming;
Campbell, Jeffrey Allen
PATENT ASSIGNEE(S): PTC Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 769 pp.
DOCUMENT TYPE: CODEN: P1XXD2
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: 2 English
PATENT INFORMATION:


PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 2006019831 A1 20060223 WO 2005-US24881 20050714

W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

US 2006189606 A1 20060824 US 2006-331180 20060113
 US 2004-587487P P 20040714
 US 2004-634979P P 20041213
 US 2005-645586P P 20050124
 US 2005-665349P P 20050328
 US 2005-675440P P 20050428
 US 2005-180961 A2 20050714
 WO 2005-US24881 A2 20050714


PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 144:354002
 GI




AB Title compds. I; X = H, NO2, cyano, CHO, (substituted) aryl, heteroaryl, CO2R, etc.; R₁ = alkyl; Y = H, haloalkyl, halo, (substituted) amino, benzofuryl, benzothienyl, dibenzofuryl, naphthyl, indolyl, etc.; Z = H, (substituted) alkyl, alkylene, aryl, methylenedioxyphenyl, etc.; R = H, halo, alkoxy; R₁ = H, OH, halo, haloalkyl, NO2, heteroaryl, heterocyclyl, etc.; R₂ = H, NO2, halo, OH, alkyl, haloalkyl, amino, alkoxy, amide, heteroaryl, etc.; R₁R₂ = OCH2O, OCH2CH2O; R₃ = H, CH2COOR, were prepared Thus, title compound (II) showed IC50 <0.5 μM in an HCV-PV screen for viral RNA reduction

IT 876742-27-7P 876742-30-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indoles for prevention or treatment of Hepatitis C virus infection)

RN 876742-27-7 CAPLUS
 CN 1H-Indole-3-carbonitrile, 1-cyclobutyl-6-(difluoromethoxy)-2-[4-(2-oxo-1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 876742-30-2 CAPLUS
 CN Cyclopropanesulfonamide, N-[4-(3-cyano-1-cyclobutyl-6-(difluoromethoxy)-1H-indol-2-yl)phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2006:75472 CAPLUS
 DOCUMENT NUMBER: 144:170878
 TITLE: Preparation of indole derivatives as viral polymerase inhibitors
 INVENTOR(S): Beaulieu, Pierre L.; Brochu, Christian; Kawai, Stephen; Rancourt, Jean; Stammers, Timothy A.; Thavonekham, Bounkham; Tsantrikos, Youla S.
 PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co. KG
 SOURCE: PCT Int. Appl., 116 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:



PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 2006007693 A1 20060126 WO 2005-CALL103 20050715

W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

US 2006052418 A1 20060309 US 2005-182987 20050715

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 144:170878
 GI




AB Title compds. I (R₁ = H or alkyl; R₂ = alkyl, alkynyl, aryl, etc.; R₃ = (un)substituted cycloalkyl; R₅ = H, alkyl, alkenyl, cycloalkyl, etc.; R₆ = H, halo, or alkyl; or R₅ and R₆ are linked to form (un)substituted oxygen heterocycle; R₇ = H, halo, NH2, alkoxy, etc.; R₈ and R₁₀ are independently alkyl or R₉ and R₁₀ are bonded together to form an (un)substituted cycloalkyl or heterocycle; X = C; A or B = N while the other of B or A = C, wherein the bond between two carbon atoms represent a double bond and the bond between a carbon and nitrogen atom is a single bond, and their pharmaceutically acceptable salts, are prepared and disclosed as viral polymerase inhibitors. Thus, e.g., II was prepared by 2-ethoxy-4-aminocinnamic acid Et ester (preparation given) with 1-aminocyclobutan-1-ylcarbonyl chloride followed by reaction with 3-cyclopentyl-2-pyridin-2-yl-1-methylindole-6-carboxylic acid followed by hydrolysis. Assays of RNA polymerase inhibition are described (no data). I are to be used as an inhibitor of RNA dependent RNA polymerases, particularly those viral polymerases within the Flaviviridae family, more particularly to HCV polymerase. Pharmaceutical compds. are claimed.

IT 874675-97-5P 874675-98-6P 874675-99-7P
 874676-00-3P 874676-01-4P 874676-02-5P
 874676-03-6P 874676-04-7P 874676-05-8P
 874676-06-9P 874676-07-0P 874676-08-1P
 874676-09-2P 874676-11-6P 874676-12-7P
 874676-13-8P 874676-14-9P 874676-15-0P
 874676-16-1P 874676-17-2P 874676-18-3P
 874676-19-4P 874676-20-7P 874676-22-9P
 874676-23-0P 874676-24-1P 874676-25-2P
 874676-26-3P 874676-27-4P 874676-28-5P
 874676-29-6P 874676-30-9P 874676-31-0P
 874676-32-1P 874676-33-2P 874676-34-3P
 874676-35-4P 874676-36-5P 874676-37-6P
 874676-38-7P 874676-39-8P 874676-40-1P
 874676-41-2P 874676-42-3P 874676-43-4P
 874676-44-5P 874676-45-6P 874676-46-7P

874675-49-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indole deriva. as viral polymerase inhibitors)


RN 874675-97-5 CAPLUS
 CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874675-98-6 CAPLUS
 CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 874675-99-7 CAPLUS
 CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-(2-propynyloxy)phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-00-3 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-methoxyphenyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-01-4 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-2-methyl-, (2S)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-02-5 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclopentyl]carbonyl]amino]-2-methoxyphenyl]-, (2S)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-03-6 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]-3-cyclopenten-1-yl]carbonyl]amino]-2-ethoxyphenyl]-, (2S)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-04-7 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(4-methoxy-2-pyrimidinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2S)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-05-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-2-fluoro-, (2S)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-06-9 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-3-methyl-2-phenyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2S)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874676-07-0 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-3-methyl-2-(2-thiazolyl)-1H-

indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2S)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-08-1 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-3-methyl-2-(2-thienyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2S)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874676-09-2 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-3-methyl-2-(2-thienyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2S)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.






RN 874676-11-6 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[2-(5-bromo-2-pyrimidinyl)-1-cyclohexyl]-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 874676-12-7 CAPLUS
CN Butanoic acid, 2-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]methylene]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-13-8 CAPLUS
CN Butanoic acid, 2-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-


methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-methoxyphenyl]methylene]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874676-14-9 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874676-15-0 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874676-16-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-3-methyl-2-pyrazinyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 874676-17-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-3-methyl-2-(2-pyridinyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-18-3 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)-


(9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874676-19-4 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 874676-20-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-chloro-2-pyridinyl)-1-cyclohexyl-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-22-9 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclopentyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)-

(2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-23-0 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[2-[[[1-cyclopentyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]-2-methyl-1-oxopropyl]amino]-2-ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-24-1 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[2-[[[1-cyclopentyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874676-25-2 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[2-[[[1-cyclopentyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]-2-methyl-1-oxopropyl]amino]-2-

ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-26-3 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[2-[[[1-cyclohexyl-3-methyl-2-(2-pyridinyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-2-fluoro-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-27-4 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[2-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-(2-methoxyethoxy)phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-28-5 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[2-[[[1-cyclopentyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-(2-methoxyethoxy)phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-29-6 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[2-[[[1-cyclohexyl-3-methyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-(2-methoxyethoxy)phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-30-9 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[2-[[[1-cyclohexyl-3-methyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-31-0 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[2-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 874676-32-1 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[2-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-hydroxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874676-33-2 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[2-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-


methyl-1H-indol-5-yl]carbonyl]amino]-2-methyl-1-oxopropyl]amino]-2-(2-methoxyethoxy)phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874676-34-3 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-[(1S)-2-methoxy-1-methylethoxy]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 874676-35-4 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-[(1S)-2-methoxy-1-methylethoxy]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 874676-36-5 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[2-(5-chloro-2-pyridinyl)-1-cyclohexyl-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-ethoxyphenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874676-37-6 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-[(1S)-2-(dimethylamino)ethoxy]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874676-38-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-(2-ethoxyethoxy)phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874676-39-8 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-(3-(dimethylamino)propoxy)phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874676-40-1 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 874676-41-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-(2-furanylmethoxy)phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 874676-42-3 CAPLUS
CN 2-Propenoic acid, 3-[4-[[[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]carbonyl]amino]-2-(2-furanylmethoxy)phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolylcarbonylaminomethylbenzimidazoles as viral polymerase inhibitors)
RN 863888-52-2 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclopentyl-3-methyl-2-(2-pyridinyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-5-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 863888-53-3 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclopentyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-5-yl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863888-54-4 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclopentyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclopentyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]-3-cyclopenten-1-yl]-1-methyl-1H-benzimidazol-5-yl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 863888-58-8 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-(2-pyridinyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-5-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




Double bond geometry as shown.




RN 863888-55-5 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclopentyl-3-methyl-2-(2-pyridinyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-56-6 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclopentyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]-3-cyclopenten-1-yl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-57-7 CAPLUS

PAGE 2-A




RN 863888-59-9 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-(2-pyridinyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-60-2 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-pyrazinyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-61-3 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-pyrazinyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-5-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-62-4 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-63-5 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-64-6 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(2-pyridinyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-65-7 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863888-66-8 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[2-(5-chloro-2-pyridinyl)-1-cyclohexyl-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 863888-67-9 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[2-(5-chloro-2-pyridinyl)-1-cyclohexyl-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 863888-68-0 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 863888-69-1 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 863888-70-4 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclopentyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




PAGE 1-A




RN 863888-71-5 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclopentyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-72-6 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-(2-pyridinyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-73-7 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[2-(5-chloro-2-pyridinyl)-1-cyclohexyl-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-74-8 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-75-9 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





RN 863888-76-0 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(5-methoxy-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-77-1 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1,6-dimethyl-1H-benzimidazol-5-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-78-2 CAPLUS
CN 1H-Indole-5-carboxamide, 1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-N-[1-[1-methyl-6-(1H-1,2,3-triazol-4-yl)-1H-benzimidazol-2-yl]cyclobutyl]- (9CI) (CA INDEX NAME)




RN 863888-79-3 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1,5-dimethyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-80-6 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1,5-dimethyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-81-7 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(4-methoxy-2-pyrimidinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-82-6 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1,5-dimethyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-83-9 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]-3-cyclopenten-1-yl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-84-0 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-fluoro-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-85-1 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(2-fluoro-4-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-86-2 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-phenyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-87-3 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-phenyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-88-4 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-(2-thiazolyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-89-5 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-(2-thiazolyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-90-8 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-(2-thienyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-91-9 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-(2-thienyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-92-0 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-(2-thienyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-93-3 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[2-(5-bromo-2-pyrimidinyl)-1-cyclohexyl-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-96-4 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[2-(5-bromo-2-pyrimidinyl)-1-cyclohexyl]-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-97-5 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(2-methoxy-3-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-98-6 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(2-fluoro-4-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863888-99-7 CAPLUS
CN Butanoic acid, 2-[[2-[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]methylene]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-00-3 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[2-(5-chloro-2-pyridinyl)-1-cyclohexyl]-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-01-4 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-02-5 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-03-6 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[2-(2-chloro-3-pyridinyl)-1-cyclohexyl]-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-04-7 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[2-(4-chloro-3-pyridinyl)-1-cyclohexyl]-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-05-8 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(2,6-dimethyl-3-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-06-9 CAPLUS
CN 2-Propenoic acid, 3-[2-[1-[[[2-(2-amino-5-fluoro-3-pyridinyl)-1-cyclohexyl]-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-07-0 CAPLUS
 CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(2-fluoro-5-methyl-3-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-08-1 CAPLUS
 CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(4-fluoro-5-methyl-3-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-09-2 CAPLUS
 CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclopentyl-2-(3-furanyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]-1-methylethyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-13-8 CAPLUS
 CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-phenyl-1H-indol-5-yl]carbonyl]amino]-1-methylethyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-14-9 CAPLUS
 CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-(3-thienyl)-1H-indol-5-yl]carbonyl]amino]-1-methylethyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-15-0 CAPLUS
 CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-(3-thienyl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-10-5 CAPLUS
 CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]-1-methylethyl]-1-methyl-1H-benzimidazol-6-yl]-2-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-11-6 CAPLUS
 CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(2-fluoro-3-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-12-7 CAPLUS
 CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclopentyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-3-methyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-16-1 CAPLUS
 CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-(1H-pyrazol-1-yl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-19-4 CAPLUS
 CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-3-methyl-2-(2-pyridinyl)-1H-indol-5-yl]carbonyl]amino]cyclopropyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-20-7 CAPLUS
 CN 2-Propenoic acid, 3-[2-[1-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclopropyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-21-8 CAPLUS
CN 2-Propenoic acid, 3-[2-[[[1-cyclopentyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclopropyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-22-9 CAPLUS
CN 2-Propenoic acid, 3-[2-[[[1-cyclopentyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-5-methoxy-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-23-0 CAPLUS
CN 2-Propenoic acid, 3-[2-[[[1-cyclohexyl-2-(5-fluoro-2-pyridinyl)-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-5-methoxy-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863889-24-1 CAPLUS
CN 2-Propenoic acid, 3-[2-[[[1-cyclohexyl-3-methyl-2-(1-methyl-1H-pyrazol-4-yl)-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863889-25-2 CAPLUS
CN 2-Propenoic acid, 3-[2-[[[2-(5-chloro-2-pyrimidinyl)-1-cyclohexyl-3-methyl-1H-indol-5-yl]carbonyl]amino]cyclobutyl]-1-methyl-1H-benzimidazol-6-yl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2005:141029 CAPLUS
DOCUMENT NUMBER: 142:240430
TITLE: Preparation of heterocyclic compounds as hepatitis C virus polymerase inhibitors

INVENTOR(S): Oka, Takahiro; Yata, Shinji; Ikegashira, Kazutoshi;
Noji, Satoru; Akaki, Tatsuo; Hirashima, Shintaro;
Niwa, Yasushi; Ando, Izuru; Sato, Toshihiro
PATENT ASSIGNER(S): Japan Tobacco Inc., Japan
SOURCE: PCT Int. Appl., 467 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NO 2005014543	A1	20050217	WO 2004-JP11640	20040806

W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RM: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TO
PRIORITY APPLN. INFO.: JP 2003-288296 A 20030806
JP 2003-288298 A 20030806
OTHER SOURCE(S): MARPAT 142:240430
OI




AB The title compds. 1 [G1 = CR1, N; G2 = CR2, N; G3 = CR3, N; G4 = CR4, N; G5, G6, G8, G9 = C, N; G7 = O, etc.; R1 - R4 = H, halo, etc.; R5, R6 = H, halo, etc.; ring Cy = (un)substituted cycloalkyl, etc.; ring A = aryl, etc.; X = H, halo, etc.] are prepared. Thus, 2-[4-[2-(4-chlorophenyl)-5-(2-oxopyrrolidin-1-yl)benzoyloxy]phenyl]-3-cyclohexyl-1-methyl-1H-indole-6-carboxylic acid was prepared in a multistep process starting from Me 3-aminobenzoate. In an in vitro test for hepatitis C virus polymerase inhibiting activity, compds. of this invention showed IC50 values of < 0.01 μM to < 1 μM. Formulations are given.
IT 844894-52-0P 844894-56-6P 844894-57-7P
844894-58-8P 844894-59-9P 844894-91-3P
844894-93-5P 844895-89-2P
RL: BSU (Biological study); UNCLASSIFIED; PAC (Pharmacological activity);
SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as hepatitis C virus polymerase inhibitors)
RN 844894-52-0 CAPLUS
CN 1H-Indole-5-carboxylic acid, 1-cyclohexyl-3-methyl-2-[4-[[2-(4-morpholinyl)-5-(2-oxo-1-pyrrolidinyl)phenyl]methoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)


monohydrochloride (9CI) (CA INDEX NAME)




RN 844894-56-6 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-[4-[[2-(4-acetyl-1-piperazinyl)-5-(2-oxo-1-pyrrolidinyl)phenyl]methoxy]phenyl]-1-cyclohexyl-3-methyl- (9CI) (CA INDEX NAME)



RN 844894-57-7 CAPLUS
CN 1H-Indole-5-carboxylic acid, 1-cyclohexyl-3-methyl-2-[4-[[2-(4-methylsulfonyl)-1-piperazinyl)-5-(2-oxo-1-pyrrolidinyl)phenyl]methoxy]phenyl]-, (9CI) (CA INDEX NAME)




RN 844894-88-8 CAPLUS
CN 1H-Indole-5-carboxylic acid, 1-cyclohexyl-2-[4-[[2-(4-(1-methylethyl)-1-piperazinyl)-5-(2-oxo-1-pyrrolidinyl)phenyl]methoxy]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 844894-89-9 CAPLUS
CN 1H-Indole-5-carboxylic acid, 1-cyclohexyl-2-[4-[[2-(4-morpholinyl)-5-(2-oxo-1-pyrrolidinyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 844894-91-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 2-[4-[[5-(acetylmethylamino)-2-(4-morpholinyl)phenyl]methoxy]phenyl]-1-cyclohexyl-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 844894-93-5 CAPLUS
CN 1H-Indole-5-carboxylic acid, 1-cyclohexyl-2-[4-[[2-(4-hydroxy-1-piperidinyl)-5-(2-oxo-1-pyrrolidinyl)phenyl]methoxy]phenyl]-3-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 844895-89-2 CAPLUS
CN 1H-Indole-5-carboxylic acid, 1-cyclohexyl-2-[4-[[2-(4-morpholinyl)-5-(2-oxo-1-pyrrolidinyl)phenyl]methoxy]phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:633560 CAPLUS
DOCUMENT NUMBER: 141:174170
TITLE: A preparation of heterocyclic compounds, useful as inhibitors of RNA dependent RNA polymerases, such as hepatitis C virus polymerase
INVENTOR(S): Poupart, Marc-Andre; Beaulieu, Pierre Louis; Rancourt, Jean
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharmas GmbH & Co Kg
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004064925	A1	20040805	WO 2004-CA17	20040119
US 2004186125	A1	20040923	US 2004-755544	20040112
US 7098221	B2	20050829		
CA 2511301	AA	20040805	CA 2004-2511301	20040119
EP 1587585	A1	20051026	EP 2004-703128	20040119

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006515364 T2 20060525 JP 2006-500428 20040119
US 2006189672 A1 20060824 US 2006-405144 20060417
PRIORITY APPLN. INFO.: US 2003-441674P P 20030122
US 2004-755544 A1 20040112
WO 2004-CA17 W 20040119

OTHER SOURCE(S): MARPAT 141:174170
GI




I



II

AB The invention relates to a preparation of heterocyclic compds. of formula I [wherein: R1 is (cyclo)alkyl, cycloalkenyl, 4 to 7-membered heterocyclic ring, etc.; R2 is halogen or (un)substituted (hetero)aryl; B is N and A is CH-, or -N-, etc.; B is C- and A is O, S, or NH, etc.; M1 and M4 are independently selected from CR3; M2 and M3, when not linked to -C(Y,Z), is CR3; R3 is H, halogen, CN, or azido, etc.], useful as inhibitors of RNA dependent RNA polymerases, particularly those viral polymerases within Flaviviridae family, more particularly to hepatitis C virus (HCV) polymerase. For instance, NS5B RNA dependent RNA polymerase inhibition of pyridinylindole derivative II was determined (compound 101, table 1; IC50 < 1μM).
IT 733035-61-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds., useful as inhibitors of RNA dependent RNA polymerases)
RN 733035-61-5 CAPLUS
CN 1H-Indole-5-carboxamide, 1-cyclopentyl-2-(3-furanyl)-3-methyl-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2004:2876 CAPLUS
 DOCUMENT NUMBER: 140:59522
 TITLE: Preparation of indole derivatives as histamine H3 antagonists
 INVENTOR(S): Aslanian, Robert G.; Berlin, Michael Y.; Mangiaracina, Pietro; McCormick, Kevin D.; Mutahi, Mwangi W.; Rosenblum, Stuart B.
 PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIKXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000831	A1	20031231	WO 2003-US19619	20030620
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, HU, ID, IL, IN, IS, JP, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2489337	AA	20031231	CA 2003-2489337	20030620
AU 2003243709	A1	20040106	AU 2003-243709	20030620
US 2004019099	A1	20040129	US 2003-600674	20030620
EP 6951871	B2	20051004		
US 1539742	A1	20050615	EP 2003-761216	20030620
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1662524	A	20050831	CN 2003-814717	20030620
JP 2005531615	T2	20051020	JP 2004-516072	20030620
ZA 2004010213	A	20051020	ZA 2004-10213	20041217
PRIORITY APPLN. INFO.:			US 2002-390987P	P 20020624
			WO 2003-US19619	N 20030620

OTHER SOURCE(S): MARPAT 140:59522
 GI



III


AB Title compds. I [wherein R1 = (un)substituted indolyl or an aza derivative thereof; R2 = (un)substituted (hetero)aryl, quinolyl, heterocycloalkyl; R3, R4 = alkyl, hydroxyl, alkoxy, etc., or R3 = O; m = independently 0-3; n = 1-3; p = 1-3; q = 1-5; X = a bond or alkylene; Y = CO, CS, COCH2, etc.; Z = a bond, alkylene, alkenylene, CO, etc.; M1 = CH or N; M2 = CR3 or N; and salts or solvates thereof] were prepared as histamine H3 antagonists in treatment of H3 receptor related diseases. For example, reaction of II with 3-(4-piperidinyl)-2-(2-pyridinyl)indole, followed by deprotection and substitution with 2-chloromethylpyridine gave III, which showed 1.50 nM binding constant with histamine H3. Thus, I and their pharmaceutical compds., as well as in combination with H1 receptor antagonists, are useful as histamine H3 antagonists for the treatment of inflammatory diseases, allergic conditions and central nervous system disorders (no data).

IT 639506-16-4P 639506-17-5P 639506-18-6P
 639506-19-7P 639506-21-1P 639506-23-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

[Preparation of indole derivs. as histamine H3 antagonists]


RN 639506-16-4 CAPLUS

CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)




RN 639506-17-5 CAPLUS

CN Piperidine, 1-[[1-[(3-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)




RN 639506-18-6 CAPLUS

CN Piperidine, 1-[[1-[(3-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)




RN 639506-19-7 CAPLUS

CN Piperidine, 1-[[1-[(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)




RN 639506-21-1 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(3-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 639506-23-3 CAPLUS

CN Piperidine, 1-[[4-fluoro-1-(4-pyridazinylmethyl)-4-piperidinyl]carbonyl]-4-[5-fluoro-2-(2-pyridinyl)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)




IT 639505-52-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

[Preparation of indole derivs. as histamine H3 antagonists]

RN 639505-52-5 CAPLUS


CN 1H-Indole, 5-fluoro-1-[1-(phenylmethyl)-4-piperidinyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2003:97397 CAPLUS
 DOCUMENT NUMBER: 138:153436
 TITLE: Preparation of indole-6-carboxamides and related compounds as hepatitis C viral polymerase inhibitors
 INVENTOR(S): Beaulieu, Pierre Louis; Fazal, Gulrez; Goulet, Sylvie; Kukolj, George; Poirier, Martin; Tchantzios, Youla S.; Jolicoeur, Eric; Gillard, James; Poupart, Marc-Andre; Rancourt, Jean
 PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
 SOURCE: PCT Int. Appl., 336 pp.
 CODEN: PIKXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003010141	A2	20030206	WO 2002-CA1128	20020718
WO 2003010141	A3	20030530		
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, JP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2449180	AA	20030206	CA 2002-2449180	20020718
US 2003176433	A1	20030918	US 2002-198680	20020718
US 2004024190	A1	20040205	US 2002-198384	20020718
EP 1414797	A2	20040506	EP 2002-752904	20020718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				



RN 347174-32-7 CAPLUS
CN 1H-indole-5-carboxylic acid, 2-[4-[(4'-chloro-4-methoxy[1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2001:489367 CAPLUS
DOCUMENT NUMBER: 135:76874
TITLE: Preparation of heterocyclic compounds as remedies for hepatitis C
INVENTOR(S): Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito
PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
SOURCE: PCT Int. Appl., 438 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047883	A1	20010705	WO 2000-JP9181	20001222
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, NG, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				

CA	2363274	AA	20010705	CA	2000-2363274	20001222
EP	1162196	A1	20011212	EP	2000-987728	20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO						
BR	2000008525	A	20020102	BR	2000-8525	20001222
TR	200103147	T1	20020621	TR	2001-3147	20001222
NZ	514403	A	20021025	NZ	2000-514403	20001222
AU	763356	B2	20030717	AU	2001-24017	20001222
RU	2223761	C2	20040220	RU	2001-126283	20001222
CN	1623984	A	20050608	CN	2004-10055872	20001222
NO	2001004134	A	20011022	NO	2001-4134	20010824
US	2003050320	A1	20030313	US	2001-939374	20010824
US	6770666	B2	20040803			
ZA	2001007870	A	20020925	ZA	2001-7870	20010928
US	2004097438	A1	20040520	US	2003-615329	20030708


PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 135:76874
G1




AB The title compds. I [the dotted line in rings S1 and S2 indicates a single or double bond; G1 = N, CR1; G2 = N, CR2; G3 = N, CR3; G4 = N, CR4; G5, G6, G7 = C, N; G8 = O, etc.; R1 - R4 = H, nitro, etc.; ring Cy = (un)substituted cycloalkyl ring, etc.; ring A = C3-C6 cycloalkyl, etc. R5, R6 = H, halo, etc.; X = H, cyano, etc.] are prepared. The benzimidazole derivative II in vitro showed IC50 of 0.011 µM against hepatitis C virus polymerase. A formulation is given.
IT 347173-49-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as remedies for hepatitis C)
RN 347173-49-3 CAPLUS
CN 1H-indole-5-carboxylic acid, 2-[4-[(4'-chloro-4-methoxy[1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, methyl ester (9CI) (CA INDEX NAME)



IT 347174-32-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. as remedies for hepatitis C)
RN 347174-32-7 CAPLUS
CN 1H-indole-5-carboxylic acid, 2-[4-[(4'-chloro-4-methoxy[1,1'-biphenyl]-2-yl)methoxy]phenyl]-1-cyclohexyl-, methyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1994:49268 CAPLUS
DOCUMENT NUMBER: 124:163257
TITLE: Organocarbonyl- and aryloxy-lanthanoids. XII. The coordination chemistry of bis(2-phenylindol-1-yl)ytterbium(III), and the x-ray crystal structures of Yb(pin)2(diglyme)(thf) and [Yb(pin)2(dme)]2 (pin = 2-phenylindol-1-yl, diglyme = bis(2-methoxyethyl) ether, thf = tetrahydrofuran, dme = 1,2-dimethoxyethane)
ABRAMS, Carmel T.; DEACON, Glen B.; FOREYTH, Craig M.; PATALINGHUG, Myona C.; SKELTON, Brian W.; WHITE, Allan H.
CORPORATE SOURCE: Chem. Dep., Monash Univ., Clayton, 3168, Australia
SOURCE: Australian Journal of Chemistry (1995), 48(12),

1933-47
CODEN: AJCHAS; ISSN: 0004-9425
PUBLISHER: Commonwealth Scientific and Industrial Research Organization
DOCUMENT TYPE: Journal
LANGUAGE: English


AB With the facile displacement being used of THF from Yb(pin)2(THF)4 (pin = 2-phenylindol-1-yl,) in toluene solution, the complexes Yb(pin)2(dme)2 (dme = 1,2-dimethoxyethane), Yb(pin)2(tmen) (tmen = N,N,N',N'-tetramethylethane-1,2-diamine) and Yb(pin)2(diglyme)(THF) (diglyme = bis(2-methoxyethyl) ether) were prepared from the resp. ligands and Yb(pin)2(THF)4. Yb(pin)2(diglyme)(THF) [monoclinic, space group P21/c, a 15.35(1), b 16.179(5), c 14.45(2) Å, β 107.51(8)°, Z = 4, R 0.044 for 2956 (I > 3σ(I)) 'observed' reflections] has a monomeric six-coordinate structure with transoid N donor atoms, N-Yb-N 143.6(4)° and an irregular coordination polyhedron described as either a distorted trigonal prism or a monocapped square pyramid. Attempted crystallization of Yb(pin)2(THF) by partial desolvation of Yb(pin)2(THF)4 in hot toluene, containing a trace of dme, gave a mixture of red Yb(pin)2(THF) and orange [Yb(pin)2(dme)]2. The latter was independently synthesized by partial desolvation of Yb(pin)2(dme)2 in toluene. An x-ray crystal structure showed [Yb(pin)2(dme)]2 [monoclinic, space group P21/c, a 11.614(2), b 15.945(7), c 15.327(4) Å, β 110.19(2)°, Z = 2 dimers, R 0.070 for 2314 (I > 3σ(I)) 'observed' reflections] to be a dimer with two bridging pin ligands, coordinated through N only. There is an approx. square pyramidal five-coordinate Yb environment with an apical dme O, and with two bridging nitrogens, a terminal N, and a dme O in the basal plane. 173612-62-9P
IT PREP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and crystal structure)
RN 173612-62-9 CAPLUS
CN Ytterbium, [1,1'-oxybis(2-methoxyethane)-O,O',O']bis(2-phenyl-1H-indol-1-yl)(tetrahydrofuran)-, (TP-6-342)- (9CI) (CA INDEX NAME)




PAGE 1-A



IT 173612-64-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and dimerization in toluene)
 RN 173612-64-1 CAPLUS
 CN Ytterbium, bis(1,2-dimethoxyethane-O,O')bis(2-phenyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)




IT 173612-65-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 173612-65-2 CAPLUS
 CN Ytterbium, bis(2-phenyl-1H-indol-1-yl)(N,N,N',N'-tetramethyl-1,2-ethanediamine-N,N')-, (T-4)- (9CI) (CA INDEX NAME)




L11 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:515146 CAPLUS
 DOCUMENT NUMBER: 123:32900
 TITLE: Synthesis of some 1-substituted-5-methoxy-2,3-diphenylindoles
 AUTHOR(S): El-Divani, H. I.; Shmeiss, N. A. M. M.; Saleh, N. M.
 CORPORATE SOURCE: Chem. Nat. Microbial Prod. Dep., Nat. Res. Cent., Cairo, Egypt
 SOURCE: Polish Journal of Chemistry (1995), 69(3), 470-5
 CODEN: PJCHDQ; ISSN: 0137-5083
 PUBLISHER: Polish Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The title compds. were prepared from 5-methoxy-2,3-diphenylindole (I, R = H). E.g. reaction of I (R = H) with EtOCCl3 gave I (R = CHCl2).
 Reaction of the latter with hydrazine gave I (R = CH(NHGH2)2).

IT 164026-79-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 164026-79-3 CAPLUS
 CN 1H-Indole, 1-(2-imidazolidinyl)-5-methoxy-2,3-diphenyl- (9CI) (CA INDEX NAME)




L11 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:334877 CAPLUS
 DOCUMENT NUMBER: 120:334877
 TITLE: Electrophotographic toner, new indole derivatives and their preparation
 INVENTOR(S): Berneth, Horst; Koecher, Matthias
 PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: Ger. Offen., 13 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4209919	A1	19930930	DE 1992-4209919	19920327
EP 563666	A1	19931006	EP 1993-104152	19930315


R: CH, DE, FR, GB, LI

JP 06049026 A2 19940222 JP 1993-85090 19930322
 PRIORITY APPL. INFO.: DE 1992-4209919 A 19920327
 OTHER SOURCE(S): MARPAT 120:334877
 GI



AB The title toner comprises a charge controlling agent from an indole derivative I [R1-R3 = H, alkyl, alkoxy, halogen, nitro, cyano, aryl; R4 = H, alkyl, cycloalkyl, aralkyl, a substituted indole group to form a dimer of I; the benzene ring may optionally be substituted]. The compound I and some of its dimer derivs. are also claimed. Preparation of the above compound comprises reacting I [R1 = H] with R1X [R1 = substituent, X = halogen, sulfate, alkyl sulfonate, aryl sulfonate etc.]. The material provides improved charging properties.

IT 155430-33-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and use of, as charge controlling agent in electrophotog. toner)
 RN 155430-33-4 CAPLUS
 CN 1H-Indole, 3,3'-(1-octadecenylidene)bis(1-cyclohexyl-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




L11 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1993:583060 CAPLUS
 DOCUMENT NUMBER: 119:183060
 TITLE: Indolylbenzoxazine and its use in thermosetting marking inks
 INVENTOR(S): Berneth, Horst
 PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: Ger. Offen., 12 pp.
 CODEN: GWXXBX

DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4139955	A1	19930609	DE 1991-4139955	19911204
CH 685011	A	19950228	CH 1992-3334	19921027
GB 2262094	A1	19930609	GB 1992-25226	19921202
GB 2262094	B2	19950705		

PRIORITY APPL. INFO.: DE 1991-4139955 A 19911204
 OTHER SOURCE(S): MARPAT 119:183060
 GI




AB The title compds. bis(alkylindolyl)benzoxazines I (R1-R6 = H, alkyl, alkoxy, etc.; R7 = aryl) and analogs thereof and inks containing them are claimed. I are useful in thermosetting marking inks. Condensation reaction of 7-nitro-2-phenyl-3,1-benzoxazin-4-one with 1-methyl-2-phenylindole gave I (R1 = Me; R2 = Ph; R3 = R4 = R5 = H, R6 = NO2, R7 = Ph) (II). Thermal printer sheets were manufactured from bisphenol A, a distearylamine derivative, kaolin, hydrolyzed polyvinyl alc. and II.


IT 150017-03-1P
 RL: PREP (Preparation)
 (preparation of, as thermosetting marking ink)
 RN 150017-03-1 CAPLUS
 CN 4H-3,1-Benzoxazin-7-amine, 6-chloro-4,4-bis(1-cyclohexyl-2-phenyl-1H-indol-3-yl)-N,N-diethyl-2-phenyl- (9CI) (CA INDEX NAME)




Absolute stereochemistry.



L11 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1977:139740 CAPLUS
 DOCUMENT NUMBER: 86:139740
 TITLE: Synthesis and pharmacological properties of
 3-acetoxyethylindoles and their derivatives
 AUTHOR(S): De Coimont, Paul; Rigerol, Charles; Broll, Madeline;
 Eysnard, Pierre; Werbenec, Jean P.
 CORPORATE SOURCE: Cent. Rech. Groupe LABAZ, Cent. Rech. Stud.
 Pharmacol., Grenoble, Fr.
 SOURCE: European Journal of Medicinal Chemistry (1976), 11(5),
 471-9
 CODEN: EJMCAS; ISSN: 0223-5234
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 Q1




AB	3-Acetoacetylindoles I (R = H, Me; R1 = Ph, H, Me, cyclopropyl, cyclopentyl, cyclohexyl, R2 = H) were prepared by treating the 3-unsubstituted indole with diketene. I (R = Me, 2-tetrahydropyranyl, CH2Ph; R1 = Ph, R2 = CH2COOR3, R3 = CH2Pr2, morpholinomethyl, piperidinomethyl, Ph, 4-ClC6H4, 4-Et2NCN3CH2CO2CH4) were prepared by treating I (R2 = Me) with R3CO2Me. I (R = H, R1 = Ph, R2 = CH2COOR3) were obtained by acid cleavage of the tetrahydropyranyl derivative. I (R = H, R1 = Ph, R2 = CHAcR4, R4 = H, R5 = Cl, Br, Et, CH2CH2Cl, R4R5 = NO2, 3-NO2CH2CH2, 4-NO2CH2CH2, CH2R2) were prepared from I (R = CH2Ac) (R = H, R1 = Ph, R2 = CH=CHNRR6R7, NR6R7 = NH2, morpholino, piperidino, 4-ClC6H4NH3) were obtained from I (R = H, R1 = Ph, R2 = CH2Ac). I (R = H, R1 = Ph, R2 = morpholinomethyl, piperidinomethyl, 4-methylpiperazinomethyl) were prepared from I (R = H, R1 = Ph, R2 = CHClAc). Various I had anticonvulsant, neuroleptic, tranquilizing, sedative, thymoanaleptic, anticholinergic, anesthetic, and anti-inflammatory activity.
IT	62367-75-3P 62367-79-7P 62367-81-1P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation and pharmacol. activity of)
RN	62367-75-3 CAPLUS
CN	1,1-Butenediols, 4-(4-morpholinyl)-1-(2-phenyl-1-(tetrahydro-2H-pyran-3-yl)-Indol-3-yl)- (9CI). [CA INDEX NAME]

c1ccc2c(c1)c(c3ccccc3n2C4CCCCC4)C(=O)CC(=O)c5ccccc5O=C1C(=C(C=C1)C2=CC=CC=C2)N(C3CCCCC3)C4=CC=CC=C4C(=O)CC(=C5C=CC(=C5)Cl)C6=CC=CC=C6

FILE 'REGISTRY' ENTERED AT 13:23:12 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Relative stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L15 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2006 ACS ON STN
RN 862892-73-7 REGISTRY
ED Entered STN: 12 Sep 2005
CN 1H-Indole-2-carboxamide, (2S)-2-cyclohexyl-N-
(pyrazinylcarbonyl)glycyl-3-methyl-L-valyloctahydro-N-
oxo-2-(phenoxyamino)ethylbutyl-, (2S,3aS,7aS)- (9CI) (CA INDEX
NAME)
FS STEREOSEARCH
MF C40 H57 N7 O7
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L15 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2006 ACS ON STN
RN 853018-28-7 REGISTRY
ED Entered STN: 27 Jun 2005
CN Spiro[1H-pyrido(3,4-b)indole-1,3'-pyrrolidine]-2(3H)-carboxamide,
N-cyclohexyl-4,9-dihydro-6-methoxy-1'-(2-phenoxyethyl)- (9CI) (CA
INDEX NAME)
MF C30 H38 N4 O3


(6CI) (CA INDEX NAME)
MF C32 H46 N2 O2
SR CAOLD
LC STN Files: CA, CAOLD, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


Uploading C:\Program Files\Stnexp\Queries\HeP C FUSED RING COMPOUNDS.str



chain nodes :
10 12 13
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
8-10 9-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-10 9-13
exact bonds :
8-9
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
12:Atom 13:Atom
Generic attributes :
10:
Saturation : Unsaturated
Type of Ring System : Monocyclic
13:
Saturation : Saturated

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L15 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2006 ACS ON STN
RN 425641-16-3 REGISTRY
ED Entered STN: 05 Jun 2002
CN 1H-Indole-3-propanamide, α-methyl-α-[[[(5-methyl-2-
phenoxyphenyl)sulfonyl]amino]-N-[[[1-(2-pyridinyl)cyclohexyl]methyl]-
[αS]- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C37 H40 N4 O4 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L15 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2006 ACS ON STN
RN 103512-41-0 REGISTRY
ED Entered STN: 02 Aug 1986
CN Indole-3-methanol, α-(cyclohexylaminomethyl)-1-decyl-2-phenoxy-

L16 STRUCTURE UPLOADED

>> D L16
L16 HAS NO ANSWERS
L16 STR



IMIDAZO[1,2-a]-
PYRIDA
SEARCHED

Structure attributes must be viewed using STN Express query preparation.

>> S L16
SAMPLE SEARCH INITIATED 13:26:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5668 TO ITERATE
35.3% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 108846 TO 117874
PROJECTED ANSWERS: 0 TO 0

L17 0 SEA SSS SAM L16

>> S L16 SSS FULL
FULL SEARCH INITIATED 13:27:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 114334 TO ITERATE

100.0% PROCESSED 114334 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.02

L18 2 SEA SSS FUL L16

>> FILE CAPLUS
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 212.40 695.02
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE 0.00 -19.50

FILE 'CAPLUS' ENTERED AT 13:27:12 ON 25 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP USAGE/TERMS' FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publisher. It is intended in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Sep 2006 VOL 145 ISS 14
FILE LAST UPDATED: 24 Sep 2006 (20060924/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

-- S L18
L19 1 L18

-- D

L19 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:5773 CAPLUS
DN 138:66657
TI Fused cyclic compounds and medicinal use thereof
IM Hashimoto, Hiromasa; Mizutani, Kenji; Yoshida, Atsuhito
PA Japan Tobacco Inc., Japan
SO PCT Int. Appl., 603 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

HASHIMOTO et al

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003000254	A1	20030103	WO 2002-JP6405	20020626
W:	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RM:	GH, GM, KE, LS, MW, ME, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG			
JP 2003212846	A2	20030730	JP 2002-185241	20020625
CA 2423800	AA	20030325	CA 2002-2423800	20020626
BR 2002005684	A	20030617	BR 2002-5684	20020626
EP 1400241	A1	20040324	EP 2002-743728	20020626
R:	AT, BR, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
ZA 2003001393	A	20040715	ZA 2003-1393	20020626
TR 200300544	T1	20050822	TR 2003-544	20020626
US 2004082635	A1	20040429	US 2003-344997	20030218
NO 2003000832	A	20030422	NO 2003-832	20030221
PRAI JP 2001-193786	A	20010626		
JP 2001-351537	A	20011116		
WO 2002-JP6405	W	20020626		
OS MARPAT 138:66657				

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

-- LOGOFF
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:Y
'Y' IS NOT VALID HERE
For an explanation, enter "HELP LOGOFF".

-- LOGOFF
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.60	696.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CAS SUBSCRIBER PRICE	0.00	-19.50

STN INTERNATIONAL LOGOFF AT 13:27:27 ON 25 SEP 2006